hypothesis,answer,strength_score,index
"Pamrevlumab (FG-3019, FibroGen)","Proposal for Pamrevlumab (FG-3019, FibroGen)

Overview of Therapeutic Candidate:
Pamrevlumab (also known as FG-3019) is a fully human recombinant monoclonal antibody developed by FibroGen designed to target connective tissue growth factor (CTGF), a matricellular protein implicated as a key mediator of fibrosis. This candidate is derived using recombinant DNA technology, wherein the antibody sequences are optimized for high affinity and specificity for CTGF. Pamrevlumab belongs to the class of biological therapeutics known as monoclonal antibodies, which have achieved significant traction as targeted therapies in numerous clinical contexts. Historically, this therapeutic class has been used to achieve precise extracellular targeting of proteins involved in pathological processes, as seen for instance in oncology and autoimmune diseases. In the context of fibrotic diseases, anti-CTGF antibodies such as pamrevlumab have been developed to neutralize a protein that is overexpressed in fibrotic tissues, thereby aiming to interrupt downstream signaling cascades that lead to fibrosis. The discovery of pamrevlumab builds on a substantial body of work that has elucidated the role of CTGF in fibroblast activation and extracellular matrix (ECM) deposition, placing it as a central node in the fibrotic process (Gomer & Lupher, 2010; Lipson et al., 2012).

Therapeutic History:
Pamrevlumab’s investigational history extends to several clinical and preclinical studies across fibrotic indications, including idiopathic pulmonary fibrosis (IPF). Several early-phase clinical trials have evaluated its safety and tolerability, starting with Phase 1 dose-escalation studies in IPF patients (ClinicalTrials.gov, 2003) that established a favorable safety profile without dose-limiting toxicities (Gomer & Lupher, 2010). Subsequent Phase 2 clinical trials (ClinicalTrials.gov, 2011; ClinicalTrials.gov, 2013) have provided encouraging efficacy signals with respect to slowing the progression of IPF; these studies focused on endpoints such as forced vital capacity (FVC) decline and quantitative radiographic measures of fibrosis. Notably, the PRAISE study, a randomized, double-blind, placebo-controlled trial, demonstrated that pamrevlumab could attenuate lung function decline and reduce high-resolution computed tomography (HRCT) fibrosis scores compared to placebo (Leask, 2019; MacIsaac et al., 2024). Furthermore, larger Phase 3 studies such as Zephyrus I (ClinicalTrials.gov, 2019) and Zephyrus II (ClinicalTrials.gov, 2020) have been initiated to further validate these findings. In parallel, preclinical studies in appropriate animal models have consistently supported the anti-fibrotic potential of CTGF inhibition by pamrevlumab, with evidence of reduced extracellular matrix deposition and diminished fibroblast activation observed in murine models (Lipson et al., 2012; Sakai et al., 2017). In addition to IPF, pamrevlumab has been evaluated in other fibrosis-related diseases, lending further weight to its potential utility in conditions characterized by excessive ECM deposition. This broad investigational history across biochemical, preclinical, and clinical domains underscores not only the rationale behind targeting CTGF but also the potential repurposing of pamrevlumab as a disease-modifying therapy in IPF (ClinicalTrials.gov search, n.d.; Thong et al., 2023).

Mechanism of Action:
The molecular mechanism of pamrevlumab is rooted in its capacity to neutralize CTGF, a central mediator of fibrosis that is upregulated downstream of pivotal cytokines such as transforming growth factor-beta (TGF-β). CTGF, also known as cellular communication network factor 2 (CCN2), is a secreted matricellular protein that modulates cell adhesion, migration, proliferation, differentiation, and extracellular matrix synthesis (Lipson et al., 2012). In fibrotic tissues such as those in IPF, CTGF is known to promote the activation of fibroblasts and their differentiation into myofibroblasts, which are the key effector cells in fibrotic remodeling. Myofibroblasts are responsible for the excessive production of collagen and other ECM proteins, leading to tissue stiffening and architectural distortion in the lung. Pamrevlumab binds CTGF with high affinity, thereby inhibiting its interaction with cell surface receptors and downstream mediators. This binding interrupts CTGF-mediated signaling cascades, which include the enhancement of TGF-β-driven profibrotic responses, ultimately leading to a reduction in fibroblast activation, collagen deposition, and contractile force generation within 3D collagen matrices (Leask, 2019; MacIsaac et al., 2024). Biochemically, by sequestering CTGF from the extracellular milieu, pamrevlumab abolishes its ability to contribute to the pathological amplification loops that sustain fibrosis, such as the positive feedback between CTGF and TGF-β signaling. This intervention has been shown to reduce collagen I expression and diminish fibroblast contractility in preclinical assays, thereby providing a sound molecular rationale for its use in IPF (Leask, 2019; MacIsaac et al., 2024). In effect, pamrevlumab exerts a targeted anti-fibrotic effect by “neutralizing” a key extracellular profibrotic signal, which offers the promise of modulating the diseased state and potentially reversing some aspects of established fibrosis.

Expected Effect:
Based on its mechanism of action, the expected effect of pamrevlumab in IPF is a significant attenuation of fibrotic progression. In cellular assays, pamrevlumab is anticipated to reduce fibroblast proliferation, prevent myofibroblast differentiation, and lower collagen deposition. These in vitro effects are supported by data showing that inhibition of CTGF correlates with reduced contractile force generation in three-dimensional collagen matrices, a key readout for fibrotic activity (Leask, 2019; MacIsaac et al., 2024). In in vivo settings, such as the clinical trials conducted in IPF patients, pamrevlumab is expected to slow the decline in forced vital capacity (FVC)—an important clinical endpoint—which reflects better preservation of lung function. Additionally, improved outcomes in quantitative imaging markers, such as lower fibrosis scores on high-resolution computed tomography scans, are anticipated as a result of reduced extracellular matrix accumulation (ClinicalTrials.gov, 2013; ClinicalTrials.gov, 2020). The therapeutic hypothesis is that by attenuating CTGF activity, pamrevlumab interrupts the downstream fibrotic cascade, stopping excessive ECM deposition, mitigating fibroblast activation, and ultimately preserving lung architecture and function. Importantly, CTGF is known to be highly expressed in IPF lung fibroblasts, and its inhibition is expected to exert a disease-modifying effect by addressing a key driver of pathological fibrosis. The fact that pamrevlumab has demonstrated signals of efficacy in Phase 2 trials further supports the expectation that it will translate into measurable clinical benefits in terms of lung function stabilization and improved patient outcomes (MacIsaac et al., 2024; Wu et al., 2024).

Overall Evaluation:
In summary, pamrevlumab represents a highly promising therapeutic candidate for idiopathic pulmonary fibrosis. Strengths of this candidate include a robust biological rationale anchored in decades of research implicating CTGF as a central mediator of fibrosis, demonstrated efficacy signals across multiple early-phase clinical trials, and a well-defined mechanism of action that directly targets key pathological processes in IPF. The compound’s ability to precisely bind and neutralize CTGF allows it to interrupt critical fibrotic cascades, providing a targeted intervention that has the potential to slow disease progression substantially. Additionally, the favorable safety profile established in Phase 1 and Phase 2 trials across fibrotic indications is encouraging, suggesting that pamrevlumab can be administered with acceptable risk in a patient population that is typically vulnerable due to advanced pulmonary dysfunction (Gomer & Lupher, 2010; Liu et al., 2025).

However, there remain certain challenges and weaknesses that warrant consideration. Despite the promising early-phase data, larger Phase 3 clinical trials have shown mixed outcomes in terms of primary efficacy endpoints. For instance, while some studies indicate that pamrevlumab slows FVC decline and improves radiographic markers of fibrosis, definitive and statistically significant long-term benefits relative to the current standards of care (nintedanib and pirfenidone) have yet to be conclusively demonstrated (ClinicalTrials.gov, 2019; MacIsaac et al., 2024). This underscores the inherent complexity of IPF pathogenesis, where multiple redundant and overlapping fibrotic pathways may attenuate the benefit of targeting a single mediator. In addition, heterogeneous patient responses and the lack of robust validated biomarkers for therapeutic monitoring in IPF are challenges that affect the overall certainty regarding clinical benefits.

Furthermore, while pamrevlumab’s mechanism—centered on CTGF inhibition—is compelling, fibrosis in IPF is a multifaceted process involving numerous cytokines, growth factors, and cellular responses. It is conceivable that combination therapy with other approved antifibrotic agents or emerging therapies might be needed to achieve synergistic efficacy. Future clinical studies would need to explore such combinations as well as refine patient selection criteria in order to identify subgroups that may derive the maximum benefit from CTGF blockade (Thong et al., 2023; Leask, 2019).

Overall, the preclinical and early clinical evidence supports the hypothesis that pamrevlumab will treat IPF by neutralizing CTGF, interrupting downstream fibroblast activation and excessive extracellular matrix deposition. Its biologic modality allows for precise extracellular targeting with an established safety profile in fibrosis indications. While further large-scale trials are needed to definitively determine its efficacy relative to currently approved therapies, the combined mechanistic, biochemical, and clinical data justify continued development of pamrevlumab as a promising candidate for modification of disease progression in IPF (ClinicalTrials.gov search, n.d.; MacIsaac et al., 2024; Sakai et al., 2017).

In conclusion, pamrevlumab exhibits several compelling attributes as a therapeutic candidate for IPF. The strengths lie in its targeted mechanism of CTGF inhibition, robust preclinical efficacy, and promising early-phase clinical signals regarding lung function preservation and safety. However, the mixed outcomes in later-phase trials and the complex, multifactorial nature of IPF pathogenesis suggest that further work—potentially including combination modalities and refinement of patient stratification—is warranted to secure its status as an effective disease-modifying therapy in IPF. The data to date provide a solid rationale for continued investment in pamrevlumab’s clinical development with the expectation that optimally designed Phase 3 trials and potential combination strategies may ultimately solidify its role in the therapeutic landscape of idiopathic pulmonary fibrosis (ClinicalTrials.gov search, n.d.; Lipson et al., 2012; Thong et al., 2023).

References
Gomer, R. H., & Lupher, M. L. (2010). Investigational approaches to therapies for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 19, 737–745. https://doi.org/10.1517/13543784.2010.484018

Leask, A. (2019). Breathe, breathe in the air: The anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful Phase II clinical trial for idiopathic pulmonary fibrosis. Journal of Cell Communication and Signaling, 13, 441–442. https://doi.org/10.1007/s12079-019-00542-6

Lipson, K. E., Wong, C., Teng, Y., & Spong, S. (2012). CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis & Tissue Repair, 5(Suppl 1), S24. https://doi.org/10.1186/1755-1536-5-s1-s24

Liu, H., Shen, J., & He, C. (2025). Advances in idiopathic pulmonary fibrosis diagnosis and treatment. Chinese Medical Journal Pulmonary and Critical Care Medicine, 3, 12–21. https://doi.org/10.1016/j.pccm.2025.02.001

MacIsaac, S., Somboonviboon, D., Scallan, C., & Kolb, M. (2024). Treatment of idiopathic pulmonary fibrosis: An update on emerging drugs in Phase II & III clinical trials. Expert Opinion on Emerging Drugs, 29, 177–186. https://doi.org/10.1080/14728214.2024.2340723

Sakai, N., Nakamura, M., Lipson, K. E., Miyake, T., Kamikawa, Y., Sagara, A., Shinozaki, Y., Kitajima, S., Toyama, T., Hara, A., Iwata, Y., Shimizu, M., Furuichi, K., Kaneko, S., Tager, A. M., & Wada, T. (2017). Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis. Scientific Reports, 7, Article 5624. https://doi.org/10.1038/s41598-017-05624-2

Thong, L., McElduff, E. J., & Henry, M. T. (2023). Trials and treatments: An update on pharmacotherapy for idiopathic pulmonary fibrosis. Life, 13(2), 486. https://doi.org/10.3390/life13020486

U.S. National Library of Medicine. (2003). Safety and tolerability study of FG-3019 in participants with idiopathic pulmonary fibrosis (NCT00074698) [Clinical trial registration]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00074698

U.S. National Library of Medicine. (2011). Safety, tolerability, and efficacy study of idiopathic pulmonary fibrosis (NCT01262001) [Clinical trial registration]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01262001

U.S. National Library of Medicine. (2013). Evaluate the safety and efficacy of FG-3019 (pamrevlumab) in participants with idiopathic pulmonary fibrosis (IPF) (NCT01890265) [Clinical trial registration]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01890265

U.S. National Library of Medicine. (2019). Zephyrus I: Evaluation of efficacy and safety of pamrevlumab in participants with idiopathic pulmonary fibrosis (IPF) (NCT03955146) [Clinical trial registration]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03955146

U.S. National Library of Medicine. (2020). Zephyrus II: Efficacy and safety study of pamrevlumab in participants with idiopathic pulmonary fibrosis (IPF) (NCT04419558) [Clinical trial registration]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04419558

Wu, X., Li, W., Luo, Z., & Chen, Y. (2024). A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: A network meta-analysis based on randomized controlled trials. BMC Pulmonary Medicine. Advance online publication. https://doi.org/10.1186/s12890-024-02861-w",1.335062884,3
"GSK3008348 (GSK, clinical candidate)","Proposal for GSK3008348 (GSK, clinical candidate)

Overview of Therapeutic Candidate:
GSK3008348 is a small‐molecule, nonpeptidic antagonist developed by GlaxoSmithKline specifically targeting the αvβ6 integrin, a cell surface receptor prominently expressed on damaged lung epithelia in idiopathic pulmonary fibrosis (IPF). Chemically derived through advanced medicinal chemistry approaches, this compound belongs to the class of integrin inhibitors that utilize rational design and structure‐activity relationship optimization to achieve high affinity and selectivity. Its design makes use of synthetic modifications—including incorporation of specific moieties that mimic key residues in the RGD motif—to efficiently bind the αvβ6 integrin with an affinity reported to be in the low picomolar range (John et al., 2020). The design and discovery process involved stereoselective synthesis routes, including techniques such as rhodium‐catalyzed asymmetric addition, to assure the correct chirality is present in the active form, which is critical for potency and specificity (Procopiou et al., 2018). As an inhaled therapeutic candidate, GSK3008348 is formulated for nebulizer administration, which allows for direct lung delivery and enhanced local concentration in fibrotic niches while minimizing systemic exposure. This mode of delivery is particularly advantageous in lung diseases, as it targets sites of pathology and reduces the likelihood of off‐target effects typically associated with systemic drug distribution (ClinicalTrials.gov, n.d.; Maden et al., 2018).

Therapeutic History:
Although GSK3008348 represents a novel application in IPF, the overall drug class of integrin antagonists has been explored for various fibrotic conditions in both preclinical and early clinical settings. Preclinical studies have demonstrated that targeting the αvβ6 integrin, which is minimally expressed in normal tissues but upregulated in sites of injury and fibrosis, can inhibit the activation of latent transforming growth factor‐β (TGF‐β) and thereby disrupt downstream profibrotic signaling cascades (Lv et al., 2019; Brzozowska & Deshmukh, 2022). Earlier clinical investigations with small-molecule inhibitors and monoclonal antibodies against αvβ6 integrin (for example, BG00011, formerly known as STX-100) have been conducted in patients with IPF, although some antibody-based treatments were halted due to safety concerns (Spagnolo et al., 2020). Specifically, GSK3008348 has undergone Phase I clinical trials in healthy volunteers and in IPF patients, as demonstrated by trials registered under ClinicalTrials.gov Identifiers NCT02612051 and NCT03069989. These early-phase trials primarily focused on safety, tolerability, pharmacokinetics (PK), and target engagement using advanced imaging techniques such as positron emission tomography (PET) with selective radioligands (Maher et al., 2020; ClinicalTrials.gov, 2017). In these studies, the compound was well tolerated at single ascending doses and exhibited favorable PK parameters with direct lung delivery, which positions it as a promising candidate for repurposing in IPF (Maden et al., 2018; ClinicalTrials.gov, n.d.). There is currently no indication of its previous use in other indications or in veterinary applications; instead, it stands as a dedicated therapeutic candidate engineered for the fibrotic pathology of IPF.

Mechanism of Action:
At the molecular level, the therapeutic rationale for employing GSK3008348 in IPF is based on its potent inhibition of the αvβ6 integrin. Under normal physiological conditions, the αvβ6 integrin is expressed at low levels on epithelial cells, but its expression is markedly upregulated in the context of tissue injury and fibrosis such as in the lungs of IPF patients (John et al., 2020; Lv et al., 2019). This integrin plays a pivotal role in converting latent TGF‐β into its active form by binding to the arginine-glycine-aspartate (RGD) motif present on the latency-associated peptide, triggering the release of active TGF‐β. Once active, TGF‐β engages its receptors on a variety of cell types, initiating downstream SMAD signaling pathways that culminate in fibroblast proliferation, myofibroblast differentiation, cytokine release, and excessive extracellular matrix deposition (Spagnolo et al., 2020; John et al., 2020).

GSK3008348 functions by binding with high affinity and selectivity to the αvβ6 integrin, thereby competitively inhibiting the interaction between the integrin and the RGD sequence of the latent TGF‐β complex. Detailed biochemical studies have shown that this compound not only blocks ligand binding but also actively triggers rapid internalization of the αvβ6 integrin from the cell surface. In normal human bronchial epithelial (NHBE) cells, the compound induces the clathrin‐mediated endocytosis of αvβ6 integrin, leading to receptor internalization and eventual lysosomal degradation. This results in a significant decrease in cell surface expression of αvβ6 integrin within minutes of exposure, with a corresponding reduction in the integrin-mediated activation of latent TGF‐β (John et al., 2020). The internalization kinetics have been measured in cell models with an effective concentration (EC50) in the low nanomolar range (approximately 0.26 nM) and show a half-life for receptor loss of about 2.6 minutes, with the receptor recycling to the cell surface taking approximately 11 hours after drug washout (John et al., 2020). This pharmacological action directly reduces the amount of active TGF‐β in the local lung microenvironment, which is critical because TGF‐β is the master regulator of fibrogenesis, driving fibroblast activation and myofibroblast differentiation via SMAD signaling cascades (John et al., 2020; Brzozowska & Deshmukh, 2022).

Furthermore, the biological relevance of αvβ6 integrin in IPF is emphasized by studies that show elevated expression levels correlate with disease severity and progression. Preclinical models, such as bleomycin-induced lung fibrosis in mice, have demonstrated that blockade of the αvβ6 integrin with agents like GSK3008348 results in decreased TGF‐β signaling, reduced collagen deposition, and lower levels of profibrotic biomarkers such as phosphorylated SMAD2 (pSmad2) and serum C3M—a marker of extracellular matrix turnover (John et al., 2020; Maher et al., 2020). Therefore, the mechanism of action of GSK3008348 is grounded in its ability to interfere with very early steps in the fibrotic cascade, hindering the activation of a critical profibrotic cytokine and thereby disrupting the pathological signaling that leads to lung tissue remodeling and fibrosis (John et al., 2020; Lv et al., 2019).

Expected Effect:
Based on its precise mechanism of action, GSK3008348 is expected to attenuate the progression of fibrosis in IPF by reducing the activation of latent TGF‐β specifically at the respiratory epithelial surface. In assays using precision-cut lung slices (PCLS) from IPF patients, treatment with GSK3008348 has been shown to reduce TGF‐β activation and downstream SMAD phosphorylation, leading to lower fibroblast activation and reduced extracellular matrix deposition (John et al., 2020; Brzozowska & Deshmukh, 2022). In 3D collagen contraction assays, which serve as robust in vitro models of fibrotic remodeling, the compound effectively inhibits fibroblast-mediated matrix contraction—a surrogate measure of tissue stiffening and fibrotic progression. Additionally, in preclinical bleomycin-induced fibrosis models, inhaled delivery of GSK3008348 resulted in decreased lung collagen content and reduction of biomarkers associated with disease progression, such as serum C3M (Maher et al., 2020).

The anticipated overall effect in patients is that by selectively preventing αvβ6 integrin-mediated TGF‐β activation, the compound will reduce the cascade of profibrotic events, including the phosphorylation of SMAD2/3 and myofibroblast differentiation, which are central to the pathogenesis of IPF. This should theoretically lead to stabilization or even improvement of lung function, reduced progression of fibrotic lesions, and an overall beneficial impact on the clinical course of IPF (Spagnolo et al., 2020; John et al., 2020). Importantly, because the αvβ6 integrin is selectively expressed on damaged epithelial cells rather than being widespread throughout the body, the targeted inhibition is expected to confer a favorable safety profile with minimal off-target effects—a critical consideration given the systemic toxicity observed with broader TGF‐β inhibitors (ClinicalTrials.gov, n.d.; Maden et al., 2018).

Overall Evaluation:
GSK3008348 presents as a promising therapeutic candidate for the treatment of IPF on several fronts. Its strengths lie primarily in its highly selective mechanism of action, targeting the αvβ6 integrin—a receptor that is not only upregulated in IPF but also pivotal in the activation of latent TGF‐β, the master cytokine in fibrogenesis (John et al., 2020; Spagnolo et al., 2020). The robust preclinical data, which include evidence from cellular assays demonstrating rapid clathrin-mediated internalization of the integrin and in vivo models of lung fibrosis showing reduced collagen deposition and favorable pharmacodynamic markers, strongly support the proposed hypothesis that inhibition of αvβ6 can attenuate downstream SMAD signaling and fibrotic progression (John et al., 2020; Maher et al., 2020).

Furthermore, the inhaled route of administration is particularly attractive as it allows for high local concentrations in the lung with reduced systemic exposure—a critical advantage over oral or parenteral systems that might otherwise lead to widespread TGF‐β inhibition and associated side effects (Maden et al., 2018; ClinicalTrials.gov, n.d.). In early-phase clinical trials (NCT02612051 and NCT03069989), the compound demonstrated satisfactory safety and PK profiles in healthy participants and in a small cohort of IPF patients, further providing proof-of-concept for its tolerability and lung targeting (Maher et al., 2020; ClinicalTrials.gov, 2017).

Nevertheless, there exist some challenges and uncertainties that warrant cautious optimism. Despite promising preclinical and early clinical data, GSK3008348 has not yet demonstrated definitive efficacy outcomes in large clinical trials, and the early termination of cohort studies suggests that further dose optimization or prolonged treatment studies are necessary to confirm its antifibrotic effects in patients (ClinicalTrials.gov, n.d.; Maden et al., 2018). Moreover, while the compound’s mechanism of inducing receptor internalization and degradation is compelling, the reversibility observed upon washout indicates that continuous dosing may be required to maintain target engagement, which could pose challenges with respect to patient adherence and long-term tolerability (John et al., 2020). In addition, though the selectivity profile is excellent relative to other integrins, off-target effects—especially in settings of chronic dosing—remain a possibility and will need to be rigorously evaluated in subsequent phase trials (Lv et al., 2019; Maden et al., 2018).

In summary, the strengths of GSK3008348 include its novel targeted mechanism of action against a key driver of fibrosis, strong preclinical evidence of efficacy in reducing TGF‐β activation and downstream fibrotic signaling, and the advantage of an inhaled formulation that promises improved safety and tissue specificity. Conversely, its limitations primarily involve the current lack of extensive clinical efficacy data, potential challenges related to maintaining sustained receptor inhibition, and the need for further phase II/III trials to establish long-term benefits and safety in a larger IPF population (John et al., 2020; Maher et al., 2020; Spagnolo et al., 2020).

Overall, based on the comprehensive literature review across biomedical, clinical, and biochemical sources, GSK3008348 is a promising therapeutic candidate for IPF. Its capability to directly interfere with αvβ6 integrin-mediated activation of latent TGF‐β, combined with a favorable safety profile demonstrated in early-phase trials, supports its continued clinical development. The hypothesis that GSK3008348 will attenuate IPF by reducing SMAD signaling, myofibroblast differentiation, and 3D matrix contraction is well-grounded in preclinical data and early translational studies. Therefore, from a drug development perspective, further investment in clinical studies is warranted to fully validate the efficacy, optimal dosing regimen, and long-term safety of GSK3008348 in IPF patients (John et al., 2020; Maher et al., 2020; ClinicalTrials.gov, n.d.).

References
Brzozowska, E., & Deshmukh, S. (2022). Integrin alpha v beta 6 (αvβ6) and its implications in cancer treatment. International Journal of Molecular Sciences, 23, Article 12346. https://doi.org/10.3390/ijms232012346

ClinicalTrials.gov. (n.d.). Search results for GSK3008348 OR αvβ6 integrin antagonist AND idiopathic pulmonary fibrosis. Retrieved from https://clinicaltrials.gov/

GlaxoSmithKline. (2015). First time in human (FTIH) study of GSK3008348 in healthy volunteers and idiopathic pulmonary fibrosis patients (ClinicalTrials.gov Identifier: NCT02612051). Retrieved from https://clinicaltrials.gov/ct2/show/NCT02612051

GlaxoSmithKline. (2017). Single doses of GSK3008348 in idiopathic pulmonary fibrosis (IPF) participants using positron emission tomography (PET) imaging (ClinicalTrials.gov Identifier: NCT03069989). Retrieved from https://clinicaltrials.gov/ct2/show/NCT03069989

John, A. E., Graves, R. H., Pun, K. T., Vitulli, G., Forty, E. J., Mercer, P. F., Morrell, J. L., Barrett, J. W., Rogers, R. F., Hafeji, M., Bibby, L. I., Gower, E., Morrison, V. S., Man, Y., Roper, J. A., Luckett, J. C., Borthwick, L. A., Barksby, B. S., Burgoyne, R. A., Barnes, R., Le, J., Flint, D. J., Pyne, S., Habgood, A., Organ, L. A., Joseph, C., Edwards-Pritchard, R. C., Maher, T. M., Fisher, A. J., Gudmann, N. S., Leeming, D. J., Chambers, R. C., Lukey, P. T., Marshall, R. P., Macdonald, S. J. F., Jenkins, R. G., & Slack, R. J. (2020). Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis. Nature Communications, 11, Article 5317. https://doi.org/10.1038/s41467-020-18397-6

Lv, M., Liu, Y., Ma, S., & Yu, Z. (2019). Current advances in idiopathic pulmonary fibrosis: The pathogenesis, therapeutic strategies and candidate molecules. Future Medicinal Chemistry, 11(19), 2595–2620. https://doi.org/10.4155/fmc-2019-0111

Maden, C. H., Fairman, D., Chalker, M., Costa, M. J., Fahy, W. A., Garman, N., Lukey, P. T., Mant, T., Parry, S., Simpson, J. K., Slack, R. J., Kendrick, S., & Marshall, R. P. (2018). Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants. European Journal of Clinical Pharmacology, 74, 701–709. https://doi.org/10.1007/s00228-018-2435-3

Maher, T. M., Simpson, J. K., Porter, J. C., Wilson, F. J., Chan, R., Eames, R., Cui, Y., Siederer, S., Parry, S., Kenny, J., Slack, R. J., Sahota, J., Paul, L., Saunders, P., Molyneaux, P. L., Lukey, P. T., Rizzo, G., Searle, G. E., Marshall, R. P., Saleem, A., Kang’ombe, A. R., Fairman, D., Fahy, W. A., & Vahdati-Bolouri, M. (2020). A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor. Respiratory Research, 21, Article 135. https://doi.org/10.1186/s12931-020-01339-7

Procopiou, P. A., Anderson, N. A., Barrett, J., Barrett, T. N., Crawford, M. H. J., Fallon, B. J., Hancock, A. P., Le, J., Lemma, S., Marshall, R. P., Morrell, J., Pritchard, J. M., Rowedder, J. E., Saklatvala, P., Slack, R. J., Sollis, S. L., Suckling, C. J., Thorp, L. R., Vitulli, G., & Macdonald, S. J. F. (2018). Discovery of (S)-3-(3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid, a nonpeptidic αvβ6 integrin inhibitor for the inhaled treatment of idiopathic pulmonary fibrosis. Journal of Medicinal Chemistry, 61, 8417–8443. https://doi.org/10.1021/acs.jmedchem.8b00959

Spagnolo, P., Bonella, F., Ryerson, C. J., Tzouvelekis, A., & Maher, T. M. (2020). Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 29, 797–808. https://doi.org/10.1080/13543784.2020.1782885",1.26377557,22
"BI 1015550 (PDE4B Inhibitor, Boehringer Ingelheim)

Below is a comprehensive evaluation of BI 1015550 as a promising repurposed therapeutic candidate for idiopathic pulmonary fibrosis (IPF). The following report is organized into five parts: an","Proposal for BI 1015550 (PDE4B Inhibitor, Boehringer Ingelheim)

Below is a comprehensive evaluation of BI 1015550 as a promising repurposed therapeutic candidate for idiopathic pulmonary fibrosis (IPF). The following report is organized into five parts: an overview of the therapeutic candidate, a summary of its therapeutic history, a detailed discussion of its mechanism of action supported by biochemical evidence, an explanation of the expected effect in preclinical and early clinical studies, and an overall evaluation that highlights its strengths and weaknesses for further development in IPF.

Overview of Therapeutic Candidate:
BI 1015550 is a small‐molecule, orally administered drug candidate developed by Boehringer Ingelheim that selectively inhibits phosphodiesterase 4B (PDE4B). As a chemically synthesized compound engineered for preferential inhibition of the PDE4B subtype, BI 1015550 belongs to the class of PDE4 inhibitors, a group known for their ability to modulate intracellular cyclic adenosine monophosphate (cAMP) levels by reducing its hydrolysis. Historically, PDE4 inhibitors have been used in the treatment of chronic inflammatory diseases such as chronic obstructive pulmonary disease (COPD) and psoriasis (ClinicalTrials.gov). BI 1015550 was discovered and optimized through iterative medicinal chemistry approaches targeting the PDE4 enzyme family, with a focus on achieving greater selectivity for the B isoform relative to subtypes A, C, and especially D. This selective inhibition is aimed at maintaining efficacy in the lung and inflammatory cells while reducing off‐target adverse effects such as the gastrointestinal symptoms commonly associated with pan‐PDE4 inhibitors (Herrmann et al., 2022; Kolb et al., 2023). In terms of therapeutic class, BI 1015550 represents a novel, precision‐oriented approach that leverages the extensive background of PDE4 inhibitor development, while addressing shortcomings of early compounds like roflumilast by concentrating on a single isoform implicated in fibrotic processes.

Therapeutic History:
The use of PDE4 inhibitors has a well‐established history in inflammatory and immune-mediated conditions. Drugs such as roflumilast, apremilast, and cilomilast have been approved or extensively investigated for conditions like COPD, psoriasis, and psoriatic arthritis due to their potent anti-inflammatory properties (Herrmann et al., 2022; Kolb et al., 2023). However, the broad activity of earlier PDE4 inhibitors was limited by adverse effects including nausea, emesis, and diarrhea, which have been primarily linked to off-target inhibition of PDE4D. Unlike its predecessors, BI 1015550 was designed to exploit the observation that the PDE4B isoform is upregulated in lung tissue and implicated in the fibrotic remodeling processes characteristic of IPF (ClinicalTrials.gov; Aringer et al., 2024). Preclinical studies have shown that in models of lung fibrosis—induced by bleomycin and silica—PDE4 inhibition can attenuate fibroblast activation, reduce inflammatory cell infiltration, and improve lung function endpoints such as forced vital capacity (FVC) (Herrmann et al., 2022; Kolb et al., 2023). Although BI 1015550 has not been historically used in IPF until its recent clinical evaluation, it builds on the extensive experience obtained with PDE4 inhibitors in related diseases. Early-phase clinical trials and preclinical evaluations in IPF models have shown evidence of lung function stabilization and anti-fibrotic effects, indicating that the candidate has potential when repurposed for treating IPF rather than its original targets (Liu et al., 2025; Thong et al., 2023).

Mechanism of Action:
At the molecular level, BI 1015550 functions by blocking the enzyme PDE4B, thereby preventing the hydrolysis of cyclic AMP (cAMP) inside target cells such as lung fibroblasts, monocytes, and macrophages. Elevated cAMP levels are known to activate protein kinase A (PKA) and exchange proteins directly activated by cyclic AMP (EPAC), which together orchestrate a cascade of downstream anti-inflammatory and anti-fibrotic effects (Kolb et al., 2023). Biochemically, this cascade interferes with pro-fibrotic signaling pathways, most notably the transforming growth factor-beta (TGF-β) pathway. TGF-β is a central mediator of myofibroblast differentiation, extracellular matrix (ECM) production, and ultimately fibrotic tissue remodeling—all hallmarks of the progression of IPF (Herrmann et al., 2022; Aringer et al., 2024). Experimental data from in vitro studies using primary lung fibroblasts derived from IPF patients demonstrate that BI 1015550 effectively suppresses TGF-β-induced upregulation of alpha-smooth muscle actin (α-SMA) and collagen types I and III, markers of myofibroblast differentiation and ECM deposition (Herrmann et al., 2022). In addition, the compound inhibits fibroblast proliferation by abrogating mitogen-induced signaling, and it reduces three-dimensional collagen gel contraction—a measure of tissue remodeling that is highly relevant to the fibrotic process (D’Agnano et al., 2024; Giulianelli et al., 2025). At the cellular signaling level, the increased cAMP levels from PDE4B inhibition also decrease the release of pro-inflammatory cytokines such as TNF-α and interleukin-2, as shown in studies of peripheral blood mononuclear cells. This dual anti-inflammatory and antifibrotic action makes BI 1015550 particularly attractive since both inflammation and fibrosis are intertwined in the pathogenesis of IPF (Herrmann et al., 2022; Kolb et al., 2023). Furthermore, combination studies have indicated that BI 1015550 can work synergistically with standard antifibrotic agents like nintedanib, enhancing its effectiveness in reducing fibrotic markers—a finding that underscores the potential for combination therapy regimens in IPF management (Herrmann et al., 2022; Kolb et al., 2023).

Expected Effect:
Given that the pathological hallmarks of IPF include persistent alveolar epithelial injury, dysregulated fibroblast activation, and excessive ECM deposition, the central hypothesis behind BI 1015550 is that by selectively inhibiting PDE4B, the drug will elevate intracellular cAMP in lung fibroblasts. This elevation is expected to directly antagonize the fibrogenic effects mediated by TGF-β, thereby reducing myofibroblast differentiation. In practical terms, in an in vitro three-dimensional collagen gel contraction assay using human IPF fibroblasts, BI 1015550 is anticipated to decrease gel contraction by inhibiting fibroblast-mediated tension forces that drive collagen deposition and scar formation (Liu et al., 2025; Giulianelli et al., 2025). In addition, the compound is expected to reduce the expression of α-SMA and collagen I at both the mRNA and protein levels, confirming its ability to modulate the key drivers of the fibrotic response. Supporting this, preclinical animal studies have documented improvements in forced vital capacity (FVC) and lung compliance following treatment with BI 1015550, suggestive of a direct benefit in terms of pulmonary function (Herrmann et al., 2022; Kolb et al., 2023). Moreover, early-phase clinical trials have reported stabilization—or even slight improvement—in FVC among IPF patients treated with BI 1015550 compared to placebo, implying that the drug may slow the rate of lung function decline. Pharmacokinetic studies further support this expectation as BI 1015550 demonstrates dose-proportional exposure and an acceptable safety profile, which is critical for long-term treatment regimens in a chronic disease such as IPF (Liu et al., 2025; MacIsaac et al., 2024). Overall, the convergence of in vitro, in vivo, and early clinical data builds a strong mechanistic rationale that BI 1015550 will exert anti-fibrotic and anti-inflammatory effects by elevating cAMP, inhibiting TGF-β-driven myofibroblast differentiation, and counteracting the fibrotic remodeling processes that underlie IPF (Thong et al., 2023; Giulianelli et al., 2025).

Overall Evaluation:
The collective evidence from biochemical, preclinical, and early clinical studies suggests that BI 1015550 possesses significant potential as a therapeutic candidate for IPF. One of the key strengths of this compound is its selectivity toward PDE4B, which is expected to provide a more favorable safety profile relative to non-selective PDE4 inhibitors that have been hindered by gastrointestinal toxicity and other systemic effects (Herrmann et al., 2022; Kolb et al., 2023). This specificity could enable clinicians to use BI 1015550 either as a monotherapy or in combination with existing antifibrotic agents such as nintedanib and pirfenidone, potentially offering additive or synergistic therapeutic benefits while minimizing adverse events. Preclinical assessments have demonstrated that BI 1015550 is capable of significantly improving lung function parameters in animal models of fibrosis, with a notable improvement in forced vital capacity as a surrogate marker for clinical benefit (Herrmann et al., 2022; Bonella et al., 2023). Moreover, early clinical trials in subjects with IPF have shown that the drug can stabilize lung function over a 12-week period—a critical observation given that standard treatments only slow the decline in FVC rather than reverse it (Liu et al., 2025; MacIsaac et al., 2024).

However, several challenges remain. One key weakness is that although the short-term data are promising, the long-term efficacy and safety of BI 1015550 must be established in larger, rigorously controlled phase III studies. Gastrointestinal adverse events, while generally mild, have been observed at rates that could affect patient adherence, particularly in those patients who are already on combination therapy with antifibrotic agents (Thong et al., 2023; Murgo, 2024). In addition, while the mechanistic rationale based on cAMP elevation and downstream suppression of TGF-β signaling is robust, direct clinical evidence of reduced fibrosis (for example, via lung tissue biomarkers or imaging assessments) remains limited at this stage. The clinical trials conducted so far have focused largely on lung function endpoints such as FVC rather than direct measures of fibrotic tissue remodeling. It will be important to confirm that the biochemical actions observed in vitro—namely the inhibition of myofibroblast differentiation and collagen production—translate into meaningful long-term clinical outcomes in the heterogeneous IPF patient population (Giulianelli et al., 2025; Smith & Jenkins, 2023).

Additional factors that add to the promise of BI 1015550 include its favorable pharmacokinetic profile, which supports oral administration—a convenient route for patients with chronic diseases like IPF—and the possibility of using the drug in combination regimens. The synergistic effects observed when BI 1015550 is combined with nintedanib in vitro suggest that a multi-targeted approach could potentiate anti-fibrotic efficacy while potentially allowing for lower doses of either agent to be used, thereby reducing dose-dependent adverse effects (Herrmann et al., 2022; Kolb et al., 2023). Nonetheless, careful clinical monitoring will be critical, especially because PDE4 inhibitors have historically been associated with neuropsychiatric adverse events, even though such events appear minimal for BI 1015550 to date (Thong et al., 2023; Vancheri et al., 2024).

In conclusion, BI 1015550 represents a highly promising therapeutic candidate for IPF with a clear, mechanistically supported rationale. Its selective PDE4B inhibition allows for an increase in intracellular cAMP levels that suppresses key fibrotic processes, including TGF-β-induced myofibroblast differentiation and collagen production. Preclinical models have indicated that this mechanism can lead to improved lung function, and early-phase clinical trials have demonstrated stabilization of forced vital capacity in IPF patients. The compound’s oral bioavailability, favorable pharmacokinetics, and potential safety advantages over non-selective PDE4 inhibitors further strengthen its development profile. However, long-term efficacy data and comprehensive safety evaluations remain to be fully established in phase III trials. Moving forward, continued research should focus on integrating direct measures of fibrosis regression (e.g., histological or biomarker endpoints) alongside pulmonary function testing to validate the antifibrotic benefits observed in early studies. If these trials confirm the promising early data, BI 1015550 may significantly expand the therapeutic arsenal available for IPF—potentially improving outcomes for a patient population with limited treatment options (Liu et al., 2025; MacIsaac et al., 2024; Kolb et al., 2023).

Overall, the evaluation strongly supports advancing BI 1015550 into late-stage clinical development as a novel therapeutic option for IPF. The candidate’s targeted mechanism of action, clinical signals of pulmonary function stabilization, and the overall favorable pharmacological profile underscore its potential to fill an unmet need in IPF treatment—while remaining cognizant of the necessity for larger and longer-term studies to definitively ascertain its long-term benefit and safety (ClinicalTrials.gov; Thong et al., 2023; Kolb et al., 2023).

References
Aringer, M., Distler, O., Hoffmann-Vold, A.-M., Kuwana, M., Prosch, H., & Volkmann, E. R. (2024). Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. RMD Open, 10, e004704. https://doi.org/10.1136/rmdopen-2024-004704

Bonella, F., Spagnolo, P., & Ryerson, C. J. (2023). Current and future treatment landscape for idiopathic pulmonary fibrosis. Drugs, 83, 1581–1593. https://doi.org/10.1007/s40265-023-01950-0

ClinicalTrials.gov. (n.d.). Search results for BI 1015550 OR PDE4B inhibitor AND idiopathic pulmonary fibrosis. Retrieved from https://clinicaltrials.gov/

D’Agnano, V., Mariniello, D. F., Ruotolo, M., Quarcio, G., Moriello, A., Conte, S., Sorrentino, A., Zamparelli, S. S., Bianco, A., & Perrotta, F. (2024). Targeting progression in pulmonary fibrosis: An overview of underlying mechanisms, molecular biomarkers, and therapeutic intervention. Life, 14, 229. https://doi.org/10.3390/life14020229

Giulianelli, G., Cocconcelli, E., Fiorentù, G., Bernardinello, N., Balestro, E., & Spagnolo, P. (2025). Idiopathic pulmonary fibrosis, today and tomorrow: Certainties and new therapeutic horizons. Pulmonary Therapy. Advance online publication. https://doi.org/10.1007/s41030-025-00296-0

Herrmann, F. E., Hesslinger, C., Wollin, L., & Nickolaus, P. (2022). Bi 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Frontiers in Pharmacology, 13, 838449. https://doi.org/10.3389/fphar.2022.838449

Kolb, M., Crestani, B., & Maher, T. M. (2023). Phosphodiesterase 4B inhibition: A potential novel strategy for treating pulmonary fibrosis. European Respiratory Review, 32, 220206. https://doi.org/10.1183/16000617.0206-2022

Liu, H., Shen, J., & He, C. (2025). Advances in idiopathic pulmonary fibrosis diagnosis and treatment. Chinese Medical Journal Pulmonary and Critical Care Medicine, 3, 12–21. https://doi.org/10.1016/j.pccm.2025.02.001

MacIsaac, S., Somboonviboon, D., Scallan, C., & Kolb, M. (2024). Treatment of idiopathic pulmonary fibrosis: An update on emerging drugs in phase II & III clinical trials. Expert Opinion on Emerging Drugs, 29, 177–186. https://doi.org/10.1080/14728214.2024.2340723

Murgo, A. (2024). Characterization and evaluation of clinically relevant readouts in a pre-clinical model of idiopathic pulmonary fibrosis (IPF). Unknown journal.

Smith, D. J. F., & Jenkins, R. G. (2023). Contemporary concise review 2022: Interstitial lung disease. Respirology, 28, 627–635. https://doi.org/10.1111/resp.14511

Thong, L., McElduff, E. J., & Henry, M. T. (2023). Trials and treatments: An update on pharmacotherapy for idiopathic pulmonary fibrosis. Life, 13, 486. https://doi.org/10.3390/life13020486

Vancheri, C., Sciacca, E., Muscato, G., Spicuzza, L., Fruciano, M., Gili, E., Sambataro, G., Palmucci, S., & Libra, A. (2024). Pharmacological treatment in idiopathic pulmonary fibrosis: Current issues and future perspectives. Multidisciplinary Respiratory Medicine. Advance online publication. https://doi.org/10.5826/mrm.2024.982",1.168576235,28
"GB0139 (TD139, Galectin-3 inhibitor, Galecto)","Proposal for GB0139 (TD139, Galectin-3 inhibitor, Galecto)

Overview of Therapeutic Candidate:
GB0139 (also known as TD139) is a synthetic, inhaled small‐molecule inhibitor designed to selectively target galectin-3, a β-galactoside binding lectin that is critically implicated in fibrotic processes. It was discovered and optimized through a medicinal chemistry program at Galecto, by designing thiodigalactoside analogues with high nanomolar affinity for the carbohydrate recognition domain of galectin-3, which confers its potent inhibitory activity. This compound belongs to the class of galectin-3 inhibitors, a group of molecules that have been rationally designed to disrupt galectin-3 interactions on cell surfaces and within the extracellular milieu, and this class has previously been explored in both cancer and fibrotic disease contexts. Its inhaled mode of delivery, via a dry powder inhaler, is specifically tailored to achieve high local concentrations in the lung while minimizing systemic exposure, which is an important consideration for treating idiopathic pulmonary fibrosis (IPF) given the localized nature of pulmonary fibrogenesis (ClinicalTrials.gov, n.d.; Case Study: Development of GB0139 for Idiopathic Pulmonary Fibrosis, n.d.).

Therapeutic History:
GB0139 has undergone extensive preclinical evaluation and early‐phase clinical investigations in IPF, with phase I/IIa studies demonstrating its safety, tolerability, and evidence of target engagement in patients. Early clinical studies, such as those registered under NCT02257177 (Galecto Biotech AB, 2014) and NCT03832946 (Galecto Biotech AB, 2019), evaluated GB0139’s pharmacokinetics and pharmacodynamics in both healthy volunteers and IPF patients, establishing that inhaled GB0139 achieves significant lung tissue exposure and reduces circulating levels of galectin-3 (Gaughan et al., 2021). Additionally, GB0139 has been assessed in contexts beyond IPF, such as COVID-19 pneumonitis, where its capacity to modulate inflammatory and fibrotic biomarkers has been demonstrated, further supporting its mechanistic rationale and smooth safety profile (Gaughan et al., 2021). Although its use in IPF has not yet led to regulatory approval, its advanced clinical evaluation underscores its potential repurposing and therapeutic value in fibrotic lung diseases (Hirani et al., 2021).

Mechanism of Action:
Galectin-3 plays a key role in the pathogenesis of IPF by modulating several profibrotic pathways. It is upregulated in IPF lungs and acts to promote fibroblast activation, myofibroblast differentiation, and extracellular matrix (ECM) deposition primarily through the potentiation of TGF-β signaling. GB0139 exerts its pharmacological effects by binding selectively to the carbohydrate recognition domain of galectin-3 with nanomolar affinity, thus inhibiting its interactions that drive the fibrogenic cascade. This inhibition has been shown to result in decreased expression of α-smooth muscle actin (αSMA) and collagen I in IPF fibroblasts, markers that reflect reduced fibroblast activation and ECM production (Gaughan et al., 2021). Mechanistically, galectin-3 inhibition by GB0139 disrupts the autocrine and paracrine signaling loops that sustain TGF-β–mediated fibroblast proliferation and myofibroblast differentiation, effectively dampening the feed-forward loop of fibrogenesis. Biochemically, by binding to galectin-3, GB0139 prevents galectin-3 from clustering with cell surface receptors and interacting with key signaling molecules involved in extracellular matrix remodeling, thereby reducing profibrotic cytokine release and altering macrophage phenotypes from a profibrotic to a more reparative profile (Hirani et al., 2021; Spagnolo et al., 2020).

Expected Effect:
In the proposed assays, such as in 3D collagen gel systems, GB0139 is expected to reduce ECM deposition and contractility by attenuating fibroblast proliferation and activation. By blocking galectin-3, the compound should interrupt the TGF-β signaling cascade that is central to fibroblast-to-myofibroblast transition, thereby reducing αSMA expression and collagen synthesis. Preclinical data indicate that treatment with GB0139 leads to dose-dependent decreases in galectin-3 levels in bronchoalveolar lavage fluid as well as plasma, correlating with reduced fibrotic biomarkers and diminished fibroblast proliferation (Hirani et al., 2021; Gaughan et al., 2021). Moreover, immunohistochemical analyses in earlier studies have demonstrated that galectin-3 is highly expressed in IPF lung tissue, particularly in fibroblasts and macrophages within fibrotic foci, thus establishing the target’s expression in the relevant cell types (Miah, 2022). The expected outcome is a restoration of normal fibroblast phenotype and decreased contractile tension in collagen matrices, which are indicative of reduced fibrogenic potential—a key mechanistic underpinning for reversing established fibrosis in IPF (Spagnolo et al., 2020; Molina-Molina, 2019).

Overall Evaluation:
Overall, GB0139 represents a promising therapeutic candidate for IPF owing to several strengths. Its high degree of selectivity for galectin-3 enables a specific interruption of fibrotic signaling pathways, notably TGF-β–mediated fibroblast activation and ECM deposition. The inhaled delivery system is an additional strength, providing direct lung targeting while limiting systemic exposure and reducing potential off-target effects (ClinicalTrials.gov, n.d.; Gaughan et al., 2021). Clinical trials to date have confirmed its safety and target engagement, as evidenced by reductions in pulmonary and circulating galectin-3 levels, as well as favorable biomarker profiles associated with diminished fibrosis (Galecto Biotech AB, 2019; Hirani et al., 2021).

However, some weaknesses remain. Although preclinical and early clinical data indicate a robust biochemical rationale, the true clinical efficacy in reversing established fibrosis in IPF remains to be definitively demonstrated in larger, long-term studies. There is also the challenge of balancing adequate drug exposure in the fibrotic lung tissue with potential safety concerns when combined with current standard-of-care therapies, as suggested by observations in some trials that noted dose-dependent adverse events when used alongside other treatments (Senior, 2022). Additionally, while the compound shows promising effects on TGF-β signaling and fibroblast proliferation in vitro, translating these anti-fibrotic effects into meaningful clinical improvement in lung function or survival in IPF patients is inherently challenging given the heterogeneity and advanced pathology seen in many patients.

In conclusion, the weight of the evidence supports further development of GB0139 as a therapeutic candidate for IPF. Its mechanism of action—selectively blocking galectin-3–mediated enhancement of TGF-β signaling and fibroblast proliferation—targets a central pathway in IPF pathogenesis. The favorable safety profile and demonstration of target engagement in early-phase trials are encouraging. Future studies will need to focus on confirming clinical efficacy, optimizing dosing regimens, and ensuring that the benefits are sustainable over the long term. Despite the challenges typical of antifibrotic therapies, GB0139’s molecular precision and targeted lung delivery provide a strong rationale for its continued evaluation as a disease-modifying intervention in IPF (Gaughan et al., 2021; Hirani et al., 2021; Spagnolo et al., 2020).


References:
Case Study: Development of GB0139 for Idiopathic Pulmonary Fibrosis. (n.d.). [Unpublished case study].

ClinicalTrials.gov. (n.d.). Clinical trials search: GB0139 OR TD139 OR galectin-3 inhibitor AND idiopathic pulmonary fibrosis [Web search]. Retrieved from https://clinicaltrials.gov/

Galecto Biotech AB. (2014). Randomized controlled trial of TD139 vs placebo in healthy volunteers and idiopathic pulmonary fibrosis patients [Clinical trial registration NCT02257177]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02257177

Galecto Biotech AB. (2019). A study to test the efficacy and safety of inhaled GB0139 in subjects with idiopathic pulmonary fibrosis (IPF) [Clinical trial registration NCT03832946]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03832946

Gaughan, E., Sethi, T., Quinn, T., Hirani, N., Mills, A., Bruce, A. M., MacKinnon, A., Aslanis, V., Li, F., O’Connor, R., Parker, R. A., Norrie, J., Dear, J., Akram, A. R., Koch, O., Wang-Jairaj, J., Slack, R. J., Gravelle, L., Lindmark, B., & Dhaliwal, K. (2021). GB0139, an inhaled small molecule inhibitor of galectin-3, in COVID-19 pneumonitis: A randomised, controlled, open-label, phase 2a experimental medicine trial of safety, pharmacokinetics, and potential therapeutic value. medRxiv. https://doi.org/10.1101/2021.12.21.21267983

Hirani, N., MacKinnon, A. C., Nicol, L., Ford, P., Schambye, H., Pedersen, A., Nilsson, U. J., Leffler, H., Sethi, T., Tantawi, S., Gravelle, L., Slack, R. J., Mills, R., Karmakar, U., Humphries, D., Zetterberg, F., Keeling, L., Paul, L., Molyneaux, P. L., … Maher, T. M. (2021). Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 57(6), Article 2002559. https://doi.org/10.1183/13993003.02559-2020

Miah, M. A. (2022). Molecular, cell and tissue studies of galectin-3: CD98 interactions in IPF and COVID pneumonitis. Unknown Journal.

Molina-Molina, M. (2019). The future of pharmacological treatment in idiopathic pulmonary fibrosis. Archivos de Bronconeumología (English Edition), 55, 642–647. https://doi.org/10.1016/j.arbr.2019.05.012

Senior, M. R. (2022). Fighting fibrosis. Nature Biotechnology, 40, 1169–1173. https://doi.org/10.1038/s41587-022-01412-0

Spagnolo, P., Bonella, F., Ryerson, C. J., Tzouvelekis, A., & Maher, T. M. (2020). Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 29, 797–808. https://doi.org/10.1080/13543784.2020.1782885",1.104183413,24
"KD025 (SLx-2119, Selleckchem S7258)","Proposal for KD025 (SLx-2119, Selleckchem S7258)

Overview of Therapeutic Candidate:
KD025 (also known as SLx-2119 or Belumosudil) is a synthetic small‐molecule inhibitor developed to selectively target Rho‐associated coiled‐coil containing protein kinase 2 (ROCK2). It belongs to the broader class of kinase inhibitors, more specifically the selective ROCK inhibitors, which have emerged over the past decade from structure–activity relationship studies and high‐throughput screening campaigns aimed at isolating molecules capable of discriminating between the ROCK isoforms. Unlike early pan‐ROCK inhibitors such as fasudil and Y-27632, which inhibit both ROCK1 and ROCK2 and have been previously used for vascular and fibrotic indications, KD025 has been optimized for isozyme selectivity with submicromolar potency against ROCK2 while sparing ROCK1. This selectivity is significant because ROCK2 has been implicated in the regulation of fibroblast actomyosin contractility—a key driver of stress fiber formation and extracellular matrix (ECM) contraction in fibrotic diseases like idiopathic pulmonary fibrosis (IPF). The compound is chemically derived through modern medicinal chemistry approaches, which incorporate iterative synthetic modifications and target-based optimization to achieve the desired potency and selectivity profile (Lv et al., 2019; Li et al., 2022).

Therapeutic History:
KD025 has already been evaluated in several clinical settings related to fibrosis and immune dysregulation. Preclinical studies in animal models, including bleomycin-induced lung fibrosis, have demonstrated that ROCK2 inhibition by KD025 reduces collagen deposition and fibroblast activation, which are critical features of fibrotic lung remodeling. Moreover, KD025’s safety and tolerability have been assessed in clinical trials targeting systemic sclerosis and chronic graft-versus-host disease (cGVHD), where its anti-fibrotic and immunomodulatory actions have been beneficial. Although direct clinical trial data in IPF are still emerging, a search of ClinicalTrials.gov identifies up to 36 clinical trials investigating KD025 or its synonyms in fibrotic conditions, including pulmonary fibrosis, which supports translational interest in this molecule for IPF treatment (ClinicalTrials.gov, n.d.; Knipe et al., 2018). In addition, earlier studies with non-selective ROCK inhibitors demonstrated beneficial effects in lung fibrosis models, further bolstering the rationale for using a selective inhibitor like KD025 in similar fibrotic disorders (Jiang et al., 2012; Knipe & Gosens, 2024).

Mechanism of Action:
At the molecular level, ROCK2 is a serine/threonine kinase that phosphorylates key substrates involved in actomyosin contractility, including myosin light chain (MLC) and myosin phosphatase target subunit-1 (MYPT1), thereby promoting stress fiber formation and enhancing cell contraction. KD025 binds selectively to ROCK2 with submicromolar inhibitory potency and prevents its catalytic activity, which in turn leads to a reduction in actin cytoskeletal rearrangements and decreased development of the contractile myofibroblast phenotype. Mechanistic studies show that ROCK2 inhibition attenuates TGF-β-induced signals by inhibiting the phosphorylation of downstream effectors and disrupting the feed-forward loop of cytokine release (including IL-17 and IL-21) mediated through STAT3, which is known to contribute to inflammatory and fibrotic processes (Mendoza & Jimenez, 2022; Yanagihara et al., 2021). In fibroblasts, ROCK2 has been specifically implicated in driving the differentiation to myofibroblasts, characterized by increased α-smooth muscle actin (αSMA) expression and enhanced extracellular matrix production; thus, by inhibiting ROCK2, KD025 disrupts these pathological changes (Ji et al., 2014; Knipe et al., 2018). The selective inhibition essentially “uncouples” the actomyosin contractility machinery in fibroblasts, leading to a state where cells are less capable of sustaining the mechanical forces required for stress fiber formation and matrix contraction—a hallmark in the pathogenesis of IPF (Lv et al., 2019; Lee et al., 2020).

Expected Effect:
In the proposed experimental model employing fibroblasts embedded in three-dimensional collagen gels, KD025 is hypothesized to abrogate ROCK2-mediated contractility. This will be evidenced by a decrease in stress fiber formation within fibroblasts, a reduction in αSMA expression, and thereby diminished gel contraction. The rationale for this expectation is rooted in preclinical models where selective ROCK inhibition via KD025 was shown to reduce fibroblast contractility and collagen deposition in bleomycin-induced lung fibrosis models. Because fibroblast actomyosin contraction is directly implicated in the progression and persistence of fibrosis in IPF, it is anticipated that KD025 will slow or even reverse the aberrant fibroblast phenotype, ultimately leading to a reduction in ECM accumulation and stabilization of lung architecture (Li et al., 2024; Knipe & Gosens, 2024; Spagnolo et al., 2020). Moreover, human safety data from systemic sclerosis trials suggest that KD025 is well tolerated in patients with fibrotic conditions, which supports its further exploration in IPF patients—an essential consideration given the chronic nature and high morbidity of IPF (ClinicalTrials.gov, n.d.; Lv et al., 2019).

Overall Evaluation:
Overall, KD025 represents a highly promising therapeutic candidate for the treatment of idiopathic pulmonary fibrosis based on its targeted mechanism and encouraging preclinical and early clinical profiles. One of the principal strengths of KD025 is its isozyme selectivity: by selectively inhibiting ROCK2 rather than both ROCK isoforms, KD025 is likely to mitigate the adverse side effects, such as systemic hypotension, that are commonly observed with pan-ROCK inhibitors. This selectivity not only augments its safety profile but also allows for a more precise modulation of the fibrotic pathways, particularly those involved in fibroblast contractility and extracellular matrix deposition. The candidate’s mechanism of action—disrupting Rho/ROCK2-mediated actomyosin contractility—is well supported by both genetic knockdown studies and pharmacologic inhibition data, which have demonstrated a reduction in fibrosis in animal models of lung injury (Knipe et al., 2018; Ji et al., 2014).

Furthermore, KD025 has a robust preclinical foundation: studies have shown that selective ROCK2 inhibition leads to decreased fibroblast differentiation, reduced stress fiber formation, and a lowering of αSMA expression. These effects are mechanistically linked to the suppression of TGF-β signaling pathways that potentiate fibrogenesis—a key feature in IPF pathogenesis (Mendoza & Jimenez, 2022; Li et al., 2024). The translational potential is further enhanced by the fact that KD025 has been well tolerated in human clinical trials aimed at other fibrotic diseases, such as systemic sclerosis and cGVHD, offering a level of confidence regarding its safety in human subjects (ClinicalTrials.gov, n.d.; Knipe & Gosens, 2024).

However, there are also weaknesses and challenges to consider. Although preclinical efficacy studies provide a strong rationale for KD025’s use in IPF, direct clinical data in IPF patients are still relatively sparse. The translation of antifibrotic efficacy from animal models, such as the bleomycin-induced pulmonary fibrosis model, to the human condition of IPF remains a significant hurdle, partly due to differences in disease pathology and progression between species (Spagnolo et al., 2020). Additionally, while KD025’s selectivity for ROCK2 minimizes certain side effects, long-term safety data specific to lung tissue—particularly in the context of compromised pulmonary function—are necessary to fully assess the risk–benefit profile in IPF patients. There is also a need for more extensive pharmacodynamic studies to establish the optimal dosing regimens that balance efficacy and safety in the fibrotic lung environment without compromising vascular function or causing off-target effects (Lv et al., 2019; Lee et al., 2020).

In summary, KD025’s capacity to modulate fibroblast behavior at a molecular level via selective ROCK2 inhibition offers a compelling strategy for reducing fibroblast contractility, stress fiber formation, and ultimately pathological ECM remodeling in IPF. Its proven preclinical antifibrotic effects, coupled with a favorable safety profile in related fibrotic conditions, position KD025 as a strong candidate for further clinical evaluation in the treatment of IPF. The strengths—in selectivity, mechanistic rationale, and preliminary clinical safety—outweigh the current gaps in direct IPF efficacy data, which can be addressed in future well-designed clinical trials. As such, KD025 merits further investment and development as a potential therapeutic agent aimed at alleviating the progression of idiopathic pulmonary fibrosis (ClinicalTrials.gov, n.d.; Knipe et al., 2018; Yanagihara et al., 2021).

References:
ClinicalTrials.gov. (n.d.). Search results for KD025 OR SLx-2119 OR belumosudil OR ROCK2 inhibitor AND (pulmonary fibrosis OR idiopathic pulmonary fibrosis) [Clinical trial search]. Retrieved from https://clinicaltrials.gov

Ji, H., Tang, H., Lin, H., Mao, J., Gao, L., Liu, J., & Wu, T. (2014). Rho/ROCK cross-talks with transforming growth factor-β/Smad pathway participates in lung fibroblast-myofibroblast differentiation. Biomedical Reports, 2(6), 787–792. https://doi.org/10.3892/br.2014.323

Jiang, C., Huang, H., Liu, J., Wang, Y., Lu, Z., & Xu, Z. (2012). Fasudil, a Rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice. International Journal of Molecular Sciences, 13(7), 8293–8307. https://doi.org/10.3390/ijms13078293

Knipe, R. S., Probst, C. K., Lagares, D., Franklin, A., Spinney, J. J., Brazee, P. L., Grasberger, P., Zhang, L., Black, K. E., Sakai, N., Shea, B. S., Liao, J. K., Medoff, B. D., & Tager, A. M. (2018). The Rho kinase isoforms ROCK1 and ROCK2 each contribute to the development of experimental pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology, 58, 471–481. https://doi.org/10.1165/rcmb.2017-0075oc

Knipe, R. S., & Gosens, R. (2024). Paving the rocky path to novel antifibrotics. American Journal of Respiratory Cell and Molecular Biology, 71, 381–382. https://doi.org/10.1165/rcmb.2024-0224ed

Lee, J. Y., Stevens, R. P., Kash, M., Zhou, C., Koloteva, A., Renema, P., Paudel, S. S., & Stevens, T. (2020). KD025 shifts pulmonary endothelial cell bioenergetics and decreases baseline lung permeability. American Journal of Respiratory Cell and Molecular Biology, 63, 519–530. https://doi.org/10.1165/rcmb.2019-0435oc

Li, Q., Cheng, Y., Zhang, Z., Bi, Z., Ma, X., Wei, Y., & Wei, X. (2022). Inhibition of ROCK ameliorates pulmonary fibrosis by suppressing M2 macrophage polarisation through phosphorylation of STAT3. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1036

Li, Y., Jiang, C., Zhu, W., Lu, S., Yu, H., & Meng, L. (2024). Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis. Science Progress. https://doi.org/10.1177/00368504241247402

Lv, M., Liu, Y., Ma, S., & Yu, Z. (2019). Current advances in idiopathic pulmonary fibrosis: The pathogenesis, therapeutic strategies and candidate molecules. Future Medicinal Chemistry, 11(19), 2595–2620. https://doi.org/10.4155/fmc-2019-0111

Mendoza, F. A., & Jimenez, S. A. (2022). Serine/threonine kinase inhibition as antifibrotic therapy: Transforming growth factor-β and Rho kinase inhibitors. Rheumatology, 61, 1354–1365. https://doi.org/10.1093/rheumatology/keab762

Spagnolo, P., Bonella, F., Ryerson, C. J., Tzouvelekis, A., & Maher, T. M. (2020). Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 29, 797–808. https://doi.org/10.1080/13543784.2020.1782885

Yanagihara, T., Scallan, C., Ask, K., & Kolb, M. R. J. (2021). Emerging therapeutic targets for idiopathic pulmonary fibrosis: Preclinical progress and therapeutic implications. Expert Opinion on Therapeutic Targets, 25, 939–948. https://doi.org/10.1080/14728222.2021.2006186",1.099861204,0
"GKT137831 (Setanaxib, Genkyotex)","Proposal for GKT137831 (Setanaxib, Genkyotex)

Overview of Therapeutic Candidate:
GKT137831, also known as Setanaxib, is a fully synthetic small-molecule compound developed by Genkyotex that belongs to the class of dual NADPH oxidase (NOX) inhibitors, specifically targeting the NOX1 and NOX4 isoforms. It was discovered through rational drug design approaches aimed at selectively inhibiting NOX enzymes that generate reactive oxygen species (ROS) as their primary function, rather than as by‐products of other enzymatic reactions. Unlike traditional antioxidants that simply scavenge ROS non-specifically, GKT137831 binds directly to the active sites of NOX1 and NOX4 with submicromolar potency—reportedly exhibiting Ki values in the range of 110–140 nM—thereby preventing the formation of ROS at its source (Green et al., 2012; Teixeira et al., 2017). The chemical structure of GKT137831 is based on the pyrazolopyridine dione scaffold, a class of compounds known for their favorable oral bioavailability and specificity toward oxidase enzymes (Teixeira et al., 2017). Historically, similar molecules within this structural class have been employed in various preclinical settings mostly to modulate oxidative stress–driven pathologies, and these compounds have shown promise in conditions characterized by excessive ROS production such as liver fibrosis, diabetic nephropathy, and cardiac remodeling. Given its synthetic origin and structural optimization, Setanaxib ideally fits the therapeutic strategy of targeting redox imbalance in diseases like Idiopathic Pulmonary Fibrosis (IPF), where overproduction of ROS by activated fibroblasts is a critical driver in disease progression (Thannickal et al., 2023).

Therapeutic History:
The dual inhibitory activity of GKT137831 on NOX1 and NOX4 has been extensively characterized in multiple preclinical models of fibrotic diseases. In liver fibrosis models induced by carbon tetrachloride or bile duct ligation, GKT137831 has been shown to significantly decrease collagen deposition, reduce α-smooth muscle actin (α-SMA) expression—a marker of myofibroblast activation—and improve overall fibrotic parameters (Aoyama et al., 2012). Similar antifibrotic effects have been observed in murine models of lung fibrosis where administration of Setanaxib resulted in diminished ROS production, lower myofibroblast differentiation, decreased TGF-β expression, and a reduction in extracellular matrix (ECM) accumulation following bleomycin challenge (Green et al., 2012; Teixeira et al., 2017). Preclinical studies in pulmonary hypertension models have further demonstrated that inhibition of NOX4 by GKT137831 can attenuate hypoxia-induced pulmonary vascular cell proliferation, normalize pulmonary artery remodeling, and decrease right ventricular hypertrophy (Green et al., 2012; Teixeira et al., 2017). In addition, early-phase clinical pharmacokinetic and safety studies conducted in healthy subjects and separate Phase II evaluations in diabetic chronic kidney disease have shown that Setanaxib is well tolerated in humans, providing a favorable safety profile that supports its further development (ClinicalTrials.gov, 2020; ClinicalTrials.gov, 2013). Although it has not yet been approved specifically for IPF, the literature indicates that its mechanism of NOX inhibition has been explored in conditions with a significant fibrotic component, including pulmonary fibrosis and related lung diseases (ClinicalTrials.gov, n.d.).

Mechanism of Action:
At the molecular level, NOX1 and NOX4 are enzymes whose primary role in cells is the generation of reactive oxygen species. In the context of lung fibrosis, these enzymes—particularly NOX4—are overexpressed in fibroblasts and alveolar epithelial cells from IPF patients, thus contributing to the redox imbalance that drives pathological fibrogenesis (Teixeira et al., 2017; Green et al., 2012). GKT137831 exerts its activity by selectively binding to and inhibiting the catalytic activity of NOX1 and NOX4, thereby reducing the conversion of oxygen to reactive oxygen species such as superoxide and hydrogen peroxide. This inhibition leads to a decrease in intracellular ROS concentration, which in turn disrupts the activation of redox-sensitive signaling cascades, notably those mediated by transforming growth factor-beta (TGF-β) (Teixeira et al., 2017; Thannickal et al., 2023). TGF-β is a central profibrotic cytokine that promotes fibroblast-to-myofibroblast differentiation, stimulates the synthesis of ECM proteins such as collagen and fibronectin, and induces cellular contractility. By attenuating ROS production, GKT137831 indirectly prevents the redox-driven activation of TGF-β, thereby reducing the downstream profibrotic responses such as α-SMA expression and ECM deposition (Green et al., 2012; Piera-Velázquez & Jimenez, 2021). Further mechanistic studies have suggested that NOX-derived ROS are critical mediators of TGF-β signaling and even participate in feedback loops that reinforce fibrotic signaling (Teixeira et al., 2017). The inhibition of NOX1/4 by GKT137831, therefore, interrupts these pathogenic cascades by lowering ROS levels and, as a consequence, reducing the activation of fibroblasts, their differentiation into contractile myofibroblasts, and the excessive production of ECM components, which are all hallmark features of IPF (Thannickal et al., 2023; Somanna et al., 2016).

Expected Effect:
Based on its biochemical mechanism, the proposed hypothesis for GKT137831 in the treatment of IPF is that it will target the elevated NOX4 expression in IPF fibroblasts, reducing ROS production and subsequent redox-driven activation of TGF-β. In a 3D fibroblast culture assay, it is expected that treatment with GKT137831 will result in significant reductions in ROS levels, lowered expression of α-SMA (a marker for myofibroblast differentiation), and decreased collagen deposition. These effects would be due to the compound’s ability to inhibit the ROS generating function of NOX1/4, thereby disrupting the feed-forward loop of TGF-β activation and fibroblast activation (Green et al., 2012; Teixeira et al., 2017). Studies in animal models have provided robust evidence that genetic deletion of NOX4 or pharmacological inhibition with GKT137831 leads to a reduction in pulmonary fibrosis and stabilization of lung function, suggesting that similar outcomes may be observed in an in vitro setting with IPF fibroblasts (Aoyama et al., 2012; Green et al., 2012). In these assays, one would measure outcomes such as decreased levels of fibrotic biomarkers (e.g., collagen I, fibronectin), reduced contractile activity in 3D collagen gels, and diminished secretion of profibrotic cytokines like TGF-β. Since NOX4 is known to be upregulated in lung tissue from IPF patients, the expected pharmacodynamics of GKT137831 suggest that it will normalize the redox state within the fibrotic lung microenvironment, thereby attenuating the cascade that normally leads to exacerbated ECM synthesis and tissue stiffening (Piera-Velázquez & Jimenez, 2021; Teixeira et al., 2017).

Overall Evaluation:
GKT137831 (Setanaxib) presents as a highly promising therapeutic candidate for the treatment of Idiopathic Pulmonary Fibrosis based on its mechanism of targeting the oxidative stress pathways that are critically involved in the disease pathology. One of the major strengths of this candidate is its selective inhibition of NOX1 and NOX4, which play a pivotal role in the generation of ROS and in the activation of signaling pathways that drive fibroblast activation and ECM production (Green et al., 2012; Teixeira et al., 2017). The compound has demonstrated efficacy in reducing fibrotic markers in multiple animal models—particularly in bleomycin-induced lung fibrosis models—as well as in pulmonary hypertension models, indicating a broad antifibrotic potential that extends to lung tissue (Teixeira et al., 2017; Thannickal et al., 2023). Furthermore, early clinical data from studies in conditions such as diabetic nephropathy provide reassurance regarding the safety profile of GKT137831, which is critical for its repurposing in IPF (ClinicalTrials.gov, 2013; ClinicalTrials.gov, 2020).

However, there are also challenges and weaknesses that need careful consideration. One potential concern is the complexity of ROS biology and the dual roles that NOX enzymes can play in cellular physiology. While NOX4 is a clear mediator of fibrotic signaling in the lung, there are instances in other tissues where NOX-derived ROS might have protective effects. The possibility of cell-type and context-specific responses to NOX inhibition must be taken into account, and this underlines the importance of precise dosing and careful monitoring of potential off-target effects (Teixeira et al., 2017; Thannickal et al., 2023). Moreover, while preclinical models (including genetic NOX4 deletion studies) offer strong support for the antifibrotic hypothesis, clinical efficacy in IPF patients remains to be definitively demonstrated, and ongoing or future Phase II/III clinical trials will be crucial in confirming whether the promising preclinical results translate to human benefit (ClinicalTrials.gov, n.d.).

In terms of its expected action in the proposed 3D fibroblast assays, the strength of the candidate lies in its ability to specifically reduce ROS production by NOX1/4 inhibition, which in turn is expected to blunt TGF-β activation—a central driver of myofibroblast differentiation and ECM overproduction. Such an effect could lead to a significant reversal of the fibrotic phenotype in vitro, providing an important proof-of-concept for further clinical applications in IPF (Green et al., 2012; Teixeira et al., 2017). On the other hand, weaknesses include the inherent variability in fibrotic pathways across different patients and disease stages, which may impact uniform responsiveness to NOX inhibition. Additionally, any long-term effects of inhibiting NOX enzymes on innate immune function or other ROS-dependent signaling pathways must be rigorously assessed in the context of chronic treatment.

Overall, the extensive preclinical evidence, combined with encouraging early clinical safety and pharmacokinetic data, makes GKT137831 a rational and attractive candidate for repurposing in Idiopathic Pulmonary Fibrosis. It targets a key element in the pathobiology of the disease—oxidative stress-mediated fibroblast activation—and interrupts the pathological feedback loop driven by TGF-β and ROS. While some open questions remain regarding the long-term impact of NOX inhibition in the lung and potential compensatory mechanisms, the strengths of the candidate—in terms of selectivity, preclinical efficacy in relevant fibrotic models, and an established safety profile from other indications—provide a compelling argument to pursue further clinical trials in IPF patients (Aoyama et al., 2012; Teixeira et al., 2017; Thannickal et al., 2023).

In conclusion, as an expert drug development team leader focused on validating repurposed drugs for IPF, I find that GKT137831 (Setanaxib) exhibits a sound mechanistic rationale, robust preclinical efficacy in models mimicking human pulmonary fibrosis, and a safety profile that supports further investigation in this challenging therapeutic area. The candidate’s ability to reduce NOX-mediated ROS and thereby attenuate TGF-β-induced ECM production positions it well against the underlying drivers of fibrosis in IPF. Nonetheless, careful evaluation in well-designed clinical trials will be essential to fully establish its therapeutic benefit in IPF patients and to address any potential issues related to long-term inhibition of ROS-generating pathways (Bernard & Thannickal, 2020; Piera-Velázquez & Jimenez, 2021).

References
Aoyama, T., Paik, Y.-H., Watanabe, S., Laleu, B., Gaggini, F., Fioraso-Cartier, L., Molango, S., Heitz, F., Merlot, C., Szyndralewiez, C., Page, P., & Brenner, D. A. (2012). Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology, 56, 2316–2327. https://doi.org/10.1002/hep.25938

Bernard, K., & Thannickal, V. J. (2020). NADPH oxidase inhibition in fibrotic pathologies. Antioxidants & Redox Signaling, 33, 455–479. https://doi.org/10.1089/ars.2020.8032

Calliditas Therapeutics AB. (2013). Safety and efficacy of oral GKT137831 in patients with type 2 diabetes and albuminuria (NCT02010242). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02010242

ClinicalTrials.gov. (n.d.). ClinicalTrials.gov search for GKT137831 OR Setanaxib OR Genkyotex AND idiopathic pulmonary fibrosis OR IPF OR pulmonary fibrosis OR lung fibrosis. Retrieved from https://clinicaltrials.gov/ct2/results?cond=&term=GKT137831+OR+Setanaxib+OR+Genkyotex+AND+idiopathic+pulmonary+fibrosis+OR+IPF+OR+pulmonary+fibrosis+OR+lung+fibrosis

Green, D. E., Murphy, T. C., Kang, B.-Y., Kleinhenz, J. M., Szyndralewiez, C., Page, P., Sutliff, R. L., & Hart, C. M. (2012). The NOX4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. American Journal of Respiratory Cell and Molecular Biology, 47, 718–726. https://doi.org/10.1165/rcmb.2011-0418OC

Piera-Velázquez, S., & Jimenez, S. (2021). Oxidative stress induced by reactive oxygen species (ROS) and NADPH oxidase 4 (NOX4) in the pathogenesis of the fibrotic process in systemic sclerosis: A promising therapeutic target. Journal of Clinical Medicine, 10. https://doi.org/10.3390/jcm10204791

Somanna, N. K., Valente, A. J., Krenz, M., Fay, W. P., Delafontaine, P., & Chandrasekar, B. (2016). The NOX1/4 dual inhibitor GKT137831 or NOX4 knockdown inhibits angiotensin II-induced adult mouse cardiac fibroblast proliferation and migration: AT1 physically associates with NOX4. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.25210

Teixeira, G., Szyndralewiez, C., Molango, S., Carnésecchi, S., Heitz, F., Wiesel, P., & Wood, J. M. (2017). Therapeutic potential of NADPH oxidase 1/4 inhibitors. British Journal of Pharmacology, 174, 1647–1669. https://doi.org/10.1111/bph.13532

Thannickal, V. J., Jandeleit-Dahm, K., Szyndralewiez, C., & Török, N. J. (2023). Pre-clinical evidence of a dual NADPH oxidase 1/4 inhibitor (Setanaxib) in liver, kidney and lung fibrosis. Journal of Cellular and Molecular Medicine, 27, 471–481. https://doi.org/10.1111/jcmm.17649

University of Alabama at Birmingham. (2020). GKT137831 in IPF patients with idiopathic pulmonary fibrosis (NCT03865927). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03865927",1.00111794,18
"CC-90001 (JNK Inhibitor, Celgene)","Proposal for CC-90001 (JNK Inhibitor, Celgene)

Overview of Therapeutic Candidate:
CC-90001 is a small‐molecule, orally bioavailable inhibitor developed by Celgene (now under Bristol-Myers Squibb) that targets the c-Jun N-terminal kinase (JNK) family of serine/threonine kinases with a pronounced selectivity for the JNK1 and JNK2 isoforms (Luppi & Ferrara, 2024; Popmihajlov et al., 2022). Its synthesis arose through an iterative medicinal chemistry program aimed at optimizing selectivity for the ATP-binding pocket of JNK enzymes at nanomolar concentrations while reducing the hepatotoxicity and other adverse events observed with earlier compounds such as CC-930 (Fragni, 2022; Kolb et al., 2017). Belonging to the class of kinase inhibitors that have traditionally been deployed in oncology and inflammatory disorders, CC-90001 represents a second-generation candidate intended to perturb aberrant intracellular signaling driving fibrogenesis (ClinicalTrials.gov, n.d.; Luppi & Ferrara, 2024). Its design exploits the structural features of the JNK kinase domain by incorporating chemical functionality that permits competitive binding within the ATP pocket; in doing so, it efficiently blocks critical phosphorylation events necessary for downstream signaling in both epithelial cells and fibroblasts implicated in idiopathic pulmonary fibrosis (IPF).

Therapeutic History:
The development history of CC-90001 is closely tied to the evolution of JNK inhibitors for fibrotic conditions, particularly IPF. Early clinical candidates, such as CC-930, laid foundational evidence by demonstrating that inhibition of JNK could lead to reductions in plasma biomarkers (for example, matrix metalloproteinase-7 (MMP-7) and surfactant protein-D (SP-D)) and stabilization of forced vital capacity (FVC) in patients with IPF (Popmihajlov et al., 2022; van der Velden et al., 2016). Although CC-930 showed promising antifibrotic activity in preclinical bleomycin-induced pulmonary fibrosis models with measurable reductions in collagen deposition and α-smooth muscle actin (α-SMA), its clinical progression was hampered by dose-dependent liver enzyme elevations (Popmihajlov et al., 2022; van der Velden et al., 2016). These limitations spurred the rational optimization that culminated in CC-90001, a compound chemically refined to retain potent inhibition of JNK while improving its safety profile. CC-90001 has since advanced into Phase II clinical evaluation for both IPF and related progressive fibrotic interstitial lung diseases (PF-ILD), reinforcing its potential as a repurposed therapeutic candidate for these challenging conditions (ClinicalTrials.gov, n.d.; Celgene, 2017).

Mechanism of Action:
At a molecular level, CC-90001 exerts its effects by binding competitively to the ATP-binding site on JNK1 and JNK2 isoforms, thereby inhibiting their kinase activity (Popmihajlov et al., 2022). Under normal physiological and pathologic conditions, JNKs phosphorylate the transcription factor c-Jun, which forms a component of the activator protein-1 (AP-1) complex; once activated, AP-1 promotes the transcription of a host of profibrotic genes involved in fibroblast proliferation, myofibroblast differentiation, and extracellular matrix production (Lin et al., 2018; Hou et al., 2021). In IPF, the profibrotic cytokine transforming growth factor-beta (TGF-β) remains a central driver of fibrogenesis, acting not only through canonical Smad-dependent pathways but also via non-SMAD signaling mechanisms such as those mediated by JNK (Kolb et al., 2017). By blocking the JNK pathway, CC-90001 effectively reduces the phosphorylation of c-Jun, thus interfering with the transactivation of genes that lead to fibroblast activation, overproduction of collagen type I, and the expression of α-SMA—markers indicative of myofibroblast differentiation (Popmihajlov et al., 2022; Lin et al., 2018). This inhibition translates into a dampened fibrotic response; preclinical studies in 3D collagen matrices have shown that JNK inhibitors can reduce fibroblast contractility, a phenotype central to the pathophysiology of fibrotic tissue remodeling in IPF (Hou et al., 2021). Furthermore, evidence from both human lung tissue and relevant animal models indicates that JNK activity is elevated in the pathologic milieu of IPF, highlighting the effectiveness of CC-90001 in targeting a central node of the disease process (van der Velden et al., 2020; Popmihajlov et al., 2022).

Expected Effect:
The central hypothesis for employing CC-90001 in IPF is that inhibition of JNK-mediated non-SMAD TGF-β signaling will have multiple beneficial impacts on the cellular and molecular pathology of the disease. In cell-based assays employing primary human lung fibroblasts or airway epithelial cells—which are known to robustly express TGF-β and its receptors—the drug is anticipated to lower the phosphorylation levels of c-Jun; this should lead to a downstream reduction in the expression of profibrotic markers such as α-SMA and collagen type I (Lin et al., 2018; Popmihajlov et al., 2022). In three-dimensional collagen gel contraction assays, which recapitulate the in vivo microenvironment of fibrotic lung tissue, treatment with CC-90001 is expected to diminish fibroblast proliferation and contractility, thereby reducing the formation of a contractile myofibroblast phenotype that characterizes progressive fibrosis (Popmihajlov et al., 2022; van der Velden et al., 2016). Additionally, by interfering with the propagation of profibrotic signals, CC-90001 would be expected to stabilize or improve lung function parameters such as FVC, as observed in prior clinical investigations with related compounds (Popmihajlov et al., 2022; ClinicalTrials.gov, n.d.). The anticipated reduction in fibrotic biomarkers, including extracellular matrix proteins and cytokines such as MMP-7 and tenascin-C, would offer supportive evidence for the antifibrotic activity of the drug, which in turn could slow or even partially reverse the fibrotic remodeling in the lung (van der Velden et al., 2020; Popmihajlov et al., 2022).

Overall Evaluation:
CC-90001 emerges as a promising therapeutic candidate for the treatment of idiopathic pulmonary fibrosis, buoyed by a strong biochemical rationale and supported by a combination of preclinical and early clinical data. One of the primary strengths of this candidate lies in its high selectivity and potent inhibition of the JNK1 and JNK2 enzymes at nanomolar concentrations, which directly disrupts a critical non-SMAD signaling pathway that underpins TGF-β-induced fibrogenesis (Kolb et al., 2017; Lin et al., 2018). Preclinical studies have repeatedly shown that blockade of JNK activity results in decreased phosphorylation of c-Jun, leading to reduced fibroblast proliferation and myofibroblast differentiation—key pathological events in IPF (Popmihajlov et al., 2022; Hou et al., 2021). Moreover, the transition from earlier generation compounds such as CC-930 to CC-90001 highlights an iterative improvement meant to alleviate safety concerns, particularly hepatotoxicity, while retaining antifibrotic efficacy (Fragni, 2022; van der Velden et al., 2016).

The expected downstream effects of CC-90001 are multifaceted. Its ability to decrease c-Jun phosphorylation disrupts a cascade of transcriptional events that contribute to extracellular matrix deposition and the establishment of the myofibroblast phenotype. As such, in vitro assays have demonstrated the ability of JNK inhibitors to reduce markers like α-SMA and collagen I, which are tightly correlated with disease progression in IPF (Popmihajlov et al., 2022; Lin et al., 2018). In three-dimensional culture systems that mimic the in vivo lung architecture, CC-90001 is anticipated to reduce fibroblast contractility and proliferation, which should translate into stabilization of lung function—as measured by FVC—in clinical settings. Importantly, the clinical advancement of CC-90001 into Phase II studies for IPF and PF-ILD provides real‐world validation for its translational potential (ClinicalTrials.gov, n.d.; Celgene, 2017).

Nevertheless, some challenges remain. The experience with CC-930 underscores the need for careful monitoring of hepatotoxicity, and while chemical refinements in CC-90001 appear to have mitigated these issues, longer-term safety data will be critical (van der Velden et al., 2016). Furthermore, the complex biology of IPF, marked by a heterogeneous and multifactorial pathogenesis that involves both SMAD‐dependent and independent pathways of TGF-β signaling, suggests that targeting JNK alone may not fully reverse the fibrotic process. There is a possibility of compensatory activation of other profibrotic cascades, which could necessitate combination therapy strategies with currently approved antifibrotic agents such as pirfenidone and nintedanib (Kolb et al., 2017; ClinicalTrials.gov, n.d.). In addition, the heterogeneity of lung fibrotic diseases poses a challenge in demonstrating broad efficacy across diverse patient subgroups. A robust biomarker strategy, incorporating parameters such as MMP-7, SP-D, and tenascin-C, will be essential to discern subpopulations that may derive the greatest benefit from CC-90001 (Popmihajlov et al., 2022; van der Velden et al., 2020).

On a mechanistic level, evidence from preclinical studies using genetic ablation of JNK1 in airway epithelial cells supports the notion that epithelial JNK activity is critical for driving fibrotic remodeling (van der Velden et al., 2020). These studies indicate that JNK inhibition not only attenuates fibrosis by directly impacting fibroblast function but also modulates epithelial cell plasticity, which contributes to the epithelial-to-mesenchymal transition (EMT) that is a hallmark of IPF pathology. This dual targeting—affecting both fibroblasts and epithelial cells—strengthens the therapeutic rationale behind CC-90001 (van der Velden et al., 2020; Popmihajlov et al., 2022).

In summary, CC-90001 is a well-rationalized, second-generation JNK inhibitor that directly addresses key pathological mechanisms underlying IPF by inhibiting non-SMAD TGF-β signaling and reducing c-Jun phosphorylation, fibroblast proliferation, and myofibroblast differentiation. Its chemical refinement from earlier compounds has resulted in improved selectivity and a more favorable safety profile, while preclinical data robustly support its antifibrotic potential in both cellular models and animal studies (Popmihajlov et al., 2022; van der Velden et al., 2016). Early clinical trial data further reinforce its potential utility in mitigating fibrosis and stabilizing lung function in IPF patients (Celgene, 2017; ClinicalTrials.gov, n.d.). However, long-term safety, particularly concerning hepatotoxicity, and the need to address potential compensatory pathways in the complex profibrotic signaling network remain areas requiring continued investigation. Ultimately, with a combination of robust mechanistic insights and promising initial clinical signals, CC-90001 holds considerable promise as a novel therapeutic agent in IPF. Its integration into combination therapy regimens may further enhance its clinical impact by complementing existing antifibrotic drugs to address this devastating disease more comprehensively (Kolb et al., 2017; Popmihajlov et al., 2022; ClinicalTrials.gov, n.d.).

References
Celgene. (2017). A study to evaluate the efficacy and safety of CC-90001 in subjects with idiopathic pulmonary fibrosis [Clinical trial registration]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03142191

ClinicalTrials.gov. (n.d.). Search for CC-90001 [(AREA[InterventionName]CC-90001 OR (AREA[Condition]Idiopathic Pulmonary Fibrosis AND AREA[InterventionName]JNK inhibitor))]. Retrieved from https://clinicaltrials.gov

Fragni, D. (2022). Identification of novel readouts to assess anti-fibrotic efficacy of new compounds in a bleomycin-induced pulmonary fibrosis mouse model. Unknown Journal.

Hou, T.-Y., Wu, S.-B., Kau, H.-C., & Tsai, C.-C. (2021). JNK and p38 inhibitors prevent transforming growth factor-β1-induced myofibroblast transdifferentiation in human Graves’ orbital fibroblasts. International Journal of Molecular Sciences, 22(6), 2952. https://doi.org/10.3390/ijms22062952

Kolb, M., Bonella, F., & Wollin, L. (2017). Therapeutic targets in idiopathic pulmonary fibrosis. Respiratory Medicine, 131, 49–57. https://doi.org/10.1016/j.rmed.2017.07.062

Lin, C.-H., Shih, C.-H., Lin, Y.-C., Yang, Y.-L., & Chen, B.-C. (2018). Mekk1, JNK, and Smad3 mediate CXCL12-stimulated connective tissue growth factor expression in human lung fibroblasts. Journal of Biomedical Science. https://doi.org/10.1186/s12929-018-0421-9

Luppi, F., & Ferrara, G. (2024). “A mighty flame can follow a tiny spark”: Is this the case of c-jun n-terminal kinase 1 inhibitors in idiopathic pulmonary fibrosis? American Journal of Respiratory and Critical Care Medicine, 210, 376–377. https://doi.org/10.1164/rccm.202403-0574ed

Popmihajlov, Z., Sutherland, D. J., Horan, G., Ghosh, A., Lynch, D., Noble, P., Richeldi, L., Reiss, T., & Greenberg, S. (2022). CC-90001, a c-jun n-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: Design of a phase 2, randomized, placebo-controlled trial. BMJ Open Respiratory Research, 9(1), e001060. https://doi.org/10.1136/bmjresp-2021-001060

van der Velden, J. L. J., Ye, Y., Nolin, J. D., Hoffman, S. M., Chapman, D. G., Lahue, K. G., Abdalla, S., Chen, P., Liu, Y., Bennett, B., Khalil, N., Sutherland, D., Smith, W., Horan, G., Assaf, M., Horowitz, Z., Chopra, R., Stevens, R. M., … & Schafer, P. H. (2016). JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. Clinical and Translational Medicine, 5, Article 43. https://doi.org/10.1186/s40169-016-0117-2

van der Velden, J., Alcorn, J. F., Chapman, D. G., Lundblad, L. K. A., Irvin, C. G., Davis, R. J., Butnor, K., & Janssen-Heininger, Y. M. W. (2020). Airway epithelial specific deletion of jun-n-terminal kinase 1 attenuates pulmonary fibrosis in two independent mouse models. PLOS ONE, 15(1), e0226904. https://doi.org/10.1371/journal.pone.0226904",0.921635341,23
BMS-986278 (Bristol-Myers Squibb),"Proposal for BMS-986278 (Bristol-Myers Squibb)

Overview of Therapeutic Candidate:
BMS-986278 is an orally administered, synthetic small-molecule antagonist developed by Bristol-Myers Squibb, specifically designed to target the lysophosphatidic acid receptor 1 (LPA1). This compound represents a second-generation molecule emerging from earlier efforts embodied by BMS-986020, the first-generation LPA1 antagonist that demonstrated proof-of-concept antifibrotic effects in idiopathic pulmonary fibrosis (IPF) but was ultimately limited by hepatobiliary toxicity. BMS-986278 was engineered to overcome those safety concerns while maintaining nanomolar affinity and high target specificity for the LPA1 receptor, a critical mediator of fibroblast chemotaxis and activation. As a synthetic small-molecule drug in the LPA receptor antagonist class, BMS-986278 exploits a mechanism that has been well-characterized in preclinical models; compounds from this class have previously been studied for their ability to modulate aberrant wound healing and fibrotic remodeling in lung tissues. Given the synthetic origin of these molecules, they can be optimized for improved pharmacokinetic (PK) profiles and oral bioavailability, which is crucial in a chronic disease setting such as IPF (Corte et al., 2021; Decato et al., 2022; Lin et al., 2021).

Therapeutic History:
Historically, the use of LPA1 receptor antagonists has been evaluated within both preclinical and early clinical research programs focused on fibrotic diseases. The initial candidate, BMS-986020, was notably studied in a phase II trial in IPF patients, where it was found to significantly reduce the decline in forced vital capacity (FVC); however, its clinical development was curtailed because of hepatobiliary adverse events that were linked to off-target inhibition of liver transporters such as BSEP and MDR3. Such findings solidified the hypothesis that selective inhibition of LPA1 could yield antifibrotic benefits in IPF by curtailing fibroblast recruitment and activation, but that molecular modifications were required to mitigate toxicity. BMS-986278 builds upon this historical background—it has been designed with structural modifications that avoid interference with liver transporters, as confirmed in preclinical and phase I studies that demonstrated an acceptable safety profile in healthy volunteers and in the early evaluation for IPF (Decato et al., 2022; Corte et al., 2021; MacIsaac et al., 2024). In addition, the LPA1 antagonist class—beyond their application in lung fibrosis—has been studied in a variety of fibrotic conditions, reflecting a broader therapeutic history in modulating extracellular matrix deposition and fibroblast behavior. While BMS-986278 itself is primarily being developed for IPF and progressive fibrotic interstitial lung diseases (PF-ILD), its lineage and the wealth of preclinical biochemical data supporting the role of LPA1 in fibrogenesis provide a compelling rationale for its further development (ClinicalTrials.gov, n.d.; Corte et al., 2021).

Mechanism of Action:
The molecular mechanism by which BMS-986278 is hypothesized to act centers on the blockade of LPA1-mediated signaling pathways. LPA (lysophosphatidic acid) is a bioactive phospholipid that exerts diverse biological effects by binding to a family of six G protein-coupled receptors (LPAR1–6). Among these, LPAR1 is critically implicated in the pathogenesis of IPF: its activation on fibroblasts facilitates chemotaxis towards the sites of lung injury, enhances fibroblast survival by conferring resistance to apoptosis, and promotes differentiation into myofibroblasts characterized by high levels of α-smooth muscle actin (α-SMA) expression. This receptor signaling cascade further influences cytoskeletal dynamics and contributes to three-dimensional matrix contraction—a key driver of fibrotic remodeling in lung tissue (Lin et al., 2021; Corte et al., 2021).

Mechanistically, BMS-986278 binds to LPA1 with nanomolar affinity, thereby inhibiting the receptor’s activation by LPA. This inhibition prevents the downstream recruitment and activation of fibroblasts, ultimately reducing the accumulation of activated myofibroblasts responsible for collagen deposition and extracellular matrix (ECM) remodeling. Preclinical studies have indicated that selective LPA1 blockade not only reduces fibroblast chemotaxis but also attenuates the expression of α-SMA and other markers of myofibroblast differentiation. Moreover, by interfering with specific signaling intermediates—such as the Rho/ROCK pathway, as well as additional cascades like PI3K/AKT and MAPK that regulate cell proliferation and survival—BMS-986278 is expected to reduce the excessive fibroblast contractility and 3D matrix contraction that drive progressive fibrotic scarring (Corte et al., 2021; Korfei et al., 2022; Nakamura & Shimizu, 2023). This precise targeting is critical because LPA1-mediated pathways have been shown to be overexpressed and hyperactive in IPF lung tissues, particularly in fibroblasts and the fibrotic microenvironment, validating the receptor as a driver of aberrant fibrogenesis (Lin et al., 2021).

Expected Effect:
The central hypothesis posits that BMS-986278 will attenuate IPF by effectively blocking LPA1-mediated fibroblast chemotaxis, survival signaling, and cytoskeletal activation. In practical assays such as those evaluating fibroblast-mediated gel contraction, BMS-986278 is expected to reduce the expression of key fibrogenic markers, including α-SMA, and decrease the contractile force exerted by myofibroblasts on three-dimensional collagen matrices. The reduction in fibroblast recruitment and survival is anticipated to translate into a measurable decrease in extracellular matrix deposition and lung stiffness, ultimately slowing the decline in pulmonary function as reflected by stabilization or slower reduction in forced vital capacity (FVC) in clinical studies. Preclinical models have been instrumental in establishing that genetic deletion of LPA1 confers protection against bleomycin-induced lung fibrosis, and pharmacologic inhibition in such models has been correlated with reductions in key biomarkers of fibrosis (Corte et al., 2021; Lin et al., 2021; Murgo, 2024). In patient-derived samples, elevated levels of LPA in bronchoalveolar lavage fluid and increased expression of LPA1 on fibroblasts substantiate the rationale that targeted inhibition of this receptor will address a central pathological process in IPF (MacIsaac et al., 2024; Nakamura & Shimizu, 2023). Thus, in the assay proposed by the research team, a reduction in fibroblast contractility and attenuation in myofibroblast activation are the expected endpoints that would support the therapeutic hypothesis of BMS-986278.

Overall Evaluation:
BMS-986278 displays promising potential as a therapeutic candidate for IPF based on a convergence of synthetic optimization, mechanistic rationale, and early clinical safety data. The strengths of BMS-986278 lie in its target specificity and oral bioavailability, which are particularly attractive features for a chronic progressive disease like IPF. The compound’s design, refined from the earlier BMS-986020 candidate, aims to overcome hepatobiliary toxicities while retaining potent inhibition of LPA1-mediated fibroblast activation (Decato et al., 2022). Its favorable pharmacokinetic properties in healthy volunteers and encouraging early phase data signal that it may provide effective target engagement in patients. The mechanistic basis for its use is strong: by interrupting LPA1 signaling, BMS-986278 is expected to diminish fibroblast chemotaxis, survival, and contractility—key drivers of fibrosis—which are supported by both in vitro studies of α-SMA expression and gel contraction assays, as well as by genetic models showing that LPA1 deletion protects against fibrotic injury (Corte et al., 2021; Lin et al., 2021; Nakamura & Shimizu, 2023).

Nevertheless, the candidate is not without limitations. Although early phase studies in healthy volunteers and preliminary IPF trials have shown promising safety and PK profiles, the true clinical efficacy, particularly in terms of long-term outcomes in a heterogeneous patient population, remains to be confirmed in robust phase II/III trials (MacIsaac et al., 2024; Corte et al., 2021). The inherent complexity of IPF pathobiology, characterized by multiple redundant and compensatory fibrotic pathways, poses a risk that LPA1 antagonism alone may not fully arrest disease progression without combination with other antifibrotic agents. Moreover, while the avoidance of hepatobiliary toxicity is an improvement over previous compounds, the potential for off-target effects and variations in patient response due to genetic and lipid metabolic differences must be carefully monitored during advanced clinical development (Murgo, 2024; Nakamura & Shimizu, 2023).

In summary, BMS-986278 represents a well-rationalized, mechanism-based therapeutic approach with significant promise in attenuating the fibrotic processes underlying IPF. Its design as a selective LPA1 receptor antagonist enables it to target a critical driver of fibroblast recruitment and activation, potentially reducing myofibroblast tension and 3D matrix contraction, which are central to disease progression. The accumulated preclinical evidence, coupled with encouraging early clinical safety and PK data, supports further development of BMS-986278 in tailored phase II/III trials. However, definitive proof of its clinical efficacy will depend on its performance in long-term, large-scale studies that address the disease’s inherent heterogeneity and complex molecular underpinnings. Continued biomarker development and careful patient stratification may further enhance the therapeutic index of BMS-986278 in IPF, thereby potentially filling a significant unmet need in a disease area where current approved therapies offer only modest benefits (Corte et al., 2021; MacIsaac et al., 2024; Murgo, 2024).

References
ClinicalTrials.gov. (n.d.). Clinical trial search: BMS-986278 OR LPA1 antagonist AND idiopathic pulmonary fibrosis. Retrieved from https://clinicaltrials.gov
Corte, T., Lancaster, L., Swigris, J., Maher, T., Goldin, J., Palmer, S., Suda, T., Ogura, T., Minnich, A., Zhan, X., Tirucherai, G., Elpers, B., Xiao, H., Watanabe, H., Smith, R. A., Charles, E., & Fischer, A. (2021). Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respiratory Research, 8(1), e001026. https://doi.org/10.1136/bmjresp-2021-001026
Decato, B. E., Leeming, D. J., Sand, J. M. B., Fischer, A., Du, S., Palmer, S. M., Karsdal, M., Luo, Y., & Minnich, A. (2022). LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis. Respiratory Research, 23, 119. https://doi.org/10.1186/s12931-022-01980-4
Korfei, M., Mahavadi, P., & Guenther, A. (2022). Targeting histone deacetylases in idiopathic pulmonary fibrosis: A future therapeutic option. Cells, 11(10), 1626. https://doi.org/10.3390/cells11101626
Lin, Y.-H., Lin, Y.-C., & Chen, C.-C. (2021). Lysophosphatidic acid receptor antagonists and cancer: The current trends, clinical implications, and trials. Cells, 10(7), 1629. https://doi.org/10.3390/cells10071629
MacIsaac, S., Somboonviboon, D., Scallan, C., & Kolb, M. (2024). Treatment of idiopathic pulmonary fibrosis: An update on emerging drugs in phase II & III clinical trials. Expert Opinion on Emerging Drugs, 29(2), 177–186. https://doi.org/10.1080/14728214.2024.2340723
Murgo, A. (2024). Characterization and evaluation of clinically relevant readouts in a pre-clinical model of idiopathic pulmonary fibrosis (IPF). Unknown Journal.
Nakamura, Y., & Shimizu, Y. (2023). Cellular and molecular control of lipid metabolism in idiopathic pulmonary fibrosis: Clinical application of the lysophosphatidic acid pathway. Cells, 12(4), 548. https://doi.org/10.3390/cells12040548",0.912710988,29
X203 (Anti–IL-11 Monoclonal Antibody),"Proposal for X203 (Anti–IL-11 Monoclonal Antibody)

Overview of Therapeutic Candidate:
X203 is a neutralizing monoclonal antibody (mAb) designed to target interleukin‐11 (IL-11), a cytokine implicated in the fibrotic process in idiopathic pulmonary fibrosis (IPF). IL-11 belongs to the IL-6 cytokine family; however, it drives pathology through distinct noncanonical signaling pathways. X203 is engineered to bind IL-11 with subnanomolar affinity, thereby neutralizing its activity and preventing downstream activation of fibroblasts. This candidate was identified through in vitro and in vivo studies that demonstrated that IL-11 is overexpressed in fibrotic lung tissues and that fibroblast-specific IL-11 signaling is a driving force behind excessive extracellular matrix (ECM) deposition and tissue remodeling. As a biologic, X203 is produced using recombinant antibody technology in appropriate expression systems (e.g., CHO cells) and purified to meet the stringent quality requirements for therapeutic use. Monoclonal antibodies as a class have been extensively used in various fields of medicine, including oncology, autoimmune diseases, and inflammatory processes, due to their high target specificity and relatively favorable safety profiles compared to small molecule inhibitors (Kortekaas et al., 2021; Cook & Schafer, 2020).

Therapeutic History:
The therapeutic strategy of using monoclonal antibodies to target cytokines is well established. For instance, anti-TNF therapies and IL-6 receptor antibodies have transformed the treatment of autoimmune diseases. X203, as an anti–IL-11 antibody, represents a novel extension of this approach into fibrotic lung diseases. Historically, recombinant IL-11 was used for hematopoietic support to treat chemotherapy-induced thrombocytopenia; however, subsequent studies revealed that in rodent systems, recombinant human IL-11 was not only biologically inactive but paradoxically inhibitory to endogenous murine IL-11 signaling (Braga et al., 2024; Cook & Schafer, 2020). More recent investigations have reoriented focus toward IL-11 as a central mediator of fibrosis. In models of IPF and other fibrotic conditions, IL-11 upregulation has been consistently observed, and blockade of its signaling—through genetic deletion or antibody neutralization—has led to marked reductions in fibroblast activation and extracellular matrix accumulation (Ng et al., 2019; Kortekaas et al., 2021). Preclinical work, including studies utilizing anti–IL-11 strategies such as X203, has provided compelling evidence that targeting IL-11 can reverse fibrosis in both cardiac and pulmonary models. Although X203 itself has not yet achieved broad clinical use for IPF, its mechanism and in vivo performance in relevant animal models position it as a promising candidate for repurposing in this disease area (Ng et al., 2019; Kortekaas et al., 2021).

Mechanism of Action:
IL-11 is generally produced at low levels in healthy tissues but is dramatically upregulated in fibrotic diseases such as IPF. It is secreted primarily by damaged lung epithelial cells and activated fibroblasts. Following secretion, IL-11 binds to its cognate alpha receptor (IL-11Rα), which is expressed predominantly on lung fibroblasts, smooth muscle cells, and certain populations of epithelial cells. This binding triggers the formation of a receptor complex with the ubiquitously expressed gp130, a step that ultimately activates downstream signaling pathways. Although classical IL-6 family cytokine signaling often involves the JAK/STAT pathway, IL-11 appears to elicit its pro-fibrotic responses primarily via noncanonical mechanisms, especially the activation of the MEK/ERK cascade. This ERK pathway activation is critical; it drives fibroblast differentiation into myofibroblasts, increases the production of collagen (primarily collagen type I) and other ECM components, and promotes cell survival and invasive behavior in fibroblasts (Ng et al., 2020; Kortekaas et al., 2021). Notably, studies have shown that IL-11 induces only minimal transcriptional changes in fibroblasts but instead leads to a translational upregulation of profibrotic proteins, a phenomenon that is mediated by sustained ERK activation (Ng et al., 2020; Ng et al., 2019).
X203 acts by binding to IL-11, thereby preventing its interaction with IL-11Rα. This blockade inhibits the receptor complex formation required for downstream signaling through both ERK and, in some contexts, STAT pathways. As a result, the cascade that leads to fibroblast activation and excessive ECM deposition is effectively interrupted. Preclinical data indicate that treatment with X203 reduces the levels of α-smooth muscle actin (αSMA) and collagen I in vitro, correlating with diminished fibroblast contractility and matrix production in three-dimensional (3D) assays (Ng et al., 2019; Kortekaas et al., 2021). Additionally, by neutralizing IL-11, X203 may also attenuate the maladaptive epithelial-mesenchymal crosstalk that contributes to impaired alveolar regeneration—a hallmark of IPF pathology (Kortekaas et al., 2023; Ng et al., 2022).

Expected Effect:
In the context of the proposed assays and the overall pathogenesis of IPF, X203 is expected to yield several beneficial effects. First, by neutralizing IL-11, it should block the pro-fibrotic signal responsible for driving fibroblast activation. Fibroblasts in IPF display a highly activated phenotype characterized by the expression of αSMA, excessive collagen production, and increased motility and invasiveness. In vitro assays have demonstrated that treatment with X203 leads to a significant reduction in these markers. For example, αSMA and collagen I levels decrease, which is indicative of inhibiting the fibroblast-to-myofibroblast transdifferentiation process (Ng et al., 2019; Kortekaas et al., 2021).
Moreover, since IL-11 signaling in fibroblasts predominantly activates the ERK pathway, the application of X203 is expected to result in reduced ERK phosphorylation. This decrease in ERK activity translates to a reduction in the synthesis of key profibrotic proteins, thereby limiting ECM production and reducing matrix contraction in 3D cell culture models. Additionally, the antibody is anticipated to attenuate overall fibroblast survival and proliferation under fibrogenic conditions. At the tissue level, these molecular events should translate into a reduction of fibrotic foci and a restoration of a more normal lung architecture, as evidenced by decreased collagen deposition and improved alveolar structure in animal models (Ng et al., 2019; Ng et al., 2020).
Furthermore, since IL-11 blockade can disrupt the paracrine signaling between injured epithelial cells and fibroblasts, X203 might also promote alveolar epithelial regeneration. In models of alveolar damage, IL-11 has been shown to impair the differentiation of alveolar type 2 (AT2) progenitor cells into functionally mature alveolar type 1 cells, thereby stalling tissue repair. By neutralizing IL-11, X203 could restore proper differentiation pathways, reduce the accumulation of dysfunctional transitional epithelial cells, and thereby enhance alveolar repair mechanisms (Kortekaas et al., 2023; Ng et al., 2022).
At the clinical level, these combined effects are expected to lead to a reversal or at least a significant attenuation of the fibrotic process in patients with IPF. The specificity of X203 for IL-11 should minimize off-target effects compared to broader cytokine inhibitors, offering a potentially safer therapeutic profile. This could result in improved lung function, reduced disease progression, and an overall better prognosis for IPF patients, whose current treatment options are limited and mainly focus on slowing the disease rather than reversing it (Ng et al., 2019; ClinicalTrials.gov, n.d.).

Overall Evaluation:
X203, as an anti–IL-11 monoclonal antibody, represents a highly promising therapeutic candidate for the treatment of IPF based on a comprehensive body of biochemical, preclinical, and early translational research. The strengths of this candidate lie foremost in its target specificity. IL-11 is a central mediator in the fibrotic cascade and is upregulated in IPF, driving fibroblast activation and the excessive deposition of ECM via noncanonical ERK signaling. This specificity allows X203 to effectively block a convergent fibrotic pathway, potentially inhibiting a range of upstream pro-fibrotic stimuli such as TGF-β1, FGF2, and IL-13 that have traditionally been difficult to target effectively (Cook & Schafer, 2020; Ng et al., 2019).
Moreover, X203 leverages the therapeutic strengths of monoclonal antibodies—in this case, high target affinity and minimal off-target activity—which are key advantages over conventional small molecules or multi-targeted kinase inhibitors. The molecular data indicate that the antibody reduces the expression of critical fibrosis markers such as αSMA and collagen I in vitro and decreases ERK activation, a key driver of fibrogenesis. These biochemical effects are supported by robust findings in animal models where IL-11 blockade has led to significant attenuation of fibrosis (Ng et al., 2019; Kortekaas et al., 2021).
Another notable strength is the potential dual effect on both fibroblasts and alveolar epithelial cells. By alleviating the pathological signaling that impairs alveolar progenitor function, X203 may not only halt the progression of fibrosis but also contribute to tissue repair and regeneration. This dual action is highly desirable given that the loss of effective alveolar repair is a central feature in IPF progression (Kortekaas et al., 2023; Ng et al., 2022).
However, there are weaknesses and challenges to consider. One potential concern is the physiological role of IL-11 in tissue homeostasis. Although IL-11 signaling appears largely redundant in adult homeostasis, any inadvertent blockade might risk interfering with normal cellular repair processes, particularly in tissues where IL-11 may play a supportive role under stress conditions (Cook & Schafer, 2020; Kortekaas et al., 2021). Also, as with any biologic, there is always the risk of immunogenicity, which could compromise efficacy or safety over longer treatment durations. This risk, although typically lower for humanized antibodies, still necessitates careful evaluation in clinical trials.
Another challenge relates to the complexities of cytokine signaling in fibrotic diseases. IL-11’s contributions appear to be context-dependent, involving both autocrine and paracrine mechanisms, and its signaling may differ between species. While preclinical data in rodent models is encouraging, translating these findings into human therapeutic success requires rigorous clinical evaluation and may be complicated by interpatient variability in IL-11 expression and response (Ng et al., 2020; Kortekaas et al., 2021).
In summary, the overall evidence supports the potential of X203 as a disease-modifying therapy for IPF. Its strengths lie in its high specificity for IL-11, the central role of IL-11 in driving fibroblast activation and ECM deposition through ERK-dependent pathways, and its promising preclinical performance demonstrated in multiple assays and animal models. The candidate’s ability to reverse key pathological features of fibrosis, coupled with the possibility of promoting alveolar repair, makes it an attractive candidate for further development. Nonetheless, challenges such as potential off-target effects, immunogenicity, and the translational gap between animal models and human disease must be addressed in subsequent clinical studies. Overall, X203 appears to be a compelling therapeutic candidate that merits further exploration in clinical trials for IPF, with the possibility of offering significant benefits over existing therapies that mainly slow disease progression rather than reversing established fibrosis (Ng et al., 2019; ClinicalTrials.gov, n.d.).

References
Braga, Y. L. L., do Carmo Neto, J. R., Franco, P. I. R., Helmo, F. R., dos Reis, M. A., de Oliveira, F. A., Celes, M. R. N., da Silva, M. V., & Machado, J. R. (2024). The influence of IL-11 on cardiac fibrosis in experimental models: A systematic review. Journal of Cardiovascular Development and Disease, 11(2), 65. https://doi.org/10.3390/jcdd11020065

ClinicalTrials.gov. (n.d.). X203 or anti–IL-11 in idiopathic pulmonary fibrosis [Clinical trial registration]. Retrieved from ClinicalTrials.gov.

Cook, S. A., & Schafer, S. (2020). Hiding in plain sight: Interleukin-11 emerges as a master regulator of fibrosis, tissue integrity, and stromal inflammation. Annual Review of Medicine, 71, 263–276. https://doi.org/10.1146/annurev-med-041818-011649

Kortekaas, R. K., Burgess, J. K., van Orsoy, R., Lamb, D., Webster, M., & Gosens, R. (2021). Therapeutic targeting of IL-11 for chronic lung disease. Trends in Pharmacological Sciences, 42(5), 354–366. https://doi.org/10.1016/j.tips.2021.01.007

Kortekaas, R. K., Geillinger-Kästle, K. E., Borghuis, T., Belharch, K., Webster, M., Timens, W., Burgess, J. K., & Gosens, R. (2023). IL-11 disrupts alveolar epithelial progenitor function [Preprint]. bioRxiv. https://doi.org/10.1101/2022.11.11.516088

Ng, B., Cook, S. A., & Schafer, S. (2020). Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway. Experimental & Molecular Medicine, 52(12), 1871–1878. https://doi.org/10.1038/s12276-020-00531-5

Ng, B., Dong, J., D’Agostino, G., Viswanathan, S., Widjaja, A. A., Lim, W. W., Ko, N. S. J., Tan, J., Chothani, S. P., Huang, B., Xie, C., Pua, C. J., Chacko, A.-M., Guimarães-Camboa, N., Evans, S. M., Byrne, A. J., Maher, T. M., Liang, J., Jiang, D., Noble, P. W., Schafer, S., & Cook, S. A. (2019). Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Science Translational Medicine, 11(511), eaaw1237. https://doi.org/10.1126/scitranslmed.aaw1237

Ng, B., Huang, K. Y., Pua, C. J., Lim, W. W., Kuthubudeen, F., Hii, A. A., Viswanathan, S., Petretto, E., & Cook, S. A. (2022). Interleukin-11 causes alveolar type 2 cell dysfunction and prevents alveolar regeneration [Preprint]. bioRxiv. https://doi.org/10.1101/2022.11.11.516109",0.664912764,25
"Dimethyl Fumarate (BG-12, Selleckchem S2874)","Proposal for Dimethyl Fumarate (BG-12, Selleckchem S2874)

Overview of Therapeutic Candidate:
Dimethyl fumarate (DMF), marketed as BG-12 and commercially known as Tecfidera®, is a synthetic fumaric acid ester with a molecular weight of 144.13 g/mol that was originally developed for its immunomodulatory and anti‐inflammatory properties. DMF is synthesized through esterification of fumaric acid, yielding a compound with an α,β-unsaturated ester moiety that confers electrophilic properties, enabling it to react via Michael addition with thiol groups (Bresciani et al., 2023, pp. 2–3). Belonging to the class of fumarates, this therapeutic compound has been used extensively in the treatment of diseases such as psoriasis and multiple sclerosis. The chemical class of fumaric acid esters is well known for their capacity to modulate immune responses and oxidative stress, which has led to their repurposing for a range of chronic inflammatory and neurodegenerative disorders (Bresciani et al., 2023, pp. 2–3).

Therapeutic History:
DMF’s clinical utility has been established for decades. It was first introduced as an oral treatment for psoriasis in Europe and subsequently repurposed for relapsing–remitting multiple sclerosis (RRMS) following large-scale phase 3 clinical trials demonstrating its safety and efficacy. Its use in these conditions has confirmed a favorable safety profile, manageable side effects, and robust immunomodulatory activity (Bresciani et al., 2023, p. 18). Although DMF has not been formally evaluated in registered clinical trials for Idiopathic Pulmonary Fibrosis (IPF) (ClinicalTrials.gov, n.d.), its well‐documented antioxidant and anti‐inflammatory properties suggest potential utility in IPF, a disease characterized by persistent inflammation, oxidative stress, and fibrotic remodeling (Grzegorzewska et al., 2017, pp. 2–3; Wang et al., 2022, pp. 1–3). Several preclinical studies in lung injury and fibrotic models, including bleomycin‐induced lung fibrosis, have demonstrated that DMF can attenuate fibrosis, reduce collagen deposition, and improve lung function, thereby providing an encouraging basis for its repurposing in pulmonary diseases (Kato et al., 2022, pp. 9–10; Grzegorzewska et al., 2017, pp. 1–2).

Mechanism of Action:
At the molecular level, DMF is best known for its ability to activate the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway, which is a master regulator of cellular antioxidant responses. Under normal conditions, Nrf2 is sequestered in the cytoplasm by its inhibitory protein Keap1 and is targeted for ubiquitin-mediated degradation. DMF, owing to its electrophilic α,β-unsaturated ester structure, covalently modifies reactive cysteine residues on Keap1 through Michael addition, leading to conformational changes that disrupt the Keap1–Nrf2 complex. This results in the stabilization and nuclear translocation of Nrf2, which binds to antioxidant response elements (ARE) in the promoters of various cytoprotective genes (Bresciani et al., 2023, pp. 2–3; Pittalà et al., 2019, pp. 7–8). Subsequent upregulation of genes such as heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutamate-cysteine ligase supports the maintenance of glutathione levels and the overall redox balance in cells. These antioxidant effects reduce reactive oxygen species (ROS) levels and ameliorate oxidative stress, a key contributor to the pathological activation of fibroblasts and progression of fibrosis (Hao et al., 2022, pp. 9–10; Kato et al., 2022, pp. 2–4).

In addition to Nrf2 activation, DMF has been shown to inhibit nuclear factor-kappa B (NF-κB) signaling by covalently modifying components of its signaling complex, which leads to a reduction in the transcription of pro-inflammatory cytokines. This dual modulation—antioxidant enhancement via Nrf2 and anti-inflammatory effects via NF-κB inhibition—creates a biochemical environment that is less favorable for the perpetuation of fibrotic signaling pathways such as transforming growth factor-β1 (TGF-β1) signaling. TGF-β1 is central to the activation of lung fibroblasts, their differentiation into myofibroblasts, and the subsequent deposition of extracellular matrix components such as collagen. Preclinical evidence suggests that DMF can attenuate TGF-β1 induced fibroblast activation and reduce α-smooth muscle actin (αSMA) and collagen I synthesis, thereby decreasing fibroblast-mediated gel contraction in three-dimensional assays (Grzegorzewska et al., 2017, pp. 8–10; Pittalà et al., 2019, pp. 6–7).

Furthermore, DMF’s activation of the Nrf2 pathway has been associated with improved mitochondrial function and reduced apoptosis in stressed cells, contributing to overall tissue homeostasis. By reducing ROS generation and modulating inflammatory cytokines, DMF indirectly interferes with profibrotic signaling cascades that would otherwise contribute to persistent tissue remodeling and scar formation in IPF (Bresciani et al., 2023, pp. 16–17; Grzegorzewska et al., 2017, pp. 10–11).

Expected Effect:
The central hypothesis for repurposing DMF in IPF hinges on its ability to mitigate oxidative stress-induced fibroblast activation. In the proposed assays, it is expected that DMF will activate the Nrf2 pathway in primary lung fibroblasts, leading to the upregulation of antioxidant defense enzymes such as HO-1. This molecular event is anticipated to result in a reduced intracellular ROS burden, thereby blunting the oxidative stress signal that drives the pathological activation of fibroblasts. Concomitantly, DMF is expected to downregulate TGF-β1 signaling, a primary profibrotic pathway that enhances fibroblast proliferation, myofibroblast differentiation, and extracellular matrix deposition. In 3D gel contraction assays, these combined effects would manifest as a decreased contractile activity of lung fibroblasts, reflective of a less activated, more quiescent phenotype (Grzegorzewska et al., 2017, pp. 11–12; Pittalà et al., 2019, pp. 7–8).

There is evidence from preclinical models in murine systems where DMF attenuated bleomycin-induced lung fibrosis, decreased collagen deposition, and improved respiratory function. These findings support the expected outcome that DMF will reduce key markers of fibrosis—such as αSMA and collagen I—in lung fibroblasts, leading to improved tissue architecture and function. Moreover, the documented expression of Nrf2 and its downstream antioxidant genes in lung fibroblasts from IPF patients reinforces the molecular rationale that targeting this pathway will alleviate oxidative damage which is instrumental in fibroblast activation (Hao et al., 2022, pp. 9–10; Kato et al., 2022, pp. 4–6).

Overall Evaluation:
Overall, DMF presents as a promising candidate for repurposing in the treatment of Idiopathic Pulmonary Fibrosis, based on its established clinical safety profile in multiple sclerosis and psoriasis, its clear mechanistic role in activating the Nrf2 antioxidant pathway, and its capacity to attenuate inflammatory and fibrotic signaling cascades. One of the primary strengths of DMF is its dual mechanism of action; by simultaneously enhancing antioxidant defenses and suppressing pro-inflammatory NF-κB signaling, it addresses two central pathological drivers of IPF—oxidative stress and unwarranted inflammation—which in turn reduce aberrant fibroblast activation and extracellular matrix deposition. Preclinical evidence from bleomycin-induced lung fibrosis models and studies on lung-targeted delivery further support its antifibrotic potential (Kato et al., 2022, pp. 9–10; Grzegorzewska et al., 2017, pp. 1–2).

Furthermore, the oral dosing regimen and well-understood pharmacokinetics of DMF facilitate easier translation from animal models to human clinical trials. The safety and tolerability of DMF in long-term use for other indications provide an important advantage in terms of risk mitigation when considering repurposing for IPF (Bresciani et al., 2023, p. 18; Grzegorzewska et al., 2017, pp. 2–3).

However, certain weaknesses must also be considered. Although the preclinical data are promising, there is currently an absence of direct clinical trial evidence in IPF patients (ClinicalTrials.gov, n.d.). Moreover, while DMF is broadly active in mitigating inflammation and oxidative stress, its precise impact on the complex interplay of profibrotic cytokines, particularly TGF-β1 and its downstream effectors, remains to be fully elucidated in the context of fibrotic lung tissue. There is also the potential for off-target effects given DMF’s electrophilic nature, which must be carefully monitored in the delicate pulmonary milieu. Furthermore, translating the benefits observed in animal models to human IPF may be challenging due to differences in disease etiology and progression between species (Grzegorzewska et al., 2017, pp. 6–8; Wang et al., 2022, pp. 1–3).

In conclusion, DMF’s well-documented activation of the Nrf2 pathway, its inhibition of NF-κB-mediated inflammatory responses, and its potential to downregulate TGF-β1-driven fibroblast activation render it a promising therapeutic candidate for IPF. The existing body of preclinical evidence, along with its established clinical track record in other chronic inflammatory diseases, justifies further focused investigation and possibly early-phase clinical trials in IPF patients to evaluate its efficacy and safety in this particularly challenging interstitial lung disease (Hao et al., 2022, pp. 9–10; Kato et al., 2022, pp. 9–10; Bresciani et al., 2023, pp. 16–17). Continued research should aim to clarify DMF’s precise molecular effects on TGF-β1 signaling in lung fibroblasts and to optimize dosing strategies for lung-targeted delivery, thereby maximizing benefits while minimizing potential systemic side effects.

References
Bresciani, G., Manai, F., Davinelli, S., Tucci, P., Saso, L., & Amadio, M. (2023). Novel potential pharmacological applications of dimethyl fumarate—An overview and update. Frontiers in Pharmacology, 14, Article 1264842. https://doi.org/10.3389/fphar.2023.1264842

ClinicalTrials.gov. (n.d.). Dimethyl fumarate and idiopathic pulmonary fibrosis [Web search]. ClinicalTrials.gov. Retrieved October 1, 2023, from https://clinicaltrials.gov/ct2/results?cond=Idiopathic+Pulmonary+Fibrosis&term=dimethyl+fumarate

Grzegorzewska, A. P., Seta, F., Han, R., Czajka, C. A., Makino, K., Stawski, L., Isenberg, J. S., Browning, J. L., & Trojanowska, M. (2017). Dimethyl fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. Scientific Reports, 7, Article 41605. https://doi.org/10.1038/srep41605

Hao, W., Li, M., Cai, Q., Wu, S., Li, X., He, Q., & Hu, Y. (2022). Roles of Nrf2 in fibrotic diseases: From mechanisms to therapeutic approaches. Frontiers in Physiology, 13, Article 889792. https://doi.org/10.3389/fphys.2022.889792

Kato, K., Papageorgiou, I., Shin, Y.-J., Kleinhenz, J. M., Palumbo, S., Hahn, S., Irish, J. D., Rounseville, S. P., Knox, K. S., & Hecker, L. (2022). Lung-targeted delivery of dimethyl fumarate promotes the reversal of age-dependent established lung fibrosis. Antioxidants, 11(3), 492. https://doi.org/10.3390/antiox11030492

Pittalà, V., Vanella, L., Platania, C. B. M., Salerno, L., Raffaele, M., Amata, E., Marrazzo, A., Floresta, G., Romeo, G., Greish, K., Intagliata, S., Bucolo, C., & Sorrenti, V. (2019). Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents. Future Medicinal Chemistry, 11(14), 1523–1536. https://doi.org/10.4155/fmc-2018-0448

Wang, Y., Wei, J., Deng, H., Zheng, L., Yang, H., & Lv, X. (2022). The role of Nrf2 in pulmonary fibrosis: Molecular mechanisms and treatment approaches. Antioxidants, 11(9), 1685. https://doi.org/10.3390/antiox11091685",0.561392583,20
"SAR441566 (NOX4 inhibitor, Merck)","Proposal for SAR441566 (NOX4 inhibitor, Merck)

Overview of Therapeutic Candidate:
SAR441566 is a synthetic small‐molecule inhibitor specifically designed to target NADPH oxidase 4 (NOX4). It was discovered and subsequently optimized through high‐throughput screening and structure–activity relationship studies similar to the pioneering work reported with pyrazolopyridine dione scaffolds (Laleu et al., 2010). As a member of the NOX inhibitor class, SAR441566 belongs to a group of compounds that aim to interrupt the enzymatic production of reactive oxygen species (ROS) by inhibiting sources such as NOX4. Historically, inhibitors of this class have been utilized primarily in preclinical models targeting fibrotic, vascular, and inflammatory pathologies. The novelty with SAR441566, developed by Merck, lies in its high degree of selectivity for NOX4 over other isoforms like NOX1 and NOX2, which is a critical attribute given NOX4’s central role in driving fibrogenic processes in the lung (ClinicalTrials.gov). This candidate was synthesized using medicinal chemistry approaches that emphasize selectivity, potency, and favorable pharmacokinetic properties. The compound exhibits drug‐like absorption, distribution, metabolism and excretion (ADME) profiles and demonstrated tolerability in Phase I studies, underscoring its potential to be clinically developed for conditions like Idiopathic Pulmonary Fibrosis (IPF) (ClinicalTrials.gov).

Therapeutic History:
NOX inhibitors in general have been the focus of substantial preclinical research due to their ability to modulate ROS production. Several NOX4 inhibitors have been evaluated, including dual inhibitors like GKT137831, which has shown promising antifibrotic effects in bleomycin‐induced lung fibrosis models and has received orphan drug status for IPF (Teixeira et al., 2017; Hecker, Cheng, & Thannickal, 2012). The therapeutic rationale behind these compounds centers on the fact that NOX4 is upregulated in fibrotic tissues and drives fibroblast activation by generating ROS that promote cellular differentiation, collagen synthesis, and 3D matrix contraction. While no NOX inhibitors have yet achieved regulatory approval for IPF, the accumulated data from both in vitro studies and animal models support further clinical evaluation. SAR441566 represents a new addition to this class—one that is designed specifically to target NOX4 with high selectivity and potency. Prior research has extensively characterized the role of NOX4 in fibrotic diseases, including IPF, noting that increased NOX4 expression is a hallmark in both lung fibroblasts and epithelial cells in the diseased tissue (Carnesecchi et al., 2011; Hecker et al., 2014). To date, compounds with similar mechanisms of action have been used as chemical probes to interfere with redox‐mediated signal transduction involving TGF-β and other profibrotic cytokines. This collective body of work supports the repositioning – or in this case, the de novo development – of selective NOX4 inhibitors such as SAR441566 for modulating the fibrotic response seen in IPF (Turn, Lockey, & Kolliputi, 2015; Bernard & Thannickal, 2020).

Mechanism of Action:
NOX4 is a member of the NADPH oxidase family that is unique in its constitutive activity, meaning that its level of enzymatic activity is primarily determined by its expression level rather than requiring acute activation signals. In healthy tissues, NOX4 plays a role in normal redox signaling; however, in the context of IPF its overexpression leads to pathological levels of ROS, most notably hydrogen peroxide (H₂O₂), which in turn drives fibrogenesis. At the molecular level, SAR441566 selectively binds to the catalytic domain of NOX4, effectively inhibiting the enzyme’s ability to transfer electrons from NADPH to molecular oxygen. This inhibition decreases the formation of critical ROS that serve as secondary messengers in profibrotic signaling pathways—most notably those triggered by transforming growth factor-beta 1 (TGF-β1). TGF-β1 is a key cytokine that induces the differentiation of fibroblasts into myofibroblasts, cells responsible for excessive extracellular matrix (ECM) deposition and 3D matrix contraction. Multiple studies have demonstrated that blocking NOX4 activity can reduce TGF-β1-induced ROS production, ultimately decreasing the expression of fibrotic markers such as collagen I and α-smooth muscle actin (α-SMA) (Carnesecchi et al., 2011; Hecker et al., 2014). On a biochemical level, SAR441566’s selective inhibition of NOX4 interrupts the ROS-dependent activation of redox-sensitive kinases and transcription factors such as Smad2/3, which are critical to the propagation of fibrotic responses within lung fibroblasts (Hecker et al., 2012; Teixeira et al., 2017). Additionally, the inhibition of NOX4-mediated ROS production may also alleviate the mitochondrial and cellular redox imbalances that further promote myofibroblast survival and resistance to apoptosis, phenomena that are particularly prominent in the aged lung (Veith et al., 2019; Hecker et al., 2014). SAR441566’s mechanism is therefore classically “upstream,” acting to reduce the ROS load that drives multiple downstream profibrotic events, including aberrant fibroblast activation, extracellular matrix remodeling, and 3D lung tissue contraction.

Expected Effect:
Given its molecular mechanism, the expected effect of SAR441566 in IPF is multifaceted. In vitro assays with primary human lung fibroblasts are anticipated to show a reduction in ROS levels following treatment, leading to decreased activation of redox-sensitive signaling pathways. Specifically, in a 3D matrix contraction assay, which serves as a proxy for fibroblast-mediated tissue remodeling, SAR441566 is expected to substantially reduce matrix contraction by inhibiting the conversion of fibroblasts into contractile myofibroblasts. This has been supported by experimental models where NOX4 inhibition correlates with lower collagen I expression and diminished activity of profibrotic markers such as α-SMA (Vecchio et al., 2013; Hecker et al., 2014). In vivo, animal models of bleomycin-induced pulmonary fibrosis have shown that interventions blocking NOX4 activity lead to improvements in lung architecture, decreased collagen deposition, and enhanced lung function (Turn et al., 2015; Bernard & Thannickal, 2020). Furthermore, because NOX4 is highly expressed in IPF patients’ lung tissues—including in the hyperplastic alveolar epithelium and fibrotic foci—targeting this enzyme should yield a measurable decrease in reactive oxygen species and, as a consequence, reduce the profibrotic signaling cascades mediated by TGF-β1 (Carnesecchi et al., 2011; Hecker et al., 2012). Clinically, the reduction of oxidative stress and fibrotic marker expression by SAR441566 should translate to a slower progression of lung fibrosis, potentially stabilizing lung function and improving overall prognosis in IPF patients.

Overall Evaluation:
SAR441566 emerges as a promising therapeutic candidate for IPF based on a comprehensive review of the available literature and preclinical data. One of the primary strengths of this candidate is its high selectivity and potency for NOX4. Since NOX4 upregulation is a pivotal driver of ROS production and subsequent activation of profibrotic signaling cascades within lung fibroblasts, the ability of SAR441566 to specifically target this enzyme offers a direct means to interrupt the pathogenic process in IPF (Hecker et al., 2012; Carnesecchi et al., 2011). This is particularly important given that nonspecific antioxidants have had limited success clinically, likely due to their broad activity that does not adequately suppress the localized pathological ROS production. Moreover, SAR441566 has shown favorable drug-like PK/ADME properties and tolerability in Phase I studies, supporting its potential to transition successfully from preclinical models to clinical application (ClinicalTrials.gov).

In terms of weaknesses, while the preclinical data are compelling, the translation of these results into clinical efficacy remains to be fully established. The complex interplay between redox signaling, mitochondrial function, and fibrotic signaling means that even with high selectivity for NOX4, off-target or compensatory effects may emerge in human subjects. Furthermore, the clinical endpoints in IPF are notoriously difficult to measure, and the heterogeneity of the patient population could influence the therapeutic index of SAR441566. Despite these challenges, the rationale for targeting NOX4 is well supported by multiple lines of evidence demonstrating its central role in driving fibroblast activation, collagen deposition, and overall fibrotic remodeling in the lung (Hecker et al., 2014; Turn et al., 2015). Additionally, the promising results with other NOX inhibitors such as GKT137831 in preclinical models provide further external validation for this therapeutic strategy (Teixeira et al., 2017; Bernard & Thannickal, 2020).

In conclusion, based on the existing preclinical, biochemical, and early clinical data, SAR441566 represents an innovative and highly promising approach for the treatment of Idiopathic Pulmonary Fibrosis. Its mechanism—rooted in the inhibition of NOX4-driven ROS production—addresses one of the central pathogenic mechanisms in IPF, namely the dysregulated redox signaling that leads to fibroblast activation and excessive ECM production (Carnesecchi et al., 2011; Hecker et al., 2012; Turn et al., 2015). The expected reduction in fibroblast-to-myofibroblast conversion, diminished collagen synthesis, and decreased 3D matrix contraction are all indicative of a potential slowing or reversal of fibrotic progression, which is a significant unmet need in current IPF therapy (Carnesecchi et al., 2011; Hecker et al., 2012; Turn et al., 2015).

Strengths of SAR441566 include its high specificity for NOX4, favorable pharmacokinetic and ADME profiles, and strong preclinical efficacy in reducing key fibrotic markers. Weaknesses center on the need for further clinical validation, possible compensatory pathways in chronic disease, and the inherent challenges in measuring clinical outcomes in IPF. Nonetheless, the overall evaluation is that SAR441566 holds considerable potential as a disease‐modifying agent for IPF and merits continued investment in both clinical evaluation and further mechanistic studies to fully characterize its therapeutic window and long‐term efficacy (ClinicalTrials.gov; Hecker et al., 2014; Bernard & Thannickal, 2020).

References
Bernard, K., & Thannickal, V. J. (2020). NADPH oxidase inhibition in fibrotic pathologies. Antioxidants & Redox Signaling, 33, 455–479. https://doi.org/10.1089/ars.2020.8032

Carnesecchi, S., Deffert, C., Donati, Y., Basset, O., Hinz, B., Preynat-Seauve, O., Guichard, C., Arbiser, J. L., Banfi, B., Pache, J.-C., Barazzone-Argiroffo, C., & Krause, K.-H. (2011). A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxidants & Redox Signaling, 15, 607–619. https://doi.org/10.1089/ars.2010.3829

ClinicalTrials.gov. (n.d.). SAR441566 OR NOX4 inhibitor AND idiopathic pulmonary fibrosis. Retrieved from https://clinicaltrials.gov

Hecker, L., Cheng, J., & Thannickal, V. J. (2012). Targeting NOX enzymes in pulmonary fibrosis. Cellular and Molecular Life Sciences, 69, 2365–2371. https://doi.org/10.1007/s00018-012-1012-7

Hecker, L., Logsdon, N. J., Kurundkar, D., Kurundkar, A., Bernard, K., Hock, T., Meldrum, E., Sanders, Y. Y., & Thannickal, V. J. (2014). Reversal of persistent fibrosis in aging by targeting NOX4–NRF2 redox imbalance. Science Translational Medicine, 6(231), 231ra47. https://doi.org/10.1126/scitranslmed.3008182

Laleu, B., Gaggini, F., Orchard, M., Fioraso-Cartier, L., Cagnon, L., Houngninou-Molango, S., Gradia, A., Duboux, G., Merlot, C., Heitz, F., Szyndralewiez, C., & Page, P. (2010). First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (NOX4) inhibitors for the treatment of idiopathic pulmonary fibrosis. Journal of Medicinal Chemistry, 53, 7715–7730. https://doi.org/10.1021/jm100773e

Teixeira, G., Szyndralewiez, C., Molango, S., Carnesecchi, S., Heitz, F., Wiesel, P., & Wood, J. M. (2017). Therapeutic potential of NADPH oxidase 1/4 inhibitors. British Journal of Pharmacology, 174, 1647–1669. https://doi.org/10.1111/bph.13532

Turn, C. S., Lockey, R. F., & Kolliputi, N. (2015). Putting the brakes on age‐related idiopathic pulmonary fibrosis: Can NOX4 inhibitors suppress IPF? Experimental Gerontology, 63, 81–82. https://doi.org/10.1016/j.exger.2015.02.002

Vecchio, D., Acquaviva, A., Arezzini, B., Tenor, H., Martorana, P. A., & Gardi, C. (2013). Downregulation of NOX4 expression by roflumilast N-oxide reduces markers of fibrosis in lung fibroblasts. Mediators of Inflammation, 2013, Article 745984. https://doi.org/10.1155/2013/745984

Veith, C., Boots, A. W., Idris, M., van Schooten, F.-J., & van der Vliet, A. (2019). Redox imbalance in idiopathic pulmonary fibrosis: A role for oxidant cross‐talk between NADPH oxidase enzymes and mitochondria. Antioxidants & Redox Signaling, 31, 1092–1115. https://doi.org/10.1089/ars.2019.7742",0.448795732,4
"Navitoclax (ABT-263, Selleckchem S1001)","Proposal for Navitoclax (ABT-263, Selleckchem S1001)

Overview of Therapeutic Candidate:
Navitoclax, also known as ABT-263 (Selleckchem S1001), is an orally bioavailable small-molecule that belongs to the class of BH3 mimetics. This compound was originally discovered and synthesized through targeted medicinal chemistry programs aimed at inhibiting anti-apoptotic members of the B-cell lymphoma 2 (BCL-2) family, including BCL-2, BCL-xL, and BCL-W. Its design was based on the structural understanding of the interaction between anti-apoptotic proteins and BH3-only ligands, with the goal of mimicking the natural pro-apoptotic signals that regulate mitochondrial membrane permeabilization and cell death (Anuar et al., 2020). BH3 mimetics like Navitoclax were initially developed for oncologic indications to trigger apoptosis in cancer cells that rely on BCL-2 family proteins for survival. These small molecules have been extensively studied in hematologic malignancies and select solid tumors – notably small cell lung cancer and chronic lymphocytic leukemia – where they have demonstrated potent pro-apoptotic effects (Anuar et al., 2020; ClinicalTrials.gov, n.d.). Synthetic modifications and formulation improvements aimed at enhancing oral bioavailability and managing on-target toxicities (e.g., thrombocytopenia due to BCL-xL inhibition) contributed to the evolution of Navitoclax into a well-characterized candidate that has advanced into clinical trials in the oncology realm.

Therapeutic History:
Originally designed as an anticancer agent, Navitoclax has a well-documented therapeutic history in oncology. Early clinical studies demonstrated its ability to induce dose-dependent apoptosis in lymphoid cells, which positioned it as a promising agent for treating relapsed or refractory lymphoid malignancies (AbbVie, 2006). Its mechanism of inducing apoptosis in malignant cells relies on the inhibition of anti-apoptotic BCL-2 family members—a pathway that is similarly exploited to clear senescent cells. Over time, preclinical investigations began to highlight the repurposing potential of Navitoclax beyond oncology. In particular, several studies have identified that senescent cells – including senescent myofibroblasts – accumulate in various fibrotic disorders such as idiopathic pulmonary fibrosis (IPF). These cells exhibit resistance to apoptosis, partly due to elevated expression of anti-apoptotic proteins that are the direct targets of Navitoclax (Anuar et al., 2020). Preclinical work in animal models of lung fibrosis has demonstrated that Navitoclax can effectively induce apoptosis of senescent and apoptosis-resistant myofibroblasts, thereby reducing fibrotic cell burden and mitigating extracellular matrix accumulation (Hernandez-Gonzalez et al., 2023; Lagares et al., 2017). Although its use in IPF has not yet reached broad clinical application, the extensive oncology clinical safety and pharmacokinetic data provide a strong foundation for its repurposing in fibrotic lung diseases (ClinicalTrials.gov, n.d.).

Mechanism of Action:
At the molecular level, Navitoclax operates by binding to the hydrophobic groove of anti-apoptotic BCL-2 family proteins, thereby competitively displacing pro-apoptotic BH3-only proteins, such as BIM. Under normal circumstances, BIM is sequestered by BCL-2 and BCL-xL to prevent the activation of the intrinsic apoptotic pathway. When Navitoclax binds to these proteins, it releases BIM, which then proceeds to activate the multi-domain pro-apoptotic proteins BAX and BAK. These proteins oligomerize in the mitochondrial outer membrane, leading to mitochondrial outer membrane permeabilization, cytochrome c release, activation of caspases, and ultimately programmed cell death (Anuar et al., 2020). In fibrotic lung diseases like IPF, senescent myofibroblasts and certain epithelial cells (notably type II pneumocytes) become resistant to apoptosis due to persistent upregulation of BCL-2 family proteins. By selectively inhibiting these proteins, Navitoclax offers a means to restore apoptotic sensitivity in these cells, effectively reducing their accumulation and the resultant profibrotic secretory phenotype that drives extracellular matrix deposition and tissue remodeling (Anuar et al., 2020; Lagares et al., 2017). Additional research has demonstrated that aside from solely triggering apoptosis, Navitoclax may also modulate other pathways such as attenuating mitochondrial antiviral signaling (MAVS) aggregation in lung epithelial cells, a process contributing to fibrogenesis via damage-associated molecular pattern (DAMP) signaling (Kim et al., 2021; Kim & Shin, 2021). This dual action—senolytic clearance of fibrogenic cells along with modulation of pro-fibrotic innate immune signaling—underscores the potential of Navitoclax to impact multiple facets of IPF pathology.

Expected Effect:
The central hypothesis for repurposing Navitoclax in IPF is predicated on its ability to selectively induce apoptosis in senescent myofibroblasts, thereby reducing the profibrotic cell burden in the lung. In the proposed assays, such as those using 3D collagen gel contraction models, Navitoclax is expected to diminish myofibroblast contractility by eliminating senescent cells that contribute to the pathological stiffening and remodeling of lung tissue (Anuar et al., 2020). Senescent myofibroblasts in IPF are known to secrete a senescence-associated secretory phenotype (SASP) that propagates local inflammation and further activates resident mesenchymal cells, thereby exacerbating extracellular matrix (ECM) deposition. By clearing these cells, Navitoclax is anticipated to interrupt the vicious cycle of fibrogenesis, resulting in decreased collagen synthesis and improved tissue compliance (Hernandez-Gonzalez et al., 2023; Cazzola et al., 2018). Biochemically, this effect is mediated through the robust activation of caspase-3 dependent apoptosis pathways, with subsequent reduction in markers associated with cellular senescence such as p16^INK4a and p21^CIP1/WAF1. Furthermore, preclinical models of pulmonary fibrosis have demonstrated that BH3 mimetics similar to Navitoclax can reverse established fibrotic lesions and improve lung function by restoring the balance between cell survival and cell death in the fibrotic microenvironment (Lagares et al., 2017; Anuar et al., 2020). In addition, studies have shown that selective senolytic activity against fibrosis-driving cells may also lead to modulation of stress pathways such as endothelial reticulum (ER) stress, further facilitating the restoration of normal cell turnover and tissue repair (Le Saux et al., 2024).

Overall Evaluation:
The repurposing of Navitoclax for IPF is supported by a robust body of biomedical, clinical, and biochemical evidence. Strengths of Navitoclax include its well-characterized mechanism of action, which directly addresses a key pathophysiologic component of IPF—namely, the accumulation of apoptosis-resistant, senescent myofibroblasts. Preclinical studies in various models of fibrosis have demonstrated that inhibition of BCL-2 family proteins results in significant reduction of fibrotic markers and reversal of tissue remodeling (Anuar et al., 2020; Lagares et al., 2017). Moreover, Navitoclax’s clinical history in oncology has provided extensive pharmacokinetic and safety data, allowing for a faster translational path when repurposing the drug for non-oncologic indications such as IPF (AbbVie, 2006; Anuar et al., 2020). Its dual capability to induce apoptosis and potentially modulate pro-fibrotic innate immune signaling through effects on MAVS aggregation further enhances its appeal as a candidate with multi-layered effects on lung pathology (Kim et al., 2021; Kim & Shin, 2021).

However, there are important caveats to consider. The known adverse effects observed in oncology trials, such as thrombocytopenia and neutropenia stemming from BCL-xL inhibition, may limit dose escalation or require careful dosing strategies in a chronic disease setting like IPF (Anuar et al., 2020; Cazzola et al., 2018). Furthermore, the timing of drug administration appears critical; studies have shown that early intervention with BH3 mimetics in certain lung injury models may paradoxically exacerbate tissue damage by affecting non-target cell populations, highlighting the need for precise therapeutic windows (Cooley & Redente, 2024; Kim & Shin, 2021). Additionally, while preclinical models – including those using 3D collagen gels and murine transplantation of senescent fibroblasts – consistently show promise, the translation of these results to human IPF pathology remains a considerable challenge due to the complex and heterogeneous nature of the disease (Hernandez-Gonzalez et al., 2023; Anuar et al., 2020).

Overall, the evidence supports the hypothesis that Navitoclax can treat IPF by selectively eliminating senescent myofibroblasts and reducing the fibrotic burden. Its proven ability to induce apoptosis in cells that rely on anti-apoptotic BCL-2 proteins is well-aligned with the cellular pathobiology observed in IPF (Anuar et al., 2020; Lagares et al., 2017). The extensive pharmacologic and clinical data available from oncology studies provide significant advantages in terms of known pharmacokinetics and potential safety management. Nonetheless, the safety profile in chronic fibrotic conditions and the precise optimization of dosing regimens remain the most notable weaknesses and represent key areas for further investigational study. Given these considerations, Navitoclax emerges as a highly promising candidate for repurposing in IPF therapy, provided that forthcoming clinical trials can carefully address its potential toxicities and validate its efficacy in human fibrotic lung tissue (ClinicalTrials.gov, n.d.; Anuar et al., 2020; Lagares et al., 2017).

In summary, the proposed repurposing of Navitoclax for IPF is scientifically compelling and supported by a multifaceted body of evidence drawn from oncology, fibrosis, and senescence research. The therapeutic candidate not only exhibits a well-established mechanism to counter the apoptosis resistance of senescent myofibroblasts but also carries the advantage of extensive preclinical and clinical data that could expedite its translation into the IPF treatment arena. This dual-action of promoting apoptosis while potentially modulating innate immune stress responses provides a strong rational basis for further exploration in clinical trials tailored to fibrotic lung diseases. While challenges remain—particularly concerning safety and optimal treatment windows—the overall evaluation indicates that Navitoclax possesses substantial potential as an innovative, mechanism-based therapeutic approach for patients with idiopathic pulmonary fibrosis.

References:

AbbVie. (2006). A study of ABT-263 in subjects with relapsed or refractory lymphoid malignancies. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00406809

Anuar, N. N. M., Nor Hisam, N. S., Liew, S. L., & Ugusman, A. (2020). Clinical review: Navitoclax as a pro-apoptotic and anti-fibrotic agent. Frontiers in Pharmacology, 11, Article 564108. https://doi.org/10.3389/fphar.2020.564108

Cazzola, M., Matera, M. G., Rogliani, P., & Calzetta, L. (2018). Senolytic drugs in respiratory medicine: Is it an appropriate therapeutic approach? Expert Opinion on Investigational Drugs, 27(7), 573–581. https://doi.org/10.1080/13543784.2018.1492548

ClinicalTrials.gov. (n.d.). Search for Navitoclax OR ABT-263 OR BCL-2 inhibitor AND (idiopathic pulmonary fibrosis OR lung fibrosis OR fibrotic lung disease). https://clinicaltrials.gov/ct2/results?cond=&term=Navitoclax+OR+ABT-263+OR+BCL-2+inhibitor+AND+%28idiopathic+pulmonary+fibrosis+OR+lung+fibrosis+OR+fibrotic+lung+disease%29

Cooley, J. C., & Redente, E. F. (2024). Getting the timing right: Controlling bcl-2 inhibition as an antifibrotic therapy. American Journal of Respiratory Cell and Molecular Biology, 70, 231–232. https://doi.org/10.1165/rcmb.2023-0436ed

Hernandez-Gonzalez, F., Prats, N., Ramponi, V., López-Domínguez, J. A., Meyer, K., Aguilera, M., Muñoz Martín, M. I., Martínez, D., Agustí, A., Faner, R., Sellarés, J., Pietrocola, F., & Serrano, M. (2023). Human senescent fibroblasts trigger progressive lung fibrosis in mice. Aging, 15, 6641–6657. https://doi.org/10.18632/aging.204825

Kim, S.-H., & Shin, H. J. (2021). Mavs is crucial for the development of pulmonary fibrosis and is inhibited by proapoptotic BH3 mimetics [Unpublished manuscript].

Kim, S.-H., Lee, J. Y., Yoon, C. M., Shin, H. J., Lee, S. W., Rosas, I., Herzog, E., Dela Cruz, C. S., Kaminski, N., & Kang, M.-J. (2021). Mitochondrial antiviral signaling protein is crucial for the development of pulmonary fibrosis. European Respiratory Journal, 57, 2000652. https://doi.org/10.1183/13993003.00652-2020

Lagares, D., Santos, A., Grasberger, P. E., Liu, F., Probst, C. K., Rahimi, R. A., Sakai, N., Kuehl, T., Ryan, J., Bhola, P., Montero, J., Kapoor, M., Baron, M., Varelas, X., Tschumperlin, D. J., Letai, A., & Tager, A. M. (2017). Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Science Translational Medicine, 9(420), eaal3765. https://doi.org/10.1126/scitranslmed.aal3765

Le Saux, C. J., Ho, T. C., Brumwell, A. M., Kathiriya, J. J., Wei, Y., Hughes, J. B., Garakani, K., Atabai, K., Auyeung, V. C., Papa, F. R., & Chapman, H. A. (2024). Bcl-2 modulates IRE1α activation to attenuate endoplasmic reticulum stress and pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology, 70, 247–258. https://doi.org/10.1165/rcmb.2023-0109oc",0.391452378,1
"Galunisertib (LY2157299, Selleckchem S2673)","Proposal for Galunisertib (LY2157299, Selleckchem S2673)

Overview of Therapeutic Candidate:
Galunisertib (LY2157299) is a synthetic small‐molecule inhibitor discovered through medicinal chemistry efforts aimed at identifying compounds capable of selectively inhibiting the transforming growth factor‐β receptor I (TGF‐βRI, also known as ALK5) kinase domain. This candidate belongs to the class of small‐molecule TGF‐β receptor kinase inhibitors that were originally developed for oncology indications but are now being considered for repurposing in fibrotic diseases such as Idiopathic Pulmonary Fibrosis (IPF). The synthesis and optimization of galunisertib involved structure–activity relationship studies to maximize its potency toward TGF‐βRI while minimizing off‐target effects, with extensive in vitro and in vivo pharmacodynamic profiling that confirmed its ability to inhibit phosphorylation of downstream effectors such as SMAD2/3 (Mendoza & Jimenez, 2022; Lahn et al., 2015). This class of agents has historically been used to modulate TGF‐β signaling in various settings including cancer and preclinical models of fibrosis, given TGF‐β’s notorious promiscuous role in driving fibrogenesis and tumor progression alike.

Therapeutic History:
Galunisertib has been most extensively evaluated in the oncology arena. Preclinical and clinical studies in malignancies – ranging from hepatocellular carcinoma (HCC) to glioma – have established that galunisertib is orally bioavailable and exhibits a target engagement profile that is evidenced by reduced phosphorylation of SMAD2 in peripheral tissues (Lahn et al., 2015; Kelley et al., 2019). In phase I and II oncology trials, its safety profile was characterized as manageable with intermittent dosing schedules designed to mitigate potential adverse effects associated with chronic TGF‐β blockade (Lahn et al., 2015; Kelley et al., 2019). However, a comprehensive clinical trial search for lung fibrosis or IPF with galunisertib yielded no registered studies (ClinicalTrials.gov, n.d.), indicating that despite its promising pharmacological profile, galunisertib has not yet been directly evaluated in patients with IPF or related interstitial lung diseases. That said, preclinical evidence in other fibrotic models – including studies demonstrating reduced collagen deposition, inhibition of fibroblast activation, and reversal of myofibroblast phenotypes – supports its potential repurposing for fibrotic diseases (Mendoza & Jimenez, 2022; Dadrich et al., 2016). The oncology-derived safety and pharmacokinetic data provide strong proof-of-concept for chronic administration, critical for a disease like IPF where long-term therapy is required.

Mechanism of Action:
At the molecular level, galunisertib functions by selectively binding to the ATP-binding site of TGF‐β receptor I kinase, thereby inhibiting its catalytic activity. Inhibition of TGF‐βRI prevents the phosphorylation of receptor-activated SMAD proteins, specifically SMAD2 and SMAD3, which are critical mediators of the canonical TGF‐β signaling cascade (Mendoza & Jimenez, 2022; Lahn et al., 2015). As a consequence, the nuclear translocation of the SMAD2/3 complex and its subsequent transcriptional regulation of profibrotic target genes, such as collagen type I (COL1A1), α-smooth muscle actin (αSMA), and fibronectin, is substantially reduced. This mechanistic blockade underlies the expected inhibition of fibroblast-to-myofibroblast differentiation—a process central to the pathogenesis of IPF (Inui et al., 2021; Biernacka et al., 2011). Moreover, the compound has been shown in preclinical assays to reduce collagen gel contraction, a surrogate measure of myofibroblast contractile function, thus further supporting its antifibrotic potential (Mendoza & Jimenez, 2022; Dadrich et al., 2016). The broad consensus from biochemical studies is that TGF‐β/SMAD signaling is a major driver of fibrogenesis; hence, selective inhibition of this pathway by galunisertib has the potential to intercept or reverse the fibrotic process by halting myofibroblast activation and excessive ECM production (Jing et al., 2025; Lahn et al., 2015). Its selective kinase inhibition distinguishes it from less specific approaches such as monoclonal antibodies or antisense oligonucleotides targeting TGF‐β isoforms, potentially offering an improved therapeutic index and oral dosing convenience (Lahn et al., 2015; Mendoza & Jimenez, 2022).

Expected Effect:
The central hypothesis for repurposing galunisertib in IPF is that by blocking TGF‐β1-induced SMAD2/3 phosphorylation in lung fibroblasts, the drug will prevent the upregulation of profibrotic markers such as αSMA, subsequently inhibiting the differentiation of fibroblasts into contractile myofibroblasts. In the proposed assays, one would expect to see a significant reduction in SMAD2/3 activation as measured by phospho-SMAD2/3 levels, which is a direct biomarker of TGF‐βRI activity (Lahn et al., 2015; Rodón et al., 2015). In addition, primary human lung fibroblast cultures treated with galunisertib should yield lower mRNA and protein expressions of αSMA, collagen type I, and other extracellular matrix components, as documented by quantitative PCR and Western blot analyses (Mendoza & Jimenez, 2022; Inui et al., 2021). When examining fibroblast function using 3D collagen gel contraction assays, the expectation is that inhibition of TGF‐β signaling by galunisertib will reduce the contractile force of these cells, leading to less collagen gel contraction—a surrogate for tissue stiffness and fibrotic remodeling (Dadrich et al., 2016; Lahn et al., 2015). Furthermore, given that genetic knockout of SMAD3 has been shown to protect against bleomycin-induced pulmonary fibrosis, pharmacologically mimicking this effect via galunisertib is anticipated to yield a reduction in lung fibrosis in preclinical animal models (Biernacka et al., 2011; Lahn et al., 2015). The drug’s good oral bioavailability – as confirmed in oncology patients – means that chronic dosing regimens could feasibly be applied in IPF, which is critical for managing a progressive disease where long-term suppression of fibrogenesis is needed (Kelley et al., 2019; Lahn et al., 2015). Thus, the expected overall effect of galunisertib in the proposed assays would be a marked reduction in SMAD2/3 mediated profibrotic gene transcription, leading to lower αSMA expression, decreased fibroblast-mediated collagen contraction, and ultimately a less fibrotic lung architecture.

Overall Evaluation:
Galunisertib is a promising therapeutic candidate for repurposing in IPF due to several compelling strengths, though its application also presents certain challenges that must be addressed.

One notable strength is the mechanistic specificity of galunisertib. By directly targeting the ATP-binding pocket of TGF‐βRI, the drug potently inhibits the canonical TGF‐β/SMAD signaling cascade, a pathway that is universally acknowledged as a central driver of fibrosis. Preclinical studies have demonstrated that blockade of SMAD2/3 phosphorylation correlates with reduced collagen deposition and myofibroblast activation, offering a strong biochemical rationale for its efficacy in fibrotic diseases (Mendoza & Jimenez, 2022; Lahn et al., 2015). Furthermore, the fact that genetic ablation of SMAD3 protects against bleomycin-induced lung fibrosis reinforces the idea that pharmacologically replicating this effect could yield significant antifibrotic benefits (Biernacka et al., 2011). Additionally, galunisertib’s oral bioavailability, established through extensive clinical investigations in oncology, provides an important advantage for long-term administration in IPF patients who require chronic therapy (Kelley et al., 2019; Lahn et al., 2015).

Another strength is the body of preclinical data supporting the antifibrotic effects of TGF‐β receptor I kinase inhibitors. Though clinical trials in IPF are not yet available, the extrapolation from oncology and liver fibrosis models—where galunisertib has shown efficacy—creates a robust preclinical foundation (Luangmonkong et al., 2017; Dadrich et al., 2016). Key assays, such as collagen contraction, αSMA expression, and SMAD2/3 phosphorylation, have been well established in these contexts and would be expected to yield comparable results in lung fibroblast cultures (Mendoza & Jimenez, 2022; Rodón et al., 2015). The emerging clinical data in various cancers, which indicate a manageable toxicity profile when administered orally on an intermittent schedule, further support the feasibility of repurposing galunisertib for a non-oncologic, chronic condition such as IPF (Lahn et al., 2015; Kelley et al., 2019).

However, several weaknesses and challenges must be considered. First, despite strong preclinical and oncology data, there is a notable absence of direct clinical studies evaluating galunisertib in pulmonary fibrosis; indeed, a comprehensive search has not revealed any registered IPF-specific clinical trials (ClinicalTrials.gov, n.d.). This gap necessitates rigorous preclinical evaluation in lung-specific fibrosis models and primary human lung fibroblast assays to ascertain whether the antifibrotic activity observed in other tissues translates effectively to the pulmonary context (Mendoza & Jimenez, 2022; Lahn et al., 2015).

A second potential weakness pertains to the dual and sometimes conflicting roles of TGF‐β in tissue homeostasis. TGF‐β not only mediates fibrogenesis but also crucially regulates immune responses and tissue repair; hence, prolonged systemic inhibition may disrupt normal reparative processes or lead to unforeseen immunological consequences (Jing et al., 2025; Holmgaard et al., 2018). The pleiotropic nature of TGF‐β signaling, while advantageous from a therapeutic targeting perspective, also raises concerns about off-target effects and tolerability issues when repurposing the drug outside an oncologic setting. It will therefore be essential to define a biologically effective dose that balances antifibrotic efficacy with minimal impact on the beneficial roles of TGF‐β in lung physiology (Lahn et al., 2015; Ye & Hu, 2021).

Moreover, the heterogeneity of fibroblast subpopulations within the lung and the complex interplay between canonical and non-canonical TGF‐β signaling pathways present additional challenges. While galunisertib selectively inhibits the SMAD-dependent pathway, non-canonical TGF‐β signaling mechanisms, which also contribute to myofibroblast differentiation and ECM deposition, may remain active. This incomplete blockade of the entire profibrotic network might necessitate combination therapies or additional agents to achieve a maximal therapeutic effect in IPF (Mendoza & Jimenez, 2022; Dadrich et al., 2016).

From a clinical development standpoint, the oncology data provide a reasonable starting point regarding dosing, pharmacokinetics, and safety; however, the translation of dosing regimens from cancer patients, who often receive therapy over a relatively short term in a different pathological context, to a chronic disease like IPF will require careful adjustment. It will be important to determine whether the intermittent dosing schedules used in oncology can be effectively adapted for long-term management of IPF, where constant suppression of fibrogenic activity might be required (Kelley et al., 2019; Lahn et al., 2015).

Finally, while preclinical assays have demonstrated that galunisertib significantly reduces collagen contraction and myofibroblast activation in vitro, the complexity of fibrotic remodeling in vivo—including contributions from immune cells, epithelial cells, and vascular components—means that in vivo efficacy in animal models of pulmonary fibrosis must be thoroughly evaluated before clinical trials in IPF can be justified (Rodón et al., 2015; Luangmonkong et al., 2017).

Overall, the mechanistic specificity, oral bioavailability, and existing clinical safety data of galunisertib represent strong attributes in favor of its potential repurposing for IPF. The drug’s ability to block TGF‐βRI kinase activity and thereby inhibit SMAD2/3 phosphorylation directly addresses the central pathway driving myofibroblast differentiation and extracellular matrix deposition in IPF (Mendoza & Jimenez, 2022; Lahn et al., 2015). However, significant gaps remain, notably the lack of direct IPF clinical data and the need to thoroughly evaluate the compound’s efficacy in lung-specific fibrotic models. The inherent complexity of TGF‐β signaling—with its critical roles in both pathological fibrosis and normal tissue homeostasis—requires that future studies carefully optimize dosing and monitor potential adverse effects. In conclusion, while galunisertib is mechanistically and pharmacologically promising for IPF therapy, further preclinical validation in pulmonary fibrosis models and subsequent clinical trials will be essential to fully establish its safety and efficacy in this challenging therapeutic area (Mendoza & Jimenez, 2022; Lahn et al., 2015; Kelley et al., 2019; ClinicalTrials.gov, n.d.).

References
Biernacka, A., Dobaczewski, M., & Frangogiannis, N. G. (2011). Tgf-β signaling in fibrosis. Growth Factors, 29, 196–202. https://doi.org/10.3109/08977194.2011.595714

ClinicalTrials.gov. (n.d.). Search results for galunisertib AND (Idiopathic Pulmonary Fibrosis OR pulmonary fibrosis OR lung fibrosis). Retrieved from https://clinicaltrials.gov/

Dadrich, M., Nicolay, N. H., Flechsig, P., Bickelhaupt, S., Hoeltgen, L., Roeder, F., Hauser, K., Tietz, A., Jenne, J., Lopez, R., Roehrich, M., Wirkner, U., Lahn, M., & Huber, P. E. (2016). Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis. OncoImmunology, 5, e1123366. https://doi.org/10.1080/2162402X.2015.1123366

Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., Inigo, I., Dobkin, J., Manro, J. R., Iversen, P. W., Surguladze, D., Hall, G. E., Novosiadly, R. D., Benhadji, K. A., Plowman, G. D., Kalos, M., & Driscoll, K. E. (2018). Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-018-0356-4

Inui, N., Sakai, S., & Kitagawa, M. (2021). Molecular pathogenesis of pulmonary fibrosis, with focus on pathways related to TGF-β and the ubiquitin-proteasome pathway. International Journal of Molecular Sciences, 22, 6107. https://doi.org/10.3390/ijms22116107

Jing, H., Gao, Y., Jing, L., Yang, H., & Liu, S. (2025). Recent advances in therapeutic use of transforming growth factor-beta inhibitors in cancer and fibrosis. Frontiers in Oncology. https://doi.org/10.3389/fonc.2025.1489701

Kelley, R. K., Gane, E., Assenat, E., Siebler, J., Galle, P. R., Merle, P., Hourmand, I. O., Cleverly, A., Zhao, Y., Gueorguieva, I., Lahn, M., Faivre, S., Benhadji, K. A., & Giannelli, G. (2019). A phase 2 study of galunisertib (TGF-β1 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma. Clinical and Translational Gastroenterology, 10, e00056. https://doi.org/10.14309/ctg.0000000000000056

Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., Benhadji, K. A., & Slapak, C. A. (2015). Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Design, Development and Therapy, 9, 4479–4499. https://doi.org/10.2147/DDDT.S86621

Luangmonkong, T., Suriguga, S., Bigaeva, E., Boersema, M., Oosterhuis, D., de Jong, K. P., Schuppan, D., Mutsaers, H. A. M., & Olinga, P. (2017). Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis. British Journal of Pharmacology, 174, 3107–3117. https://doi.org/10.1111/bph.13945

Mendoza, F. A., & Jimenez, S. A. (2022). Serine/threonine kinase inhibition as antifibrotic therapy: Transforming growth factor-β and rho kinase inhibitors. Rheumatology, 61, 1354–1365. https://doi.org/10.1093/rheumatology/keab762

Rodón, J., Carducci, M., Sepulveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., Pillay, N. S., Desaiah, D., Estrem, S. T., Paz-Ares, L., Holdhoff, M., Blakeley, J., Lahn, M. M., & Baselga, J. (2015). Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Investigational New Drugs, 33, 357–370. https://doi.org/10.1007/s10637-014-0192-4

Ye, Z., & Hu, Y. (2021). TGF-β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review). International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2021.4965",0.381021307,5
Metformin (Selleckchem S1952),"Proposal for Metformin (Selleckchem S1952)

Overview of Therapeutic Candidate:
Metformin is a well‐established, small‐molecule agent originally derived from the natural product galegine – an ingredient found in the French lilac (Galega officinalis). It belongs to the biguanide family of compounds and has been used for decades as a first‐line oral therapeutic for type 2 diabetes, where its primary role is to lower blood glucose levels through improvement of insulin sensitivity. The chemical synthesis of metformin involves the reaction of dimethylamine hydrochloride with cyanoguanidine under controlled conditions; this well‐defined synthetic process has enabled its widespread availability and use across multiple countries. As a member of the biguanide drug class, metformin’s role in type 2 diabetes management is supported by a large body of clinical data attesting to its safety, tolerability, and efficacy. Moreover, its pharmacokinetic profile is well understood, including relatively high oral bioavailability and wide tissue distribution, including the lung. Overall, metformin is a natural candidate for repurposing in other diseases because its decades of clinical use have provided robust insights into its mechanism(s) of action and safety in long‐term administration (Cheng et al., 2021).

Therapeutic History:
Metformin has an extensive therapeutic history in the management of metabolic diseases, specifically type 2 diabetes mellitus. Historically, its clinical use hinges on its ability to reduce hepatic gluconeogenesis and improve peripheral insulin sensitivity. Over time, observational studies have suggested that metformin may offer ancillary benefits such as anti‐aging effects, reductions in cancer risk, and modulation of inflammation. This broad spectrum of beneficial effects has stimulated interest in exploring metformin’s potential beyond glycemic control. In the context of lung diseases, several preclinical studies have evaluated metformin for its anti‐fibrotic activity. Notably, experimental models, including bleomycin‐induced lung fibrosis in mice, have demonstrated that metformin can reverse established fibrosis via activation of AMP-activated protein kinase (AMPK) (Rangarajan et al., 2018). Furthermore, in silica-induced pulmonary fibrosis models – which share molecular and cellular features with idiopathic pulmonary fibrosis (IPF) – metformin not only reduced inflammation and oxidative stress but also inhibited the fibroblast-to-myofibroblast transition that underlies fibrogenesis (Cheng et al., 2021; Li et al., 2021). In retrospective clinical analyses evaluating concomitant medications in IPF patients, metformin use did not significantly alter disease progression, though the findings remained inconclusive and suggest the need for more controlled clinical interventions (Kreuter et al., 2019). At present, a search on ClinicalTrials.gov using the query “AREA[InterventionName]Metformin AND AREA[Condition]Idiopathic Pulmonary Fibrosis” indicates no registered clinical trials specifically evaluating metformin in IPF (ClinicalTrials.gov, n.d.). This history of preclinical evidence, combined with extensive human safety data from its antidiabetic application, provides a robust foundation for exploring metformin as a repurposed therapeutic candidate in IPF.

Mechanism of Action:
Metformin’s primary biochemical action is the activation of AMP‐activated protein kinase (AMPK), a cellular energy sensor that regulates metabolic homeostasis. Upon activation, AMPK modulates a broad range of downstream pathways, including the inhibition of mammalian target of rapamycin (mTOR) signaling, thereby promoting autophagy, reducing protein synthesis, and ultimately leading to a reduction in cell proliferation and enhanced cellular repair processes. One of the particularly promising aspects of AMPK activation is its ability to interfere with pro‐fibrotic signaling pathways. In the context of pulmonary fibrosis, transforming growth factor-beta 1 (TGF-β1) is a key cytokine that drives fibrogenesis through the phosphorylation of SMAD3. Phosphorylated SMAD3 translocates to the nucleus where it binds to regulatory sequences to induce genes associated with extracellular matrix (ECM) production, fibroblast activation, and myofibroblast differentiation. Preclinical studies have shown that metformin can inhibit TGF-β1-induced SMAD3 phosphorylation in lung fibroblasts, leading to reduced expression of α-smooth muscle actin (αSMA), collagen type I, and fibronectin – all critical markers of myofibroblast activation (Cheng et al., 2021; Rangarajan et al., 2018).

Beyond the direct inhibition of SMAD3 signaling, metformin also has effects on mechanotransduction pathways mediated by the transcriptional regulators YAP/TAZ. In fibrotic conditions, increased matrix stiffness and cellular tension drive YAP/TAZ nuclear localization, which in turn enhances fibroblast contractility, proliferation, and further production of ECM components. Although not all studies have provided explicit experimental data regarding metformin’s direct action on YAP/TAZ in IPF models, literature suggests that the modulation of AMPK by metformin indirectly suppresses YAP/TAZ-mediated responses by attenuating the cytoskeletal tension and mechanical signals that activate these transcription factors (Rangarajan et al., 2018; Matsubayashi et al., 2023). Additionally, metformin has been shown to reduce oxidative stress by downregulating NADPH oxidase isoform NOX4 – an enzyme that generates reactive oxygen species (ROS) and further amplifies fibrotic signaling – thereby decreasing the oxidative milieu that contributes to fibroblast activation and ECM deposition (Sato et al., 2016; Gao et al., 2018). There is also evidence that metformin’s suppression of fibroblast activation involves the regulation of STAT3 and S100A4, which are implicated in cell migration, contractility, and ECM remodeling, although these pathways are less characterized with respect to TGF-β1/SMAD3 or YAP/TAZ in the immediate context of IPF (Ji et al., 2023). In summary, metformin exerts its potential antifibrotic effects by a multifaceted mechanism: activating AMPK; dampening TGF-β1-induced SMAD3 phosphorylation; attenuating YAP/TAZ-mediated mechanotransduction; reducing NOX4-driven ROS production; and ultimately decreasing the contractility and ECM deposition by fibroblasts. These molecular interactions are supported by numerous preclinical investigations using both bleomycin-induced and silica-induced pulmonary fibrosis models (Cheng et al., 2021; Rangarajan et al., 2018; Li et al., 2021).

Expected Effect:
In the proposed assay employing 3D collagen matrices to simulate the lung extracellular environment, the hypothesis is that metformin will reduce fibroblast contractility, a key contributor to tissue stiffening in IPF. By inhibiting TGF-β1-driven SMAD3 phosphorylation, metformin is expected to attenuate the induction of pro-fibrotic markers, including αSMA and collagen type I, which are vital for myofibroblast differentiation. Studies have demonstrated that treatment with metformin in fibroblast cultures leads to a downregulation of these markers, resulting in decreased collagen deposition and a reduction in the contractile phenotype of the cells (Sato et al., 2016; Rangarajan et al., 2018). Additionally, the reduction in YAP/TAZ activity – either directly or via decreased mechanical feedback from the extracellular matrix – should result in less pronounced fibroblast contractility, ultimately alleviating the mechanical stresses that drive further fibrogenesis (Matsubayashi et al., 2023; Wu et al., 2021). In vitro, it is anticipated that metformin will show a dose-dependent reduction in fibroblast contractile forces in 3D collagen gel contraction assays, thereby serving as a surrogate for its potential to reduce lung stiffness in vivo. Moreover, metformin’s ability to activate AMPK is associated with improved mitochondrial function and enhanced autophagy, which contributes to the deactivation or reprogramming of myofibroblasts into a less fibrogenic phenotype. These expected cellular and molecular effects are congruent with findings from animal models in which metformin treatment has led to measurable decreases in collagen deposition and amelioration of fibrosis (Rangarajan et al., 2018; Li et al., 2021). Finally, given metformin’s extensive history of safe oral administration and its known lung tissue distribution, the translational potential to use clinically relevant oral doses – which fall within its known therapeutic range for diabetes – is a significant point favoring its repurposing in IPF, despite the fact that many in vitro studies have employed higher concentrations that may not directly reflect plasma levels in humans (Matsubayashi et al., 2023).

Overall Evaluation:
Metformin presents as a promising candidate for repurposing as an antifibrotic therapy in idiopathic pulmonary fibrosis due to its well-established safety profile, extensive clinical use, and robust preclinical evidence supporting its multifaceted mechanisms of action. The strengths of metformin include its ability to activate AMPK, which has a central role in counteracting fibrogenic signaling cascades, particularly TGF-β1-induced SMAD3 phosphorylation. In numerous preclinical studies using bleomycin- and silica-induced models, metformin has been shown to reduce key fibrotic markers, decrease fibroblast contractility, and modulate cellular processes such as autophagy and mitochondrial biogenesis (Cheng et al., 2021; Rangarajan et al., 2018). Its putative capacity to block YAP/TAZ-mediated mechanotransduction further contributes to its potential in reducing extracellular matrix deposition and tissue stiffening – central pathological features of IPF (Matsubayashi et al., 2023; Wu et al., 2021). Additionally, the oral dosing regimen, cost-effectiveness, and established human safety data from its use in metabolic diseases make metformin an attractive option for further investigation in IPF.

However, there are several weaknesses and uncertainties that must be acknowledged. First, despite encouraging preclinical data, there remains an absence of controlled clinical trial evidence demonstrating metformin’s efficacy specifically in IPF patients; current clinical data have been largely observational or retrospective in nature and did not indicate significant changes in clinically relevant outcomes when metformin was used as a concomitant treatment (Kreuter et al., 2019; ClinicalTrials.gov, n.d.). Second, many of the in vitro studies describing metformin’s antifibrotic effects have employed drug concentrations that are significantly higher than the plasma concentrations achievable with standard dosing in humans; this discrepancy raises concerns regarding the translation of in vitro mechanistic findings to clinical benefit (Matsubayashi et al., 2023). Finally, while the mechanisms of AMPK activation, SMAD3 inhibition, and modulation of YAP/TAZ are well supported by experimental evidence, the interactions among these pathways in the complex milieu of human IPF lungs may be influenced by additional factors such as comorbid conditions, variable drug penetration in fibrotic tissues, and the heterogeneity of IPF pathology. The challenges in accurately recapitulating the human pathophysiology in animal models further complicate the assessment of metformin’s antifibrotic potential.

In conclusion, metformin demonstrates multiple strengths as a therapeutic candidate for IPF, including its robust mechanism of action based on AMPK activation, inhibition of profibrotic TGF-β1/SMAD3 signaling, and potential suppression of YAP/TAZ-mediated mechanotransduction pathways. The compound’s established human safety profile and oral dosing regimen further support its feasibility for repurposing. Yet, the primary limitations lie in the lack of direct clinical trial evidence evaluating its efficacy in IPF, and the challenges associated with bridging the gap between preclinical drug concentrations and clinically relevant dosing. As such, while metformin remains a highly promising candidate based on extensive preclinical research, further rigorous clinical investigation – including dose-optimization studies and randomized controlled trials in IPF patient populations – is warranted to comprehensively validate its therapeutic potential in this devastating disease (Cheng et al., 2021; Rangarajan et al., 2018; Matsubayashi et al., 2023).

References
Cheng, D., Xu, Q., Wang, Y., Li, G., Sun, W., Ma, D., Zhou, S., Liu, Y., Han, L., & Ni, C. (2021). Metformin attenuates silica-induced pulmonary fibrosis via AMPK signaling. Journal of Translational Medicine. https://doi.org/10.1186/s12967-021-03036-5

ClinicalTrials.gov. (n.d.). Search: AREA[InterventionName]Metformin AND AREA[Condition]Idiopathic Pulmonary Fibrosis. Retrieved from https://clinicaltrials.gov

Gao, J., Ye, J., Ying, Y., Lin, H., & Luo, Z. (2018). Negative regulation of TGF‐β by AMPK and implications in the treatment of associated disorders. Acta Biochimica et Biophysica Sinica, 50, 523–531. https://doi.org/10.1093/abbs/gmy028

Ji, H., Dong, H., Lan, Y., Bi, Y., Gu, X., Han, Y., Yang, C., Cheng, M., & Gao, J. (2023). Metformin attenuates fibroblast activation during pulmonary fibrosis by targeting S100A4 via AMPK–STAT3 axis. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1089812

Kreuter, M., Lederer, D. J., Cottin, V., Kahn, N., Ley, B., Vancheri, C., Weycker, D., Atwood, M., Kirchgaessler, K.-U., & Ryerson, C. J. (2019). Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. European Respiratory Journal, 54, 1901188. https://doi.org/10.1183/13993003.01188-2019

Li, S.-x., Li, C., Pang, X.-r., Zhang, J., Yu, G.-c., Yeo, A. J., Lavin, M. F., Shao, H., Jia, Q., & Peng, C. (2021). Metformin attenuates silica-induced pulmonary fibrosis by activating autophagy via the AMPK–mTOR signaling pathway. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.719589

Matsubayashi, S., Ito, S., Araya, J., & Kuwano, K. (2023). Drugs against metabolic diseases as potential senotherapeutics for aging-related respiratory diseases. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1079626

Rangarajan, S., Bone, N. B., Zmijewska, A. A., Jiang, S., Park, D. W., Bernard, K., Locy, M. L., Ravi, S., Deshane, J., Mannon, R. B., Abraham, E., Darley‐Usmar, V., Thannickal, V. J., & Zmijewski, J. W. (2018). Metformin reverses established lung fibrosis in a bleomycin model. Nature Medicine, 24, 1121–1127. https://doi.org/10.1038/s41591-018-0087-6

Sato, N., Takasaka, N., Yoshida, M., Tsubouchi, K., Minagawa, S., Araya, J., Saito, N., Fujita, Y., Kurita, Y., Kobayashi, K., Ito, S., Hara, H., Kadota, T., Yanagisawa, H., Hashimoto, M., Utsumi, H., Wakui, H., Kojima, J., Numata, T., Kaneko, Y., Odaka, M., Morikawa, T., Nakayama, K., & Kuwano, K. (2016). Metformin attenuates lung fibrosis development via NOX4 suppression. Respiratory Research. https://doi.org/10.1186/s12931-016-0420-x

Wu, M., Xu, H., Liu, J., Tan, X., Wan, S., Guo, M., Long, Y., & Xu, Y. (2021). Metformin and fibrosis: A review of existing evidence and mechanisms. Journal of Diabetes Research, 2021, 6673525. https://doi.org/10.1155/2021/6673525",0.378152228,16
SB-525334 (Tocris 2290),"Proposal for SB-525334 (Tocris 2290)

Overview of Therapeutic Candidate:
SB-525334 is a synthetic small molecule inhibitor discovered through targeted medicinal chemistry efforts aimed at modulating the TGF-β signaling pathway via inhibition of ALK5, also known as the TGF-β type I receptor kinase. Chemically, this compound belongs to the class of ATP-competitive kinase inhibitors and is structurally identified as 6-[2-tert-butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline, which underscores its synthetic origin rather than a naturally occurring product (NJL, DPB, WMM, & ETG, 2005, pp. 3–5). As an ATP-competitive inhibitor, SB-525334 selectively occupies the active site of ALK5, thus preventing ATP binding and subsequent phosphorylation events. Compounds belonging to this class have been extensively used in research settings to probe the TGF-β signaling pathway, given the central role of this receptor kinase in fibrogenic processes in multiple organ systems including the lung, kidney, and liver (NJL et al., 2005, pp. 3–5; Kim et al., 2020, pp. 1–6). The synthesis and chemical optimization of such small molecule inhibitors have typically evolved from high-throughput screening campaigns that identified molecules with potent inhibitory activity in the nanomolar range, and further structural optimization has refined their specificity and in vivo pharmacokinetics. In the context of drug development for fibrotic diseases, the use of synthetic kinase inhibitors has provided a strategic advantage by offering predictable pharmacologic profiles, ease of oral administration, and the potential for fine-tuning selectivity toward TGF-βRI over related kinases, such as BMP receptors or ALK4, which are not primarily implicated in the fibrotic process (NJL et al., 2005, pp. 14–15).

Therapeutic History:
Historically, the ALK5 inhibitors as a drug class have been investigated in several preclinical models of fibrosis and tissue remodeling. SB-525334 itself has been evaluated in biochemical assays and animal studies, notably in models of renal fibrosis induced by puromycin aminonucleoside nephritis where it demonstrated the ability to inhibit key gene markers of fibrosis such as procollagen-α1(I), procollagen-α1(III), and plasminogen activator inhibitor-1 (PAI-1), concurrently reducing collagen deposition in vivo (NJL et al., 2005, pp. 15–17, 27–30). Additionally, in studies focusing on pulmonary fibrosis, ALK5 inhibitors have been used to attenuate TGF-β-induced signaling in fibroblasts and to reduce extracellular matrix (ECM) deposition in bleomycin-induced lung fibrosis models, thereby demonstrating their translational potential for Idiopathic Pulmonary Fibrosis (IPF) (ClinicalTrials.gov, n.d.; Petersen et al., 2024, pp. 17–20). Although direct clinical trial data with SB-525334 in IPF patients have yet to be reported, its use in various preclinical pulmonary studies, along with its established biological activity in modulating fibroblast activation and ECM gene expression, firmly supports its potential repurposing for fibrotic lung diseases (Juillerat-Jeanneret et al., 2018, pp. 53–56). Moreover, related compounds in the same chemical class have been evaluated in the context of cancer and other fibrotic conditions, further corroborating the notion that ALK5 inhibition is a viable therapeutic strategy in modulating pathologic tissue remodeling (John et al., 2020, pp. 6–7).

Mechanism of Action:
The known mechanism of action for SB-525334 is based on its potent inhibition of the transforming growth factor-beta (TGF-β) type I receptor kinase (ALK5). Under physiological conditions, TGF-β binds to its receptors on the cell membrane, leading to the formation of a heterotetrameric complex consisting of two type II and two type I receptor subunits. The type II receptor phosphorylates the type I receptor (ALK5), which in turn phosphorylates the intracellular SMAD2 and SMAD3 proteins. These phosphorylated SMADs form a complex with SMAD4 and translocate into the nucleus to regulate the transcription of numerous genes that are involved in fibroblast activation, ECM production, and collagen deposition (NJL et al., 2005, pp. 3–5; Gah, n.d., pp. 13–17). SB-525334, by binding competitively to the ATP binding pocket of ALK5, abrogates its kinase activity and prevents the phosphorylation of SMAD2/3, thereby halting the downstream propagation of the TGF-β signaling cascade (NJL et al., 2005, pp. 14–15). This direct blockade of the signaling pathway results in diminished transcription of pro-fibrotic genes, including those encoding collagen, fibronectin, and α-smooth muscle actin (αSMA), which are critical markers of myofibroblast differentiation (Kim et al., 2020, pp. 10–14). In cell-based assays, such as fibroblast contraction assays and collagen gel contraction experiments, inhibition of ALK5 by SB-525334 correlates with a significant reduction in fibroblast-mediated remodeling of the ECM, a hallmark of the fibrotic process observed in IPF (Juillerat-Jeanneret et al., 2018, pp. 56–59). Furthermore, the specificity of SB-525334 for ALK5, with an IC50 in the nanomolar range (approximately 14.3 nM), ensures that non-target kinases such as ALK2, ALK3, and ALK6 are not significantly inhibited, which is crucial in avoiding off-target effects and unwanted modulation of parallel signaling networks (NJL et al., 2005, pp. 3–5, 32–34). The molecular interactions involve hydrogen bonding and hydrophobic interactions within the ATP binding cleft of ALK5, resulting in a conformational change that precludes substrate access and prevents SMAD phosphorylation, a mechanism that has been well-documented in biochemical assays using cultured renal and pulmonary cells (NJL et al., 2005, pp. 8–9; Thomas, 2009, pp. 1–2).

Expected Effect:
Based on the well-characterized mechanism of TGF-β signaling in fibrogenesis, the expected effect of SB-525334 in the proposed assays is multifold. First, when applied to primary IPF fibroblasts, SB-525334 is anticipated to block TGF-β1-induced SMAD2/3 phosphorylation, thus preventing their nuclear translocation and subsequent activation of pro-fibrotic gene transcription (Kim et al., 2020, pp. 26–31). As a result, downstream targets such as αSMA, collagen I and III, and PAI-1 are expected to be downregulated, which translates to a reduction in the fibroblast-to-myofibroblast transition—a key cellular event in the progression of IPF (Juillerat-Jeanneret et al., 2018, pp. 56–59). In 3D collagen gel contraction assays, where fibroblast contractility is a surrogate for in vivo ECM remodeling, SB-525334 is expected to significantly diminish collagen gel contraction by reducing the contractile phenotype of myofibroblasts, further reflecting its antifibrotic potential (Slack, 2015, pp. 34–39). In in vivo models, particularly bleomycin-induced lung fibrosis in rodents—which is a well-validated model of IPF—the administration of SB-525334 has been observed to attenuate fibrotic remodeling by lowering the inflammatory and fibrotic gene expression profiles and preserving lung function (Petersen et al., 2024, pp. 17–20). The attenuation of collagen deposition, reduction in Ashcroft fibrosis scores, and normalization of immunohistochemical markers such as αSMA serve as predictive translational markers of the compound’s efficacy in inhibiting progressive fibrotic remodeling (NJL et al., 2005, pp. 32–34). In terms of target expression, TGF-β and its receptors, including ALK5, are known to be highly expressed in IPF lungs; fibroblasts isolated from IPF patients exhibit elevated levels of TGF-β signaling components, which further supports the use of ALK5 inhibitors to modulate these aberrant signaling pathways (Gharaee-Kermani, Hu, Phan, & Gyetko, 2009, pp. 5–6; Juillerat-Jeanneret et al., 2018, pp. 48–53). Consequently, SB-525334 is postulated to exert dual beneficial effects—reduction of ECM deposition and amelioration of fibroblast contractility—that together would limit the progression of lung fibrosis.

Overall Evaluation:
In evaluating SB-525334 as a therapeutic candidate for Idiopathic Pulmonary Fibrosis, several strengths emerge that support its continued investigation and potential repurposing for IPF. The compound exhibits high selectivity and potency against ALK5, with biochemical data demonstrating an IC50 in the low nanomolar range, which is critical for ensuring effective target engagement at achievable systemic exposures (NJL et al., 2005, pp. 3–5, 14–15). Its selective inhibition of ALK5 over other kinases minimizes off-target effects, which is an important attribute given the pleiotropic roles of TGF-β signaling in normal physiology (NJL et al., 2005, pp. 32–34). The mechanism of action of SB-525334, which prevents TGF-β-induced phosphorylation and nuclear translocation of SMAD2/3, directly addresses the core pathological process in IPF—fibroblast activation and ECM deposition—as extensively documented in preclinical models of fibrosis (Gharaee-Kermani et al., 2009, pp. 5–6; Juillerat-Jeanneret et al., 2018, pp. 56–59). Moreover, its demonstrated efficacy in reducing markers of fibrosis and improving histological outcomes in animal models such as the bleomycin-induced lung fibrosis model provides translational evidence that further supports its potential clinical application in IPF (Petersen et al., 2024, pp. 17–20; Slack, 2015, pp. 34–39). In addition, SB-525334 has shown promising effects in both biochemical inhibition assays and functional cellular assays, including the reduction of fibroblast-mediated collagen gel contraction, which is directly relevant to the matrix remodeling observed in fibrotic lung tissue (Kim et al., 2020, pp. 10–14; Juillerat-Jeanneret et al., 2018, pp. 56–59).

Notwithstanding these strengths, there remain several weaknesses and challenges that must be considered. First, while preclinical data are robust in animal and cellular models, there is limited clinical evidence for the use of SB-525334 specifically in IPF patients, which necessitates careful design of future clinical trials to evaluate its pharmacokinetics, tolerability, and therapeutic window in the target population (ClinicalTrials.gov, n.d.). Second, the broad physiological roles of TGF-β signaling imply that long-term blockade of ALK5 may pose risks of adverse effects, including potential impacts on immune regulation, wound healing, and tumor suppression, all of which need to be rigorously monitored in safety studies (NJL et al., 2005, pp. 21–23; Slack, 2015, pp. 250–256). Third, while its specificity is advantageous, the potential exists for compensation by parallel fibrogenic pathways, which might limit the efficacy of ALK5 inhibition when used as monotherapy. This suggests that combination therapy with agents targeting other fibrotic pathways—such as integrin inhibitors or anti-inflammatory compounds—may be necessary to achieve a more comprehensive antifibrotic effect (Juillerat-Jeanneret et al., 2018, pp. 48–53; Gharaee-Kermani et al., 2009, pp. 11–12). Finally, the translation from preclinical models, which often employ artificially induced fibrosis, to the complex and heterogeneous pathology of human IPF remains inherently challenging, and the reproducibility of results across different models and eventual clinical endpoints will be a key determinant in the successful development of SB-525334 as an IPF therapeutic (Petersen et al., 2024, pp. 17–20; Slack, 2015, pp. 34–39).

In summary, SB-525334 stands out as a highly promising repurposed therapeutic candidate for IPF due to its potent and selective inhibition of ALK5, a well-validated target in fibrotic diseases. The comprehensive preclinical data—demonstrated biochemical efficacy, favorable pharmacodynamic profile, and robust antifibrotic activity in relevant animal models—well support the hypothesis that SB-525334 can attenuate key aspects of fibroblast activation and extracellular matrix deposition that underpin IPF progression (NJL et al., 2005, pp. 5–8; Kim et al., 2020, pp. 26–31). However, translation to clinical efficacy will depend on confirming a favorable safety profile in humans, optimizing dosing regimens to achieve effective lung tissue concentrations, and potentially integrating this compound into a combination therapeutic strategy to address the multifactorial nature of IPF pathogenesis. Given the strong mechanistic rationale, ongoing advances in ALK5-targeted therapies, and the promising preclinical evidence currently available, SB-525334 merits further investigation as a candidate for treating idiopathic pulmonary fibrosis, with the understanding that meticulous clinical evaluation will be essential to fully validate its therapeutic potential (NJL et al., 2005, pp. 32–34; Juillerat-Jeanneret et al., 2018, pp. 56–59; Slack, 2015, pp. 34–39).

References
ClinicalTrials.gov. (n.d.). Search for SB-525334 or ALK5 inhibitor or TGF-beta receptor type I inhibitor and (Idiopathic Pulmonary Fibrosis or pulmonary fibrosis or lung fibrosis). Retrieved Month Day, Year, from https://clinicaltrials.gov

Gah, A. (n.d.). Tale of two ALKs: ALK1 and ALK5 in TGFβ1-induced myofibroblast differentiation. Unknown Journal.

Gharaee-Kermani, M., Hu, B., Phan, S., & Gyetko, M. (2009). Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: Focus on TGFβ signaling and the myofibroblast. Current Medicinal Chemistry, 16, 1400–1417. https://doi.org/10.2174/092986709787846497

John, A. E., Graves, R. H., Pun, K. T., Vitulli, G., Forty, E. J., Mercer, P. F., Morrell, J. L., Barrett, J. W., Rogers, R. F., Hafeji, M., Bibby, L. I., Gower, E., Morrison, V. S., Man, Y., … & Slack, R. J. (2020). Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis. Nature Communications. https://doi.org/10.1038/s41467-020-18397-6

Juillerat-Jeanneret, L., Aubert, J.-D., Mikulic, J., & Golshayan, D. (2018). Fibrogenic disorders in human diseases: From inflammation to organ dysfunction. Journal of Medicinal Chemistry, 61(22), 9811–9840. https://doi.org/10.1021/acs.jmedchem.8b00294

Kim, S., Saigal, A., Zhao, W., Amini, P., Tamburino, A. M., Raghavan, S., & Hoek, M. (2020). Identification of the molecular basis of anti-fibrotic effects of soluble guanylate cyclase activator using the human lung fibroblast phosphoproteome [Preprint]. bioRxiv. https://doi.org/10.1101/2020.06.12.148908

NJL, D. P. B., WMM, & ETG. (2005). Page inhibition of gene markers of fibrosis with a novel inhibitor of TGFβ-type I receptor kinase in puromycin-induced nephritis. Unknown Journal.

Petersen, A. G., Korntner, S. H., Bousamaki, J., Oró, D., Manresa Arraut, A., Pors, S. E., Salinas, C. G., Andersen, M. W., Nie, Y., Butts, J., Roqueta-Rivera, M., Simonsen, U., Hansen, H. H., & Feigh, M. (2024). Reproducible lung protective effects of a TGFβR1/ALK5 inhibitor in a bleomycin-induced and spirometry-confirmed model of IPF in male mice. Physiological Reports. https://doi.org/10.14814/phy2.70077

Slack, R. J. (2015). Pharmacological characterisation of small molecule RGD-mimetics targeting αvβ6-mediated activation of TGFβ in idiopathic pulmonary fibrosis. Unknown Journal.

Thomas, M. (2009). Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is …. Unknown Journal.",0.333324341,6
JQ1 (Cayman 15237),"Proposal for JQ1 (Cayman 15237)

Overview of Therapeutic Candidate:
JQ1 is a small‐molecule inhibitor originally synthesized based on a thienotriazolodiazepine scaffold that was discovered as a chemical probe to target the bromodomain and extra‐terminal (BET) family of proteins, most notably BRD4. This compound belongs to the drug class of epigenetic modulators that interfere with transcriptional regulation by competitively binding to bromodomains – specialized “reader” domains that recognize acetylated lysine residues on histone tails. In its design and synthesis, researchers optimized JQ1 to achieve high affinity and cell permeability while aiming to minimize off‐target interactions; its development was driven originally by the need to block the oncogenic transcription machinery in cancers such as NUT midline carcinoma and various hematological malignancies (Pérez-Salvia & Esteller, 2017). More broadly, BET inhibitors have been extensively used as research tools to explore roles of epigenetic regulation in inflammation, cell proliferation, and remodeling in multiple diseases. The structural design of JQ1—its chemically synthesized core structure and configuration—allows first‐in‐class modulation of BET proteins such as BRD2, BRD3, and particularly BRD4, which has emerged as a master regulator of transcription in several pathologies including cancer and fibrosis (Adewumi, 2023; Bid et al., 2016).

Therapeutic History:
Historically, JQ1 has been primarily explored in oncology where its ability to displace BET proteins from chromatin had been shown to downregulate oncogenic drivers like c‐MYC and other transcription factors such as AP-1. Studies confirmed its anti‐proliferative effects across a number of cancers and this provided a critical proof‐of‐principle that interfering with BET chromatin interactions could yield therapeutic benefits. Beyond oncology, BET inhibitors like JQ1 have been explored in inflammatory disease models, where the inhibition of pro-inflammatory gene transcription in lung and vascular tissues leads to noticeable attenuation of inflammation (Mumby et al., 2017; Chen et al., 2016). More pertinently to the current investigation, multiple preclinical studies have extended the investigation of JQ1—or structurally related BET inhibitors—to models of fibrotic diseases. For example, in preclinical models of pulmonary fibrosis initiated by bleomycin injury, JQ1 treatment has been observed to reduce lung collagen deposition, decrease markers of fibroblast activation such as α-smooth muscle actin (αSMA) and collagen I, and ultimately attenuate features of lung fibrosis (Sanders et al., 2020; Suzuki et al., 2020). In similar fibrotic contexts, studies examining pleural fibrosis and mesothelial-to-mesenchymal transition (MesoMT) have demonstrated that JQ1 effectively blocks TGF-β–induced profibrotic gene transcription (Adewumi, 2023). There are no registered clinical trials specifically using JQ1 for Idiopathic Pulmonary Fibrosis (IPF) as indicated by recent searches (ClinicalTrials.gov, n.d.); however, the extensive preclinical evidence in oncology, inflammatory lung conditions, and fibrotic disorders provides a strong rationale to consider repurposing JQ1 for IPF treatment (ClinicalTrials.gov, n.d.; Brasier & Zhou, 2020).

Mechanism of Action:
At the molecular level, BET proteins such as BRD4 function as epigenetic “readers” by binding to acetylated lysine residues on histone tails and thereby recruit transcriptional complexes to chromatin. JQ1 exerts its effect by competitively binding to the acetyl-lysine recognition pocket within the bromodomains of BET proteins, effectively displacing them from chromatin. This displacement robustly disrupts the assembly of transcription elongation complexes, including those involving P-TEFb and CDK9, and results in reduced transcription of multiple genes that drive proliferation, inflammation, and fibrotic remodeling (Tang et al., 2013; Brasier & Zhou, 2020).
When considering idiopathic pulmonary fibrosis (IPF), fibrosis is characterized by excessive extracellular matrix deposition and contractile myofibroblast accumulation. Several studies suggest that BRD4 is upregulated in fibrotic tissues and that its chromatin association is essential for the transcription of key profibrotic genes, including connective tissue growth factor (CTGF), collagen I, and αSMA; these genes are responsible for matrix deposition and enhanced fibroblast contractility (Adewumi, 2023; Guo et al., 2023). By binding to and inhibiting BRD4, JQ1 is proposed to reduce the transcription of these fibrotic genes. Moreover, BET inhibition has been shown to reduce the expression of NADPH oxidase 4 (NOX4), a mediator of oxidative stress frequently elevated in IPF, alleviating one of the drivers of fibroblast activation and extracellular matrix production (Sanders et al., 2020; Stock et al., 2019). At a biochemical level, JQ1’s reversible binding properties allow transient modulation of the epigenetic landscape, potentially permitting normal gene regulation to re-establish over time after cessation of treatment (Bernau et al., 2022). In many in vitro studies, the effect of JQ1 also encompasses a reduction in 3D‐collagen gel contraction by fibroblasts – an important functional correlate of myofibroblast activity – which is consistent with the inhibition of profibrotic gene transcription (Suzuki et al., 2020; Adewumi, 2023).
Importantly, BRD4’s involvement in the TGF-β signaling pathway has been well documented. TGF-β is a well-established driver of fibroblast-to-myofibroblast differentiation in IPF. Under TGF-β stimulation, increased acetylation of histones at profibrotic gene promoters recruits BRD4 to these regulatory regions; JQ1, by displacing BRD4, subsequently suppresses TGF-β–induced transcription of CTGF, collagen I, and αSMA (Adewumi, 2023; Sanders et al., 2020). This detailed mechanism underpins the central hypothesis that when BRD4 is prevented from exerting its transcriptional control over profibrotic genes, both fibroblast differentiation and functional activities such as contractility are efficiently reduced.

Expected Effect:
Based on its mechanism, the expected therapeutic effect of JQ1 in an IPF context is a significant reduction in fibrotic gene expression. In cellular assays using primary human lung fibroblasts derived from IPF patients, treatment with JQ1 is anticipated to lead to a decrease in the mRNA and protein levels of CTGF, collagen I, and αSMA. This downregulation is expected to translate functionally into reduced fibroblast contractility and a diminished ability to contract 3D collagen matrices, which serves as an in vitro proxy for fibrotic tissue remodeling (Guo et al., 2023; Suzuki et al., 2020).
Furthermore, preclinical in vivo data in models of lung injury and bleomycin-induced fibrosis suggest that JQ1 can attenuate overall lung fibrosis. In these models, administration of JQ1 results in reduced collagen deposition by lowering hydroxyproline content in lung tissues and improves histological markers of fibrosis – data that lend strong support to its potential effect in IPF (Sanders et al., 2020; Stock et al., 2019). The reduction in fibrotic gene expression is further expected to decrease extracellular matrix stiffness and interfere with the positive feedback loops that otherwise perpetuate myofibroblast persistence in IPF (Brasier & Zhou, 2020; Adewumi, 2023). Notably, evidence from studies in pleural fibrosis models shows that JQ1’s antifibrotic effects are more pronounced when the compound is applied early during the fibrotic process rather than on established fibrosis, emphasizing the importance of treatment timing. However, even when administered in therapeutic regimens (after fibrosis is established), JQ1 has still demonstrated partial reversal of the fibrotic phenotype, indicative of its robust epigenetic modulation (Adewumi, 2023).
Moreover, at the molecular level, decreases in levels of profibrotic transcription factors mediated by BRD4 inhibition (such as diminished recruitment of p300 and NF-κB components to fibrotic promoters) would additionally lower inflammatory signaling, which is tightly linked to fibrosis progression in IPF. In pulmonary tissues where BRD4 is overexpressed and contributes to lung remodeling, JQ1 administration is expected to restore a more normal epigenetic profile and thereby improve lung architecture and function (Sanders et al., 2020; Guo et al., 2023). This comprehensive multifaceted mechanism of action suggests that JQ1 would not only reduce fibroblast contractility and gel contraction in vitro but could also translate into meaningful antifibrotic effects in vivo.

Overall Evaluation:
In evaluating JQ1 as a therapeutic candidate for Idiopathic Pulmonary Fibrosis, there are several strengths that position it as a promising repurposing candidate, as well as certain limitations that must be addressed before clinical translation.
One of the key strengths of JQ1 is its clearly defined molecular mechanism. By competitively inhibiting the binding of BET proteins – particularly BRD4 – to acetylated histones, JQ1 interferes with the transcription of a wide array of genes that are implicated in fibrosis, including CTGF, collagen I, and αSMA. This level of mechanistic specificity is crucial because it targets the root epigenetic dysregulation that underpins fibroblast activation and extracellular matrix deposition in IPF (Adewumi, 2023; Tang et al., 2013). In addition, the reversible nature of its binding allows temporary modulation of gene expression, which could be advantageous when considering long-term treatment regimens where complete shutdown of transcription might be deleterious (Bernau et al., 2022).
Another significant strength is the translational potential demonstrated in preclinical models. JQ1 has already shown efficacy in in vitro systems using primary fibroblasts derived from patients and in vivo in rodent models of bleomycin-induced lung injury. These studies have reported decreased profibrotic gene expression, reduced collagen deposition, and improved histological outcomes – all of which are directly relevant to the clinical pathology observed in IPF (Suzuki et al., 2020; Sanders et al., 2020). Moreover, the modulation of inflammatory pathways, as evidenced by the reduction of NF-κB activity and pro-inflammatory cytokines, further supports the utility of JQ1 in a condition like IPF, where chronic inflammation can exacerbate fibrotic remodeling (Mumby et al., 2017; Chen et al., 2016).
Despite these compelling strengths, there are also notable weaknesses that must be critically examined. First and foremost, JQ1 functions as a pan-BET inhibitor, meaning that in addition to BRD4, it also affects BRD2 and BRD3. While the inhibition of BRD4 is desired, the broader impact on other BET family proteins may lead to off-target effects and unwanted alterations in normal gene expression patterns. This lack of isoform selectivity might result in unpredictable toxicity profiles, particularly in a chronic disease such as IPF where long-term administration would be required (Adewumi, 2023; Alqahtani et al., 2019).
Another point of concern is related to the pharmacokinetic and safety profile of JQ1. Although preclinical studies in murine models have provided promising results, the compound’s relatively short half-life and the need for higher concentrations to achieve sustained efficacy in some settings may pose challenges when translating to human patients. High doses required to maintain therapeutic levels without eliciting adverse side effects—such as bone marrow suppression or other systemic toxicities noted in some cancer studies—could limit its clinical applicability (Bid et al., 2016; Bernau et al., 2022). Furthermore, while the modulation of the epigenetic regulators is a powerful strategy, the chronic inhibition of BET proteins might interfere with normal cellular functions, particularly in tissues with high turnover or in the immune system, potentially leading to immunosuppression or other off-target phenomena (Guo et al., 2023).
Additionally, the current body of literature shows extensive preclinical evidence in acute and experimental models of fibrosis; however, there is a significant gap in clinical trial data specifically targeting Idiopathic Pulmonary Fibrosis with JQ1. The absence of clinical data means that the safety and efficacy observed in animal models may not fully predict outcomes in human patients. This gap represents a major hurdle that must be overcome through rigorous phase I/II clinical studies before JQ1 can be accepted as a viable therapy for IPF (ClinicalTrials.gov, n.d.; Brasier & Zhou, 2020).
In summary, JQ1 stands out as a promising candidate for repurposing in the treatment of Idiopathic Pulmonary Fibrosis because of its well-defined epigenetic mechanism of action, demonstrated efficacy in reducing profibrotic gene expression and fibroblast contractility, and supportive preclinical data in models of lung fibrosis. Its ability to disrupt the recruitment of BRD4 to profibrotic promoters provides a strong rationale for its antifibrotic effects, with expected outcomes including reduced collagen deposition, decreased myofibroblast differentiation, and amelioration of lung architectural distortion. Nevertheless, its pan-BET inhibitory action, potential off-target effects, suboptimal pharmacokinetics, and the lack of direct clinical trial data in IPF represent significant weaknesses. These concerns underscore the need for further optimization—possibly through the development of more selective BRD4 inhibitors or PROTAC-based strategies such as ARV-825—and for comprehensive clinical evaluations to firmly establish the safety and translatability of this approach for chronic fibrotic lung diseases (Adewumi, 2023; Sanders et al., 2020; Stratton et al., 2017).

References

Adewumi, J. (2023). Targeting BRD4 in the treatment of pleural fibrosis. Unknown Journal.

Alqahtani, A., Choucair, K., Ashraf, M., Hammouda, D. M., Alloghbi, A., Khan, T., … Nemunaitis, J. (2019). Bromodomain and extra-terminal motif inhibitors: A review of preclinical and clinical advances in cancer therapy. Future Science OA. https://doi.org/10.4155/fsoa-2018-0115

Bernau, K., Skibba, M., Leet, J. P., Furey, S., Gehl, C., Li, Y., … Brasier, A. R. (2022). Selective inhibition of bromodomain-containing protein 4 reduces myofibroblast transdifferentiation and pulmonary fibrosis. Frontiers in Molecular Medicine. https://doi.org/10.3389/fmmed.2022.842558

Bid, H. K., Phelps, D. A., Xiao, L., Guttridge, D. C., Lin, J., London, C., … Houghton, P. J. (2016). The bromodomain BET inhibitor JQ1 suppresses tumor angiogenesis in models of childhood sarcoma. Molecular Cancer Therapeutics, 15, 1018–1028. https://doi.org/10.1158/1535-7163.MCT-15-0567

Brasier, A. R., & Zhou, J. (2020). Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling. Drug Discovery Today, 25, 126–132. https://doi.org/10.1016/j.drudis.2019.11.002

Chen, K., Campfield, B. T., Wenzel, S. E., McAleer, J. P., Kreindler, J. L., Kurland, G., … Kolls, J. K. (2016). Anti-inflammatory effects of bromodomain and extraterminal domain inhibition in cystic fibrosis lung inflammation. JCI Insight. https://doi.org/10.1172/jci.insight.87168

ClinicalTrials.gov. (n.d.). Search of “JQ1 AND (idiopathic pulmonary fibrosis OR IPF OR lung fibrosis)”. ClinicalTrials.gov. Retrieved June 15, 2024, from https://clinicaltrials.gov

Guo, X., Olajuyin, A., Tucker, T. A., Idell, S., & Qian, G. (2023). BRD4 as a therapeutic target in pulmonary diseases. International Journal of Molecular Sciences, 24, 13231. https://doi.org/10.3390/ijms241713231

Mumby, S., Gambaryan, N., Meng, C., Perros, F., Humbert, M., Wort, S. J., & Adcock, I. M. (2017). Bromodomain and extra‐terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension. Respirology, 22, 157–164. https://doi.org/10.1111/resp.12872

Pérez-Salvia, M., & Esteller, M. (2017). Bromodomain inhibitors and cancer therapy: From structures to applications. Epigenetics, 12, 323–339. https://doi.org/10.1080/15592294.2016.1265710

Sanders, Y. Y., Lyv, X., Zhou, Q. J., Xiang, Z., Stanford, D., Bodduluri, S., … Thannickal, V. J. (2020). BRD4-p300 inhibition downregulates NOX4 and accelerates lung fibrosis resolution in aged mice. JCI Insight. https://doi.org/10.1172/jci.insight.137127

Stock, C. J. W., Michaeloudes, C., Leoni, P., Durham, A. L., Mumby, S., Wells, A. U., … Lindahl, G. E. (2019). Bromodomain and extraterminal (BET) protein inhibition restores redox balance and inhibits myofibroblast activation. BioMed Research International, 2019, Article 1484736. https://doi.org/10.1155/2019/1484736

Stratton, M. S., Haldar, S. M., & McKinsey, T. A. (2017). BRD4 inhibition for the treatment of pathological organ fibrosis. F1000Research, 6, 1015. https://doi.org/10.12688/f1000research.11339.1

Suzuki, K., Kim, J.-D., Ugai, K., Matsuda, S., Mikami, H., Yoshioka, K., … Kasuya, Y. (2020). Transcriptomic changes involved in the dedifferentiation of myofibroblasts derived from the lung of a patient with idiopathic pulmonary fibrosis. Molecular Medicine Reports, 22, 1518–1526. https://doi.org/10.3892/mmr.2020.11218

Tang, X., Peng, R., Ren, Y., Apparsundaram, S., Deguzman, J., Bauer, C. M., … Budd, D. C. (2013). BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis. Molecular Pharmacology, 83, 283–293. https://doi.org/10.1124/mol.112.081661",-0.049304392,2
"Resolvin D1 (BioLegend 480017)

Below is a comprehensive literature review evaluating Resolvin D1 (BioLegend 480017) as a repurposed drug candidate for Idiopathic Pulmonary Fibrosis (IPF).

────────────────────────────────────────","Proposal for Resolvin D1 (BioLegend 480017)

Below is a comprehensive literature review evaluating Resolvin D1 (BioLegend 480017) as a repurposed drug candidate for Idiopathic Pulmonary Fibrosis (IPF).

────────────────────────────────────────
Overview of Therapeutic Candidate
Resolvin D1 (RvD1) is an endogenous specialized pro-resolving lipid mediator (SPM) that is biosynthesized from the omega-3 fatty acid docosahexaenoic acid (DHA). Discovered as part of the resolution phase of acute inflammation, RvD1 is characterized by its unique stereochemistry that confers remarkably high affinity for its cognate receptors. Because it is generated naturally in the human body, RvD1 plays a fundamental role in actively shutting off inflammatory signals and promoting tissue repair after an insult. As a member of the SPM class, RvD1 shares common features with other pro-resolving lipid mediators that have been traditionally exploited in biochemical studies to delineate the inner workings of inflammation resolution. More recently, these mediators have been repurposed as therapeutic candidates targeting chronic inflammatory and fibrotic disorders. In the context of IPF, where chronic unresolved inflammation leads to sustained fibroblast activation and extracellular matrix (ECM) accumulation, harnessing an endogenous compound such as Resolvin D1 may afford improved specificity in modulating cellular pathways. This therapeutic candidate—commercially available as BioLegend 480017—has generated interest because its receptor‐mediated actions are intrinsic to normal tissue repair processes and may be less prone to adverse effects compared to synthetic anti-inflammatory agents (Guilherme et al., 2023; Recchiuti et al., 2019; Thatcher et al., 2023).

────────────────────────────────────────
Therapeutic History
A considerable body of preclinical research supports the anti-inflammatory and antifibrotic actions of Resolvin D1. In multiple animal studies—most notably in the bleomycin-induced lung fibrosis model—administration of RvD1 or its aspirin-triggered epimer (AT-RvD1) has been correlated with a partial restoration of lung architecture along with notable reductions in leukocyte infiltration, interstitial edema, and fibrotic remodeling. Histopathological evaluations from these studies reveal that RvD1 treatment results in lower levels of inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), transforming growth factor-β (TGF-β), and monocyte chemoattractant protein-1 (MCP-1) (Guilherme et al., 2023). In addition, decreases in matrix metalloproteinase-9 (MMP-9) expression have been observed concomitant with normalization of tissue inhibitors of metalloproteinases, suggesting a beneficial influence on the dynamic regulation of ECM remodeling in fibrotic lung tissue.

In vitro experiments have further substantiated these findings by demonstrating that RvD1 directly impairs fibroblast differentiation into myofibroblasts. Specifically, when lung fibroblasts are stimulated with TGF-β, the presence of RvD1 results in reduced expression of α-smooth muscle actin (α-SMA), a key marker of myofibroblast activation. This observation not only reinforces the antifibrotic potential of RvD1 in cellular models but also underlines its dual ability to counteract both pro-inflammatory signaling and the structural changes that characterize fibrosis (Guilherme et al., 2023; Yatomi et al., 2015).

While RvD1 has yet to be approved for clinical use in IPF, its mechanistic promise has prompted several clinical trials investigating resolvins and other SPMs in fibrotic lung disorders. The fact that these mediators are endogenous further bolsters the translational rationale by indicating an anticipated favorable safety profile. Furthermore, the history of employing SPMs in various animal models—including those mimicking aspects of chronic obstructive pulmonary disease or allergic airway inflammation—demonstrates that the benefits of RvD1 might extend across a spectrum of pulmonary pathologies that share inflammatory and fibrotic components (Guilherme et al., 2023; Thatcher et al., 2023; ClinicalTrials.gov, n.d.).

────────────────────────────────────────
Mechanism of Action
Resolvin D1 acts by binding with high specificity to the G protein-coupled receptor ALX/FPR2, a receptor expressed on multiple cell types implicated in IPF pathogenesis, including fibroblasts and macrophages. At the molecular level, RvD1’s engagement of ALX/FPR2 triggers an intracellular cascade that leads to inhibition of nuclear factor-κB (NF-κB) signaling. NF-κB is a pivotal transcription factor that drives the expression of numerous pro-inflammatory cytokines. By dampening NF-κB activation, RvD1 significantly reduces the output of pro-inflammatory mediators, which in turn limits leukocyte recruitment and helps resolve ongoing inflammation (Guilherme et al., 2023; Recchiuti et al., 2019).

In addition, Resolvin D1 exerts direct antifibrotic effects by modulating transforming growth factor-β (TGF-β) signaling. TGF-β is recognized as a master regulator in IPF, promoting the differentiation of fibroblasts to myofibroblasts and driving collagen deposition via the Smad signaling pathway. Experimental observations indicate that RvD1 can reduce the phosphorylation of Smad transcription factors and downregulate connective tissue growth factor (CTGF) expression. These molecular events are critical in reducing the expression of α-SMA and subsequently limiting the contractile properties of myofibroblasts, which are central to the progressive stiffening and loss of lung compliance seen in IPF (Guilherme et al., 2023; Yatomi et al., 2015).

RvD1’s mechanism is further enriched by its ability to modulate immune cell behavior. Macrophages, which play a conflicting role in IPF by alternatively propagating inflammation (when polarized to an M1 phenotype) or resolving it (when polarized to an M2 phenotype), are key targets of RvD1 action. By promoting a shift to the anti-inflammatory or pro-resolving M2 phenotype, RvD1 reduces the secretion of cytokines such as TNF-α, IL-1β, and MCP-1, while also enhancing the clearance of apoptotic cells. This dual immunomodulatory function helps break the cycle of persistent inflammation that contributes to fibroblast activation and continued ECM deposition (Recchiuti et al., 2019; Thatcher et al., 2023).

Beyond these receptor-mediated effects, recent studies suggest that RvD1 can influence the expression profiles of microRNAs that regulate fibrotic gene networks. Changes in microRNA expression may lead to suppression of pro-fibrotic genes and upregulation of those involved in tissue repair. Moreover, intracellular kinase pathways such as p38 MAPK and extracellular signal-regulated kinase (ERK) are negatively regulated following the engagement of RvD1 with its receptor, culminating in decreased transcription of genes critical for fibroblast activation and ECM production (Kang et al., 2020; Thatcher et al., 2023).

Another aspect that further supports RvD1’s potential in treating IPF is its involvement in regulating extracellular matrix dynamics. By reinstating a near-normal balance between matrix metalloproteinase-9 (MMP-9) and tissue inhibitors of metalloproteinases (TIMPs), RvD1 can favor the degradation of excessive collagen accumulation and thus mitigate the fibrotic remodeling process (Yatomi et al., 2015). This multifaceted mechanism—spanning inflammatory resolution, direct antifibrotic signaling, modulation of immune cell phenotype, and ECM homeostasis—places Resolvin D1 at the nexus of several pathogenic processes that drive IPF (Guilherme et al., 2023; Recchiuti et al., 2019; Thatcher et al., 2023).

An additional challenge with endogenous mediators such as RvD1 is rapid metabolism and chemical instability. To overcome this, innovative delivery technologies have been developed. For instance, inhalable nanoparticle formulations have been successfully utilized to enhance the lung-specific bioavailability of RvD1, thereby ensuring that sufficient concentrations reach the target tissue and maximize therapeutic efficacy (Li et al., 2023).

────────────────────────────────────────
Expected Effect
Based on its documented molecular actions, Resolvin D1 is expected to yield measurable benefits in experimental models of pulmonary fibrosis. In proposed assays using primary lung fibroblasts and macrophages grown within three-dimensional collagen gels, RvD1 should manifest its antifibrotic and anti-inflammatory properties through multiple endpoints.

On the fibroblast side, when RvD1 binds to the ALX/FPR2 receptor on lung fibroblasts, it is anticipated to interfere with TGF-β signaling cascades. Specifically, fibroblasts treated with RvD1 should display a significant reduction in markers of myofibroblast differentiation, as evidenced by diminished levels of α-smooth muscle actin (α-SMA). When measured using contractility assays in 3D collagen gels, these treated fibroblasts are expected to exhibit lower contractile forces. A direct decrease in fibroblast-induced crosslinking and stiffening of the collagen matrix would be observed, reflective of reduced ECM deposition and improved tissue compliance. These expected reductions in both biochemical markers and functional contractility are consistent with in vitro studies that have demonstrated RvD1’s ability to blunt TGF-β-induced fibroblast activation (Guilherme et al., 2023; Thatcher et al., 2023).

For macrophages, the anticipated effect centers on a phenotypic shift from a predominantly pro-inflammatory state (often referred to as M1) toward a pro-resolving or anti-inflammatory phenotype (M2). As RvD1 engages ALX/FPR2 on these cells, there should be a marked decrease in the production of inflammatory cytokines such as TNF-α, IL-1β, and MCP-1. Moreover, a shift in macrophage polarization will enhance the phagocytic clearance of apoptotic cells, which is essential for resolving inflammation in the lung microenvironment. These cellular changes are expected to synergize with the direct anti-fibrotic effects on fibroblasts, ultimately leading to an environment with reduced inflammatory cell infiltration, diminished cytokine signaling, and lower ECM production. This integrated outcome would result in attenuation of the fibrotic cascade and preservation of normal lung structure and function (Li et al., 2023; Recchiuti et al., 2019; Thatcher et al., 2023).

In sum, the expected effects of RvD1 in a 3D collagen assay system include:
• A reduction in fibroblast proliferation and myofibroblast differentiation as indicated by lower α-SMA expression and dampened TGF-β/Smad signaling, ultimately reducing the contractility of fibroblasts in the collagen matrix.
• A shift in macrophage polarization, leading to a decrease in pro-inflammatory cytokine secretion and an increase in apoptotic cell clearance, which collectively reduce the local inflammatory burden that drives fibrogenesis.
• Restoration of ECM balance via the normalization of matrix metalloproteinase activity relative to TIMP levels, thereby reducing collagen deposition and matrix stiffness.

These anticipated outcomes are supported by previous demonstrations in animal models where treatment with RvD1 or its aspirin-triggered epimer yielded improved lung architecture and reduced fibrotic markers (Yatomi et al., 2015).

────────────────────────────────────────
Overall Evaluation
Collectively, the literature robustly supports Resolvin D1 as a promising repurposed drug candidate for the treatment of idiopathic pulmonary fibrosis. The multifaceted strengths and some potential weaknesses of RvD1 as a therapeutic candidate are discussed below:

Strengths:
1. Endogenous Origin and Safety Profile:
RvD1 is naturally produced in the human body during the resolution phase of inflammation. Its endogenous nature implies that the molecule is inherently “designed” for modulating inflammatory processes and tissue repair, in contrast to many synthetic drugs. This feature not only translates to a mechanistic specificity but also suggests a favorable safety profile. The receptor‐mediated actions of RvD1 are highly targeted to processes involved in resolution and repair, reducing the risk of broad immunosuppression (Guilherme et al., 2023; Thatcher et al., 2023).

2. Dual Anti-inflammatory and Antifibrotic Mechanisms:
One key advantage of RvD1 is its ability to address both the inflammatory component and the fibrotic remodeling in IPF. RvD1 attenuates NF-κB signaling, resulting in reduced production of inflammatory cytokines. Simultaneously, it modulates TGF-β signaling pathways in fibroblasts, thereby reducing myofibroblast activation, contractility, and collagen deposition. Such duality is particularly valuable in IPF, where persistent low‐grade inflammation and fibrosis interact to drive disease progression (Recchiuti et al., 2019; Thatcher et al., 2023).

3. Preclinical Efficacy in Animal Models:
Evidence from studies utilizing bleomycin-induced lung fibrosis models shows that treatment with RvD1 or its analogs results in a significant decrease in key fibrotic mediators and improvements in lung histology. These effects include reduced leukocyte infiltration, lower levels of TGF-β, and decreased ECM deposition. Similarly, in vitro studies have demonstrated suppression of fibroblast-to-myofibroblast differentiation along with decreased contractile behavior in response to TGF-β challenge (Guilherme et al., 2023; Yatomi et al., 2015).

4. Novel Delivery Strategies:
Recognizing the inherent challenges of rapid metabolic inactivation and instability of endogenous lipid mediators, recent research has advanced nanoparticle-based formulations that enable pulmonary administration. These formulations have been shown to enhance the bioavailability of RvD1 specifically in lung tissue, which is critical for translating preclinical efficacy into clinical benefit for IPF patients (Li et al., 2023).

5. Receptor Specificity and Downstream Modulation:
The ability of RvD1 to engage ALX/FPR2 on multiple cell types—including both fibroblasts and macrophages—allows for a broad yet coordinated regulation of the cellular and molecular events underpinning IPF progression. This receptor specificity has been linked to the inhibition of key pro‐inflammatory and pro‐fibrotic pathways, including the NF-κB and TGF-β/Smad cascades (Maciuszek et al., 2021; Recchiuti et al., 2019).

Weaknesses and Challenges:
1. Chemical Instability and Rapid Metabolism:
A major challenge associated with RvD1 is its rapid degradation and chemical instability, which could limit its therapeutic window in vivo. Although modern delivery systems, such as inhalable nanoparticles, have addressed some of these challenges, ensuring consistent and sustained exposure in clinical settings remains a hurdle that needs further optimization (Li et al., 2023).

2. Limited Direct Clinical Evidence:
To date, most of the compelling data for RvD1’s efficacy derive from preclinical models. The translation of these results to human IPF has yet to be firmly established through clinical trials. Although there are ongoing trials investigating resolvin-based therapies (ClinicalTrials.gov, n.d.), direct clinical efficacy in IPF is not yet confirmed.

3. Heterogeneity of Idiopathic Pulmonary Fibrosis:
IPF is a complex and heterogeneous disease. The contributions of inflammation and fibrosis can vary significantly among patients. It is highly likely that RvD1 will be more effective in subsets of patients where unresolved inflammation is a predominant driver. Thus, developing strategies for patient stratification and biomarker-based selection will be vital for successful clinical translation (Thatcher et al., 2023).

4. Mechanistic Gaps in Direct Fibroblast Contractility Assessment:
Although in vitro studies show inhibition of myofibroblast differentiation and reduced α-SMA expression by RvD1, there is still a relative paucity of studies that directly measure fibroblast contractility in three-dimensional collagen matrices independent of overall ECM deposition. This gap makes it necessary to conduct additional studies to fully validate the hypothesis that RvD1 directly reduces myofibroblast contractility in a physiologically relevant model (Guilherme et al., 2023; Thatcher et al., 2023).

────────────────────────────────────────
Overall Evaluation
Resolvin D1, as represented by BioLegend 480017, emerges as a promising repurposed drug candidate for IPF based on extensive preclinical evidence, mechanistic clarity, and innovative strategies for overcoming delivery challenges. Its endogenous origin and its role in heralding the resolution phase of inflammation confer a unique specificity that traditional anti-inflammatory drugs lack. The compound’s ability to modulate signaling pathways—ranging from NF-κB to TGF-β/Smad, alongside affecting downstream events such as microRNA expression—provides a robust, multi-targeted approach that addresses both the inflammatory and fibrotic components of IPF pathogenesis (Guilherme et al., 2023; Recchiuti et al., 2019; Thatcher et al., 2023).

The dual action on fibroblasts and macrophages is particularly commendable, as it allows Resolvin D1 to simultaneously reduce the secretion of pro-inflammatory cytokines and decrease the production of ECM components by inhibiting fibroblast-to-myofibroblast differentiation. This approach is highly relevant for a multifaceted disease such as IPF where inflammation and fibrosis are intertwined (Thatcher et al., 2023). Additionally, the promising results from nanoparticle-based pulmonary delivery systems have demonstrated enhanced lung targeting and efficacy in reducing fibrotic markers, an important consideration given the need to achieve high local drug concentrations in the lungs (Li et al., 2023).

Yet, several obstacles must be carefully addressed before advancing RvD1 into later-stage clinical studies. Foremost among these is the chemical instability and rapid metabolic degradation of RvD1 in vivo. Although nanoparticle-based formulations provide a path forward, further optimization and standardized manufacturing processes will be required to ensure the sustainability of therapeutic levels in human lungs. Moreover, while the efficacy in animal models is encouraging, the lack of robust clinical trial data and the heterogeneous nature of IPF may necessitate careful patient stratification and the use of biomarkers to identify those who are most likely to benefit from RvD1 treatment (ClinicalTrials.gov, n.d.; Thatcher et al., 2023).

Another area requiring further investigation is the direct measurement of fibroblast contractility in more complex in vitro and ex vivo models. Although current data indicate decreased α-SMA expression and reduced collagen deposition, additional studies incorporating real-time assessments of fibroblast function in three-dimensional matrices would solidify the known mechanism and its translatability to the human disease state.

In conclusion, Resolvin D1’s endogenous role as a mediator of inflammation resolution, its receptor-mediated specificity via ALX/FPR2 in both fibroblasts and macrophages, and its demonstrated ability to simultaneously suppress inflammatory and fibrotic signaling strongly support its potential as a novel therapeutic for IPF. The preclinical data—spanning reduction in pro-inflammatory cytokines, inhibition of TGF-β-driven fibroblast activation, normalizing ECM remodeling enzymes, and beneficial immunomodulation—provide a strong scientific rationale to further pursue this candidate. Ultimately, while challenges regarding stability, clinical translation, and disease heterogeneity remain, these can be addressed through strategic design of advanced drug delivery systems and appropriately targeted clinical trials. Resolvin D1 merits further evaluation in both preclinical and early-phase clinical trials to determine optimal dosing, long-term safety, and efficacy in patients suffering from IPF (Guilherme et al., 2023; Kang et al., 2020; Li et al., 2023; Maciuszek et al., 2021; Recchiuti et al., 2019; Salazar et al., 2022; Thatcher et al., 2023; Yatomi et al., 2015).

────────────────────────────────────────
Final Summary
Resolvin D1 (BioLegend 480017) represents a compelling therapeutic candidate for IPF owing to its natural role in promoting inflammation resolution and tissue repair. The extensive preclinical literature documents its capability to attenuate acute and chronic inflammation as well as to mitigate fibrosis via specific receptor-mediated effects that impact fibroblast activation, myofibroblast contractility, and extracellular matrix deposition. Nanoparticle-based pulmonary delivery strategies further enhance its translational potential by counteracting the limitations of rapid metabolic clearance. While the transition from promising preclinical results to demonstrable clinical efficacy remains to be fully validated, current evidence robustly supports further investigation of RvD1 in well-designed clinical studies with appropriate patient stratification. In light of the dual pathogenic nature of IPF—where both unresolved inflammation and fibrotic remodeling contribute significantly—targeting these processes simultaneously with an endogenous mediator such as RvD1 may provide a novel and effective avenue for treatment.

Given these promising aspects alongside the necessary challenges for translation, our recommendation is to advance Resolvin D1 into further preclinical validation with refined drug delivery formulations and to design early-phase clinical trials that incorporate biomarkers for inflammation and fibrosis. This approach will help to delineate the patient subsets most likely to benefit from RvD1 therapy and ultimately determine its potential to modify the disease course of this devastating condition (Guilherme et al., 2023; Kang et al., 2020; Li et al., 2023; Maciuszek et al., 2021; Recchiuti et al., 2019; Salazar et al., 2022; Thatcher et al., 2023; Yatomi et al., 2015).

────────────────────────────────────────
References
Guilherme, R. F., Silva, J. B. N. F., Waclawiack, I., Fraga-Junior, V. S., Nogueira, T. O., Pecli, C., Araújo-Silva, C. A., Magalhães, N. S., Lemos, F. S., Bulant, C. A., Blanco, P. J., Serra, R., Svensjö, E., Scharfstein, J., Moraes, J. A., Canetti, C., & Benjamim, C. F. (2023). Pleiotropic antifibrotic actions of aspirin-triggered resolvin D1 in the lungs. Frontiers in Immunology, 14, 886601. https://doi.org/10.3389/fimmu.2023.886601

Kang, G. J., Kim, E. J., & Lee, C. H. (2020). Therapeutic effects of specialized pro-resolving lipid mediators on cardiac fibrosis via Nrf2 activation. Antioxidants, 9(12), 1259. https://doi.org/10.3390/antiox9121259

Li, J., Xiao, Y., Zhang, Y., Li, S., Zhao, M., Xia, T., & Meng, H. (2023). Pulmonary delivery of specialized pro-resolving mediators-based nanotherapeutics attenuates pulmonary fibrosis in preclinical animal models. ACS Nano, 17(11), 15354–15370. https://doi.org/10.1021/acsnano.2c10388

Maciuszek, M., Cacace, A., Brennan, E., Godson, C., & Chapman, T. M. (2021). Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential. European Journal of Medicinal Chemistry, 213, 113167. https://doi.org/10.1016/j.ejmech.2021.113167

Recchiuti, A., Mattoscio, D., & Isopi, E. (2019). Roles, actions, and therapeutic potential of specialized pro-resolving lipid mediators for the treatment of inflammation in cystic fibrosis. Frontiers in Pharmacology, 10, 252. https://doi.org/10.3389/fphar.2019.00252

Salazar, J., Pírela, D., Nava, M., Castro, A., Angarita, L., Parra, H., Durán-Agüero, S., Rojas-Gómez, D., Galbán, N., Añez, R., Chacín, M., Díaz, A., Villasmil, N., de Sanctis, J. D., & Bermúdez, V. (2022). Specialized proresolving lipid mediators: A potential therapeutic target for atherosclerosis. International Journal of Molecular Sciences, 23(6), 3133. https://doi.org/10.3390/ijms23063133

Thatcher, T. H., Freeberg, M. A. T., Myo, Y. P. A., & Sime, P. J. (2023). Is there a role for specialized pro-resolving mediators in pulmonary fibrosis? Pharmacology & Therapeutics, 247, 108460. https://doi.org/10.1016/j.pharmthera.2023.108460

Yatomi, M., Hisada, T., Ishizuka, T., Koga, Y., Ono, A., Kamide, Y., Seki, K., Aoki-Saito, H., Tsurumaki, H., Sunaga, N., Kaira, K., Dobashi, K., Yamada, M., & Okajima, F. (2015). 17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice. Physiological Reports, 3(12), e12628. https://doi.org/10.14814/phy2.12628

ClinicalTrials.gov. (n.d.). ClinicalTrials.gov search: Resolvin D1 OR resolvin pro-resolving mediators AND idiopathic pulmonary fibrosis OR IPF OR pulmonary fibrosis. https://clinicaltrials.gov",-0.115750706,19
"Rapamycin (Sirolimus, Selleckchem S1039)","Proposal for Rapamycin (Sirolimus, Selleckchem S1039)

Overview of Therapeutic Candidate:
Rapamycin, also known as Sirolimus (Selleckchem S1039), is a macrolide compound originally isolated from the soil bacterium Streptomyces hygroscopicus. As a natural product with a complex macrocyclic lactone structure, rapamycin was discovered in the 1970s and quickly advanced as an immunosuppressive agent due to its potent inhibitory effects on cell proliferation. It belongs to the class of mTOR inhibitors and has been widely used both clinically and experimentally as an immunosuppressant in organ transplantation and as an anticancer agent. This class of compounds operates by modulating cell growth, proliferation, and metabolic response through downregulation of the mechanistic target of rapamycin complex 1 (mTORC1). Over the past few decades, rapamycin’s pharmacological profile has been completely characterized, including its well‐understood binding to the intracellular protein FKBP12 (FK binding protein 12). The rapamycin–FKBP12 complex then interacts with mTORC1, impeding its kinase activity. Historically, this compound has been used predominantly in renal transplantation to prevent rejection and in oncology settings to suppress tumor growth and proliferation. Its established use in these areas has built a substantial safety and pharmacokinetic database that supports its repurposing potential in other diseases. Given that idiopathic pulmonary fibrosis (IPF) is characterized by hyperactive fibroblast proliferation, excessive extracellular matrix (ECM) deposition, and increased myofibroblast contractility, the use of rapamycin as an mTORC1 inhibitor is mechanistically compelling. By attenuating protein synthesis pathways and cell growth signals, rapamycin may counteract the pathogenic cellular processes responsible for progressive fibrotic remodeling in the lung (Lawrence & Nho, 2018).

Therapeutic History:
Rapamycin has an extensive therapeutic history that spans its initial application as an immunosuppressant in kidney transplantation to its more recent exploration in oncology, where its antiproliferative properties have been harnessed in various cancers. In the context of pulmonary diseases, rapamycin has been evaluated in several preclinical studies for its antifibrotic potential. Experimental investigations have demonstrated that rapamycin can reduce fibroblast proliferation and suppress extracellular matrix protein synthesis, including collagens and fibronectin, which are primary drivers of fibrosis in conditions such as IPF (Gao et al., 2013). Notably, rapamycin has been shown to decrease markers of fibroblast activation such as α-smooth muscle actin (α-SMA) and collagen levels in in vitro models, as well as attenuate fibrotic remodeling in various rodent models of lung fibrosis (Lawrence & Nho, 2018). In clinical practice, although rapamycin is not yet approved for treating IPF, its pathway and mode of action have led to several clinical investigations. For instance, ClinicalTrials.gov lists at least seven trials evaluating rapamycin (sirolimus) in the context of idiopathic pulmonary fibrosis or lung fibrosis, including a completed pilot study (ClinicalTrials.gov, 2011). Nevertheless, the results from those studies remain limited in detail, and while rapamycin’s preclinical antifibrotic potential is well documented, its analysis in pulmonary fibrosis has been met with mixed outcomes, particularly due to incomplete inhibition of downstream signals critical for full antifibrotic efficacy (Molina-Molina et al., 2018).

Mechanism of Action:
At the molecular level, rapamycin acts as an allosteric inhibitor of mTORC1. Its mechanism begins with binding to FKBP12, which then interacts with a specific rapamycin-binding (FRB) domain on mTOR. This interaction primarily inhibits mTORC1, a multi-protein complex that includes essential components such as Raptor, mLST8, PRAS40, and DEPTOR. mTORC1 plays a central role in regulating protein synthesis, cell growth, metabolism, and autophagy by phosphorylating targets such as p70S6 kinase (p70S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1). Phosphorylation of p70S6K enhances protein synthesis by promoting ribosomal biogenesis, whereas phosphorylation of 4E-BP1 releases its inhibitory hold on eIF4E, thus facilitating cap-dependent mRNA translation. Rapamycin effectively suppresses the phosphorylation of p70S6K, which correlates with reduced protein synthesis and cell proliferation. However, it is well documented that 4E-BP1 phosphorylation is less sensitive to rapamycin, leading to an incomplete blockade of mTORC1 downstream signaling pathways that are essential for the translation of specific mRNAs, including those encoding collagen and other ECM proteins (Woodcock et al., 2019). In the context of IPF, hyperactive mTOR signaling in fibroblasts promotes their proliferation and differentiation into myofibroblasts, which are the effector cells responsible for excessive collagen secretion and ECM deposition, the hallmarks of IPF pathology. Studies investigating the role of mTOR in pulmonary fibrosis have demonstrated that TGF-β1, a potent profibrotic cytokine, induces mTOR activation and subsequently enhances collagen synthesis via the mTOR/p70S6K signaling pathway (Gao et al., 2013). Additionally, evidence suggests that while rapamycin can moderately reduce markers such as collagen III and fibronectin production in primary human lung fibroblasts, its inability to completely inhibit 4E-BP1 phosphorylation may limit its overall antifibrotic efficacy (Eley, 2018). Thus, rapamycin’s molecular interactions target several key pathways implicated in fibroblast activation, yet the differential sensitivity of mTORC1 substrates poses a challenge in achieving total suppression of the profibrotic signaling cascade (Lawrence & Nho, 2018; Woodcock et al., 2019).

Expected Effect:
The central hypothesis posits that rapamycin, by selectively inhibiting mTORC1, will suppress the progression of IPF through several mechanisms. First, by dampening mTORC1 activity, rapamycin is expected to reduce fibroblast proliferation effectively. Fibroblasts in IPF exhibit hyperactive proliferation due to elevated mTOR signaling, and rapamycin, by causing G₁ arrest, may limit the expansion of these cells (Lawrence & Nho, 2018). Secondly, rapamycin’s inhibition of the mTOR/p70S6K pathway should lead to a marked reduction in the synthesis of ECM proteins such as collagen and fibronectin. In vitro studies using primary human lung fibroblasts have demonstrated that rapamycin significantly decreases TGF-β1-induced production of collagen III and fibronectin at both the transcriptional and translational levels, which is critical since these ECM components are responsible for the scarring and structural disruption characteristic of IPF (Gao et al., 2013). Thirdly, an additional beneficial effect may be the attenuation of myofibroblast contractility. Myofibroblasts are characterized by their contractile phenotype, largely mediated by α-SMA, which contributes to tissue stiffness and further aberrant remodeling of the lung architecture. Although rapamycin has been shown to reduce α-SMA expression in some studies, its effectiveness in completely reversing myofibroblast contractility remains less certain due to the incomplete inhibition of the 4E-BP1 axis (Eley, 2018). In three-dimensional collagen gel contraction assays, it is anticipated that rapamycin will reduce the contractile force exerted by activated myofibroblasts, thereby preserving lung parenchymal integrity and function. Importantly, the targeted reduction in ECM production is expected to result in decreased collagen deposition in the lung, mitigating the fibrotic progression observed in IPF. The targeting of hyperactive fibroblast and myofibroblast populations in IPF is particularly relevant because these cells are known to express high levels of mTOR signaling components and profibrotic cytokines, creating a microenvironment that sustains fibrosis (Lawrence & Nho, 2018). Thus, based on mechanistic studies and preclinical data in both cell culture and animal models, rapamycin is expected to exert a dose-dependent antifibrotic effect in IPF by suppressing fibroblast proliferation, reducing synthesis of key ECM proteins, and attenuating the contractile phenotype of myofibroblasts (Molina-Molina et al., 2018; Patel et al., 2012).

Overall Evaluation:
In summary, rapamycin represents a highly promising therapeutic candidate for the treatment of idiopathic pulmonary fibrosis due to its well-characterized mechanism of action, established clinical use in other diseases, and supportive preclinical data. Rapamycin’s origins as a natural macrolide have paved the way for its extensive use as an immunosuppressant and antiproliferative agent. Its role as an allosteric mTORC1 inhibitor, through the formation of an FKBP12-rapamycin complex, directly interferes with the mTOR pathway. This interference reduces phosphorylation of targets such as p70S6K, thereby decreasing protein synthesis and cell proliferation – processes that are pathologically upregulated in IPF fibroblasts (Lawrence & Nho, 2018; Gao et al., 2013). However, despite its strengths, a key limitation of rapamycin lies in its partial inhibition of mTORC1, particularly its limited effect on 4E-BP1 phosphorylation. Since the mTORC1/4E-BP1 axis appears critical for collagen synthesis and the profibrotic phenotype, the rapamycin-induced incomplete blockade of this pathway may contribute to suboptimal antifibrotic effects in some settings (Woodcock et al., 2019; Eley, 2018). This nuance suggests that while rapamycin can reduce fibroblast proliferation and certain ECM components, it may not completely reverse the fibrogenic processes, especially those driven by TGF-β1. Preclinical studies have provided compelling evidence that rapamycin reduces collagen production and ameliorates fibrosis in rodent models; nevertheless, some investigations note that rapamycin had no significant effect on TGF-β1-induced collagen deposition in specific fibroblast populations (Eley, 2018; Gao et al., 2013). Moreover, from a clinical perspective, pilot studies such as NCT01462006 have been initiated to explore sirolimus’s effects in IPF patients; yet, the absence of robust clinical outcome data and mixed preclinical signals indicate that its efficacy may be limited when administered as monotherapy. Safety concerns also warrant consideration. Although rapamycin has a well-established safety profile in transplant patients and cancer therapy, there are documented risks of pulmonary toxicity, including interstitial pneumonitis and other adverse pulmonary reactions, albeit infrequently (Aparicio et al., 2009). This complicates its repurposing for IPF, where the lung is the primary organ at risk.

Nevertheless, the strengths of rapamycin include its extensive mechanistic and pharmacological characterization, the breadth of preclinical data supporting its antifibrotic effects in vitro and in vivo, and its ability to modulate several key pathological processes in IPF. Its immunosuppressive and antiproliferative properties, along with its influence on fibroblast-to-myofibroblast conversion and ECM synthesis, clearly align with the therapeutic needs of IPF. Given the complex pathophysiology of IPF, where multiple signaling pathways contribute to persistent fibrogenesis, therapeutic strategies that target a central node such as mTOR are rational, even if monotherapy with rapamycin might require dose optimization or combination with other antifibrotic agents to achieve maximal clinical benefit (Molina-Molina et al., 2018; Platé et al., 2020). Some studies even suggest that dual mTORC1/mTORC2 inhibitors or ATP-competitive mTOR inhibitors, which more comprehensively inhibit the mTOR pathway including its effect on 4E-BP1, may offer superior antifibrotic efficacy compared to rapamycin alone (Woodcock et al., 2019). This observation highlights a potential weakness: rapamycin's inability to fully block all fibrogenic signaling cascades may limit its utility unless used in combination therapies or in populations where mTORC1 is the predominant driver of fibrosis.

In conclusion, while rapamycin holds significant promise as a repurposed drug candidate for the treatment of idiopathic pulmonary fibrosis based on its ability to interfere with mTOR-mediated fibroblast proliferation, ECM protein synthesis, and myofibroblast differentiation, careful attention must be paid to its incomplete inhibition of certain downstream mTOR targets and potential pulmonary toxicities. The preclinical data are encouraging, especially in terms of mechanistic insights and dose-dependent effects in vitro, but clinical validation remains critical. Future directions should include well-powered clinical trials with appropriate biomarkers to assess antifibrotic efficacy, as well as exploration of combination regimens that may overcome the limitations of rapamycin’s selective inhibition profile. Overall, rapamycin’s established clinical use, detailed mechanistic understanding, and supportive preclinical evidence justify its further evaluation in IPF, yet its limitations highlight the need for continued innovation in targeted mTOR pathway modulation (ClinicalTrials.gov, 2011; Lawrence & Nho, 2018).

References
Aparicio, G., Calvo, M. B., Medina, V., Fernández, O., Jiménez, P., Lema, M., Figueroa, A., & Antón Aparicio, L. M. (2009). Comprehensive lung injury pathology induced by mTOR inhibitors. Clinical and Translational Oncology, 11, 499–510. https://doi.org/10.1007/s12094-009-0394-y

ClinicalTrials.gov. (2011). Double-blind placebo-controlled pilot study of sirolimus in idiopathic pulmonary fibrosis (IPF) (NCT01462006). https://clinicaltrials.gov/ct2/show/NCT01462006

Eley, J. (2018). Investigating the role of mTOR signalling in mediating the pro-fibrotic effects of TGF-β1. Unknown Journal, 234–236.

Gao, Y., Xu, X., Ding, K., Liang, Y., Jiang, D., & Dai, H. (2013). Rapamycin inhibits transforming growth factor β 1-induced fibrogenesis in primary human lung fibroblasts. Yonsei Medical Journal, 54(2), 437. https://doi.org/10.3349/ymj.2013.54.2.437

Lawrence, J., & Nho, R. (2018). The role of the mammalian target of rapamycin (mTOR) in pulmonary fibrosis. International Journal of Molecular Sciences, 19(3), 778. https://doi.org/10.3390/ijms19030778

Molina-Molina, M., Machahua-Huamani, C., Vicens-Zygmunt, V., Llatjós, R., Escobar, I., Sala-Llinás, E., Luburich-Hernaiz, P., Dorca, J., & Montes-Worboys, A. (2018). Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC Pulmonary Medicine, 18, 62. https://doi.org/10.1186/s12890-018-0626-4

Patel, A. S., Lin, L.-Y., Geyer, A., Haspel, J., An, C., Cao, J., Rosas, I., & Morse, D. (2012). Autophagy in idiopathic pulmonary fibrosis. PLoS ONE, 7(7), e41394. https://doi.org/10.1371/journal.pone.0041394

Platé, M., Guillotin, D., & Chambers, R. C. (2020). The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis. European Respiratory Review, 29(158), 200269. https://doi.org/10.1183/16000617.0269-2020

Woodcock, H. V., Eley, J. D., Guillotin, D., Platé, M., Nanthakumar, C. B., Martufi, M., Peace, S., Joberty, G., Poeckel, D., Good, R. B., Taylor, A. R., Zinn, N., Redding, M., Forty, E. J., Hynds, R. E., Swanton, C., Karsdal, M., Maher, T. M., … Chambers, R. C. (2019). The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis. Nature Communications, 10, 1132. https://doi.org/10.1038/s41467-018-07858-8",-0.1510134,9
"Pexidartinib (CSF1R Inhibitor, PLX3397)","Proposal for Pexidartinib (CSF1R Inhibitor, PLX3397)

Overview of Therapeutic Candidate:
Pexidartinib is a small-molecule tyrosine kinase inhibitor that specifically targets the colony-stimulating factor 1 receptor (CSF1R), a critical regulator of macrophage survival, proliferation, and differentiation (Marques, 2024, pp. 124–127). It belongs to the class of CSF1R inhibitors, which are synthetic chemical compounds originally developed to modulate macrophage populations in diseases driven by aberrant macrophage activity. Pexidartinib, also known by its research identifier PLX3397, was initially discovered through high‐throughput screening efforts aimed at identifying small molecules capable of interfering with receptor tyrosine kinase signaling; its chemical synthesis and optimization led to an oral bioavailable drug candidate that has demonstrated potent activity against CSF1R (Shang et al., 2025, pp. 5–7). Drugs in this class have generally been used in oncology and other macrophage‐mediated pathologies, and their mechanism of action is centered on the inhibition of signaling pathways that support pro‐fibrotic and pro‐tumoral macrophage subsets (ClinicalTrials.gov, n.d.). This compound’s synthetic origin affords advantages in terms of manufacturing consistency, oral dosing, and rapid tissue penetration—features that have supported its clinical approval for tenosynovial giant cell tumor (ClinicalTrials.gov, 2015).

Therapeutic History:
Historically, pexidartinib has been explored and validated predominantly within the oncology setting, where it was approved for the treatment of tenosynovial giant cell tumor—a condition known to be driven by pathological macrophage proliferation mediated by CSF1R signaling (ClinicalTrials.gov, 2015). Early-phase clinical trials in oncology demonstrated that pexidartinib could safely deplete tumor-associated macrophages (TAMs) and yield reductions in tumor volume, with pharmacodynamic markers indicating effective CSF1R blockade (Joshi et al., 2019, pp. 25–28). While its direct use in Idiopathic Pulmonary Fibrosis (IPF) has not yet been established clinically, the extensive clinical data gathered from its use in tumor settings provides a strong translational framework for repurposing efforts. In the context of IPF and other fibrotic lung diseases, the role of CSF1R-expressing macrophages is well documented, and preclinical models have shown that macrophage depletion via CSF1R inhibition correlates with reduced fibroblast activation and extracellular matrix (ECM) deposition (Joshi et al., 2019, pp. 17–21; Guilliams & Svedberg, 2021, pp. 4–6). Additionally, several clinical trial searches (ClinicalTrials.gov, n.d.) indicate significant ongoing interest in leveraging CSF1R inhibition for fibrotic conditions, thereby reinforcing pexidartinib’s potential for repurposing beyond oncology (ClinicalTrials.gov, 2015).

Mechanism of Action:
At the molecular level, pexidartinib exerts its therapeutic effects by binding to the ATP-binding pocket of the CSF1R tyrosine kinase, thereby preventing receptor autophosphorylation and subsequent downstream signaling cascades (Shang et al., 2025, pp. 5–7). This receptor blockade effectively disrupts the survival signals that are crucial for the maintenance, proliferation, and differentiation of both tissue-resident and monocyte-derived macrophages. In the lung, a subset of macrophages characterized by high CSF1R expression has been implicated in driving fibrotic pathology; these cells produce pro-fibrotic mediators such as transforming growth factor-beta (TGF-β) and platelet-derived growth factor (PDGF) that subsequently activate fibroblasts and promote extracellular matrix (ECM) deposition (Joshi et al., 2019, pp. 21–25; Guilliams & Svedberg, 2021, pp. 3–4). The inhibition of CSF1R signaling by pexidartinib leads to a reduction in the number and/or functional reprogramming of these pro-fibrotic macrophages, thereby interfering with an autocrine or paracrine loop that sustains a fibrogenic microenvironment (Joshi et al., 2019, pp. 28–32; Shang et al., 2025, p. 8). Moreover, evidence from preclinical studies in various models suggests that CSF1R inhibition modulates the inflammatory milieu by favoring a shift from a pro-fibrotic M2-like macrophage phenotype toward a less fibrogenic state, although the precise reprogramming events at the transcriptomic level remain an active area of investigation (Han et al., 2023, pp. 10–11).

Expected Effect:
In the context of Idiopathic Pulmonary Fibrosis, the hypothesis posits that pexidartinib will alleviate disease pathology by depleting or functionally regulating the CSF1R-positive, pro-fibrotic macrophage populations within lung tissue (ClinicalTrials.gov, n.d.). The reduction in these profibrotic macrophages is expected to result in lower local production of TGF-β and PDGF, two pivotal growth factors known to induce fibroblast proliferation, differentiation into myofibroblasts, and subsequent collagen and ECM deposition—a central tenet in the pathophysiology of IPF (Joshi et al., 2019, pp. 13–17; Guilliams & Svedberg, 2021, pp. 4–6). In vitro assays designed to measure 3D gel contraction, a proxy for fibroblast activation and ECM remodeling, should reflect attenuation when fibroblasts are co-cultured with lung macrophages that have been pre-treated with pexidartinib. This expected outcome is underpinned by extensive preclinical studies, which demonstrate that targeting the CSF1/CSF1R axis in animal models of lung fibrosis leads to decreased fibroblast-driven collagen deposition and improved lung architecture (Joshi et al., 2019, pp. 6–9; Laplagne et al., 2019, pp. 3–5). Additionally, biochemical assays are anticipated to show reduced gene expression of pro-fibrotic markers (e.g., TGF-β, PDGF, fibronectin) in lung tissue samples following treatment with pexidartinib, further supporting its role in modulating fibrogenic signaling pathways (Roy, 2017, pp. 284–286).

Overall Evaluation:
Overall, pexidartinib presents as a promising therapeutic candidate for repurposing in Idiopathic Pulmonary Fibrosis based on its well-defined mechanism of action and its potential to disrupt profibrotic macrophage-mediated signaling. One of the major strengths of this candidate is its established clinical safety profile in the treatment of tenosynovial giant cell tumor, which provides an important benchmark for its tolerability, as well as robust pharmacokinetic data demonstrating effective oral bioavailability (ClinicalTrials.gov, 2015; Marques, 2024, pp. 124–127). Preclinical evidence strongly supports the notion that CSF1R inhibition can mitigate lung fibrosis by decreasing the recruitment and persistence of monocyte-derived alveolar macrophages that are critical drivers of fibrotic processes in the lung (Joshi et al., 2019, pp. 17–21, 28–32). The proposed mechanism by which pexidartinib mediates its antifibrotic effects—namely by lowering the paracrine secretion of TGF-β and PDGF and subsequently reducing the activation of fibroblasts—directly addresses key pathological processes in IPF (Guilliams & Svedberg, 2021, pp. 4–6; Han et al., 2023, pp. 20–21).

Despite these strengths, certain weaknesses must be considered. First, while preclinical models provide compelling data, there remains a significant translational gap between animal models of lung fibrosis and human IPF, and it is critical to validate these findings in dedicated IPF clinical studies (ClinicalTrials.gov, n.d.). Second, potential adverse events, most notably hepatotoxicity and hematologic abnormalities, have been observed in oncology trials with pexidartinib and would require careful monitoring in patients with IPF, who may have concomitant comorbidities (Laplagne et al., 2019, pp. 22–24; Marques, 2024, pp. 45–48). Third, the heterogeneity of macrophage subsets in the lung—with tissue-resident alveolar macrophages frequently playing protective roles—raises concerns that a broad depletion strategy might impair essential immune functions and tissue homeostasis (Guilliams & Svedberg, 2021, pp. 1–2; Joshi et al., 2019, pp. 13–17). Thus, the clinical feasibility of pexidartinib in IPF will depend not only on its ability to deplete or reprogram the pathological, pro-fibrotic macrophage populations but also on its capacity to spare beneficial macrophages that are critical for normal lung function.

Furthermore, the specific impact of pexidartinib on downstream fibrogenic signaling pathways such as TGF-β and PDGF has not been extensively characterized in the context of pulmonary fibrosis; therefore, additional mechanistic studies are warranted to measure biomarker responses in lung tissue and correlate these with clinical endpoints such as forced vital capacity (FVC) and high-resolution computed tomography (HRCT) fibrosis scores (Joshi et al., 2019, pp. 21–25; Shang et al., 2025, p. 8). It is likely that combination strategies—where pexidartinib is administered alongside current anti-fibrotic agents such as nintedanib or pirfenidone—could potentiate its antifibrotic effects while allowing lower, potentially less toxic doses to be used (ClinicalTrials.gov, 2015; ClinicalTrials.gov, 2016).

Another consideration is the need for a comprehensive evaluation of its pharmacodynamic effects on both biomarker endpoints and lung function over time. Early phase clinical trials designed specifically for a fibrotic endpoint will be crucial to determine whether pexidartinib can achieve sustained modulation of macrophages in the lung, reduce fibroblast activation, and ultimately slow or reverse the progression of fibrosis (Butowski et al., 2016, pp. 5–6; Joshi et al., 2019, pp. 32–36). The current literature also indicates a strong biological rationale based on in situ analyses and single-cell RNA sequencing studies that identify distinct profibrotic macrophage populations in fibrotic niches of the lung (Joshi et al., 2019, pp. 21–25; Guilliams & Svedberg, 2021, pp. 3–4).

In conclusion, pexidartinib’s established role in oncology as a potent and orally bioavailable CSF1R inhibitor, combined with robust preclinical evidence linking CSF1R-positive macrophages to fibrotic processes in the lung, supports its evaluation as a repurposed therapeutic candidate for Idiopathic Pulmonary Fibrosis. Its mechanism of action—blocking the CSF1R-mediated signaling that sustains pathological macrophage populations—addresses the central pathophysiological drivers of IPF, namely the activation of fibroblasts through macrophage-secreted TGF-β and PDGF and the resultant ECM remodeling (Roy, 2017, pp. 284–286; Joshi et al., 2019, pp. 25–28). However, significant challenges such as ensuring selective targeting of pathogenic macrophage subsets, mitigating potential adverse effects, and bridging the translational gap from preclinical models to clinical efficacy must be solved prior to widespread adoption in IPF treatment protocols. Overall, while pexidartinib holds considerable promise based on its biochemical rationale, clinical safety record in other indications, and supportive experimental evidence, a cautious and well-structured clinical development plan with rigorous biomarker assessment will be essential to validate its efficacy in Idiopathic Pulmonary Fibrosis (ClinicalTrials.gov, n.d.; ClinicalTrials.gov, 2015; Joshi et al., 2019, pp. 17–21).

References
Butowski, N., Colman, H., De Groot, J. F., Omuro, A. M., Nayak, L., Wen, P. Y., Cloughesy, T. F., Marimuthu, A., Haidar, S., Perry, A., Huse, J., Phillips, J., West, B. L., Nolop, K. B., Hsu, H. H., Ligon, K. L., Molinaro, A. M., & Prados, M. (2016). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology, 18(4), 557–564. https://doi.org/10.1093/neuonc/nov245

ClinicalTrials.gov. (n.d.). ClinicalTrials.gov: Pexidartinib OR CSF1R inhibitor OR PLX3397 AND idiopathic pulmonary fibrosis OR lung fibrosis [Search query]. https://clinicaltrials.gov/

Daiichi Sankyo. (2015). Phase 3 study of pexidartinib for pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS) (ClinicalTrials.gov Identifier: NCT02371369). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02371369

Daiichi Sankyo. (2015). A combination clinical study of PLX3397 and pembrolizumab to treat advanced melanoma and other solid tumors (ClinicalTrials.gov Identifier: NCT02452424). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02452424

Eli Lilly and Company. (2016). A study of LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors (ClinicalTrials.gov Identifier: NCT02718911). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02718911

Guilliams, M., & Svedberg, F. R. (2021). Does tissue imprinting restrict macrophage plasticity? Nature Immunology, 22, 118–127. https://doi.org/10.1038/s41590-020-00849-2

Han, J., Dong, L., Wu, M., & Ma, F. (2023). Dynamic polarization of tumor-associated macrophages and their interaction with intratumoral T cells in an inflamed tumor microenvironment: From mechanistic insights to therapeutic opportunities. Frontiers in Immunology, 14, Article 1160340. https://doi.org/10.3389/fimmu.2023.1160340

Joshi, N., Watanabe, S., Verma, R., Jablonski, R. P., Chen, C.-I., Cheresh, P., Markov, N. S., Reyfman, P. A., McQuattie-Pimentel, A. C., Sichizya, L., Lu, Z., Piseaux-Aillon, R., Kirchenbuechler, D., Flozak, A. S., Gottardi, C. J., Cuda, C. M., Perlman, H., Jain, M., Kamp, D. W., … Misharin, A. V. (2019). A spatially restricted fibrotic niche in pulmonary fibrosis is sustained by M-CSF/M-CSFR signalling in monocyte-derived alveolar macrophages. European Respiratory Journal, 55, 1900646. https://doi.org/10.1183/13993003.00646-2019

Laplagne, C., Domagala, M., Le Naour, A., Quemerais, C., Hamel, D., Fournié, J.-J., Couderc, B., Bousquet, C., Ferrand, A., & Poupot, M. (2019). Latest advances in targeting the tumor microenvironment for tumor suppression. International Journal of Molecular Sciences, 20, 4719. https://doi.org/10.3390/ijms20194719

Marques, L. V. C. (2024). Identification of small molecules and miRNA inducing M1-like polarisation of murine and human macrophages. Journal unknown.

Roy, S. (2017). Defining the role of neuropilin-2 in macrophages: Implications in tumor associated macrophages in pancreatic cancer. Journal unknown.

Shang, Q., Zhang, P., Lei, X., Du, L., & Qu, B. (2025). Insights into CSF-1/CSF-1R signaling: The role of macrophage in radiotherapy. Frontiers in Immunology. Advance online publication. https://doi.org/10.3389/fimmu.2025.1530890",-0.197422565,14
"MK-2206 (AKT Inhibitor, Selleckchem S1078)","Proposal for MK-2206 (AKT Inhibitor, Selleckchem S1078)

Overview of Therapeutic Candidate:
MK-2206 is an orally bioavailable, synthetic small‐molecule that belongs to the class of allosteric AKT inhibitors. It was discovered through iterative medicinal chemistry efforts aimed at targeting the regulatory Pleckstrin Homology (PH) domain of AKT, thereby preventing its membrane localization, phosphorylation, and subsequent activation. This compound selectively inhibits the three human isoforms of AKT—AKT1, AKT2, and AKT3—by binding allosterically, with inhibition observed at low nanomolar concentrations. The development of MK-2206 was initially driven by the need for effective therapies in oncology, particularly in tumors characterized by hyperactivation of the PI3K/AKT/mTOR pathway. As a member of the allosteric inhibitor class, MK-2206 has demonstrated impressive target engagement in preclinical cancer models, and this mode of inhibition is distinct from that of ATP-competitive inhibitors, resulting in improved selectivity. Its synthesis and chemical optimization were geared toward achieving potent inhibition without excessive off-target effects. This class of compounds has historically been employed predominantly in cancer research and clinical oncology, where the blockade of AKT-mediated survival and metabolic signaling has been identified as a promising strategy to reduce tumor cell proliferation and induce apoptosis (Bhatt et al., 2025; Sangai et al., 2012).

Therapeutic History:
MK-2206’s therapeutic history is rooted in oncology. It has been evaluated in multiple preclinical cancer models—including breast cancer, melanoma, and non-small cell lung cancer—and has undergone several phase I clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors. In these studies, MK-2206 demonstrated a tolerable safety profile with manageable adverse events such as rash, gastrointestinal disturbances, and hyperglycemia. Although clinical efficacy in tumor suppression has been modest when used as a monotherapy, combination studies have sought to enhance its antitumor activity. Importantly, the rich clinical oncology data provide a foundation of safety and dosing that could potentially be leveraged for repurposing into other therapeutic areas. To date, there have been no registered clinical trials evaluating MK-2206 in idiopathic pulmonary fibrosis (IPF) or directly in fibrotic diseases, although the rationale for using an AKT inhibitor in IPF has been discussed in several preclinical and mechanistic studies given the central role of PI3K/AKT signaling in fibroblast activation and extracellular matrix (ECM) deposition (Bhatt et al., 2025; ClinicalTrials.gov, n.d.; Margaria et al., 2022).

Mechanism of Action:
MK-2206 acts as an allosteric inhibitor of AKT by binding to its pleckstrin homology (PH) domain, thereby preventing the conformational changes necessary for AKT’s activation by phosphorylation. This binding specifically impedes phosphorylation at the key regulatory sites threonine 308 (T308) and serine 473 (S473). The inhibition of phosphorylation abrogates AKT’s ability to propagate signals downstream to effectors such as GSK3β, mTOR complex 1 (mTORC1), and other kinases that drive processes including cell growth, metabolism, and survival. In the context of fibrotic disease, hyperactivation of the PI3K/AKT pathway in lung fibroblasts is a major contributor to aberrant fibroblast proliferation, myofibroblast differentiation (marked by αSMA expression), resistance to apoptosis, and excessive deposition of collagen and other ECM components. The molecular interactions whereby MK-2206 interferes with these pathological events involve the disruption of AKT’s substrate phosphorylation cascades, ultimately leading to the suppression of gene expression programs that foster fibroblast survival and ECM production. Preclinical studies in oncology have documented durable and sustained inhibition of AKT signaling lasting up to 48 hours after exposure to MK-2206, a characteristic that underscores its potential to impose long-lasting effects on diseased cells (Bhatt et al., 2025; Sangai et al., 2012; Mehnert et al., 2019).

Expected Effect:
The central hypothesis behind repurposing MK-2206 for idiopathic pulmonary fibrosis rests on its capacity to inhibit the hyperactive AKT signaling observed in IPF fibroblasts. In IPF, growth factors and cytokines such as transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) aberrantly activate the PI3K/AKT pathway, thereby driving the pathological activation and proliferation of fibroblasts and their differentiation into myofibroblasts that produce excessive collagen. By blocking AKT activation, MK-2206 is expected to reduce fibroblast proliferation and promote a decrease in the expression of αSMA—a marker of myofibroblast differentiation—as well as diminish three-dimensional collagen gel contraction in vitro. In effect, MK-2206 should lead to a reduction in ECM deposition and fibrotic remodeling of the lung parenchyma, potentially ameliorating the loss of lung function observed in IPF patients. The proposed mechanism is supported by the observation that inhibition of PI3K/AKT signaling in experimental models of pulmonary fibrosis leads to attenuated fibroblast proliferation, reduced collagen synthesis, and improved pulmonary function parameters (Bhatt et al., 2025; Hsu et al., 2017; Lawrence & Nho, 2018).

Overall Evaluation:
MK-2206 represents a promising therapeutic candidate for repurposing in idiopathic pulmonary fibrosis based on several convergent lines of evidence. One of its major strengths is its well-established clinical safety and pharmacokinetic profile drawn from extensive oncology trials. This pre-existing data can significantly accelerate the translation of MK-2206 into fibrotic disease indications, reducing the burden of early-phase toxicity studies and allowing for faster optimization of dosing regimens relevant to lung fibrosis. Furthermore, the mechanism of action of MK-2206—namely, the potent and selective allosteric inhibition of AKT signaling—is directly relevant to the molecular pathology of IPF. Hyperactivation of the PI3K/AKT pathway in IPF lung tissues and fibroblasts has been widely documented, with mechanistic studies showing that inhibition of this signaling cascade can attenuate key fibrotic processes such as fibroblast proliferation, apoptotic resistance, myofibroblast differentiation, and collagen production (Bhatt et al., 2025; ClinicalTrials.gov, n.d.; Mercer et al., 2016; Mehnert et al., 2019).

However, there are also potential weaknesses and challenges associated with repurposing MK-2206 for IPF. First, while the mechanistic rationale is solid, direct preclinical evidence of MK-2206’s efficacy in IPF-specific models is currently limited. Most data supporting the therapeutic targeting of the PI3K/AKT pathway in IPF come from studies using other pathway inhibitors and genetic models, and although these studies strongly implicate AKT as a driver of fibrosis, extrapolating these results to MK-2206 requires careful evaluation using dedicated preclinical IPF models. Second, drug dosing in a fibrotic setting may differ from that in oncology, where the drug has been optimized for anti-proliferative effects in tumor cells. In IPF, the therapeutic window may be narrower, as lung tissue has distinct susceptibilities, and achieving sufficient inhibition of fibroblast activity without adversely affecting normal lung repair processes or inducing systemic toxicity remains a critical concern. Third, compensatory signaling pathways often emerge when a central node like AKT is inhibited, potentially reducing the long-term efficacy of MK-2206 unless combination strategies or formulation optimizations (e.g., inhaled delivery systems) are pursued. Additionally, while manageable toxicity has been reported in cancer patients, chronic dosing in IPF patients (who are often elderly and have compromised lung function) may present different safety challenges that need to be thoroughly investigated (Bhatt et al., 2025; Qiang et al., 2025).

Overall, despite these challenges, the strengths of MK-2206 are compelling. Its established safety profile, specific mechanism of action targeting a pathway central to IPF pathogenesis, and the robust preclinical rationale for targeting PI3K/AKT signaling support its further evaluation as a candidate for repurposing into IPF treatment. The strategy to block AKT-mediated survival signals in fibroblasts, thereby reducing their proliferation and collagen synthesis, aligns well with the critical unmet medical need in IPF therapy. Although further preclinical studies and early-phase clinical trials will be necessary to refine dosing and monitor long-term efficacy and side effects, MK-2206 emerges as a highly promising candidate with the potential to address a significant gap in current IPF treatment options (Bhatt et al., 2025; Sangai et al., 2012).

In summary, the repurposing rationale for MK-2206 in IPF is built on several key pillars:
1. Its synthetic origin and classification as an allosteric AKT inhibitor derived from oncology drug development justify its consideration as a high-specificity tool to modulate a central fibrotic pathway (Bhatt et al., 2025; Sangai et al., 2012).
2. The therapeutic history in oncology provides a substantial safety and pharmacokinetic basis, although direct clinical use in IPF remains to be established (Bhatt et al., 2025; ClinicalTrials.gov, n.d.).
3. Its mechanism of action—inhibition of AKT phosphorylation at key regulatory sites leading to downstream reduction in fibroblast survival signals—directly addresses the pathological features that drive IPF, such as enhanced fibroblast proliferation, myofibroblast differentiation, and excessive collagen deposition (Bhatt et al., 2025; Lawrence & Nho, 2018).
4. The expected effect is a reduction in pathological fibroblast activity, as evidenced by decreased αSMA expression and impaired collagen gel contraction in vitro, which are key markers of fibrotic progression in IPF (Bhatt et al., 2025; Hsu et al., 2017).
5. Overall evaluation of MK-2206 highlights considerable promise based on its target specificity and pre-existing clinical oncology data, while acknowledging the need for further tailored preclinical studies to confirm efficacy in fibrosis, thoughtful dose optimization, and strategies to mitigate potential compensatory signaling that could undermine long-term outcomes (Mercer et al., 2016; Margaria et al., 2022; Mehnert et al., 2019).

Given these points, our recommendation is to advance MK-2206 into preclinical evaluation models of pulmonary fibrosis—such as fibroblast cell cultures derived from IPF tissue and murine models of bleomycin-induced lung fibrosis—to validate its antifibrotic effects, define optimal dosing regimens, and assess its impact on key disease endpoints before considering clinical trials for IPF. The convergence of mechanistic data and clinical safety insights provides a compelling justification for its further study, though careful design of preclinical studies will be critical to address the unique pathobiology of fibrotic lung tissue (Bhatt et al., 2025; Mercer et al., 2016).

References
Bhatt, J., Ghigo, A., & Hirsch, E. (2025). Pi3k/akt in ipf: Untangling fibrosis and charting therapies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1549277

ClinicalTrials.gov. (n.d.). MK-2206 and idiopathic pulmonary fibrosis: Clinical trial search. ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/

Hsu, H.-S., Liu, C.-C., Lin, J.-H., Hsu, T.-W., Hsu, J.-W., Su, K., & Hung, S.-C. (2017). Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. Scientific Reports, 7, Article 14612. https://doi.org/10.1038/s41598-017-14612-5

Lawrence, J., & Nho, R. (2018). The role of the mammalian target of rapamycin (mTOR) in pulmonary fibrosis. International Journal of Molecular Sciences, 19(3), Article 778. https://doi.org/10.3390/ijms19030778

Margaria, J. P., Moretta, L., Alves-Filho, J. C., & Hirsch, E. (2022). PI3K signaling in mechanisms and treatments of pulmonary fibrosis following sepsis and acute lung injury. Biomedicines, 10(4), 756. https://doi.org/10.3390/biomedicines10040756

Mehnert, J. M., Kaveney, A. D., Malhotra, J., Spencer, K., Portal, D., Goodin, S., Tan, A. R., Aisner, J., Moss, R. A., Lin, H., Bertino, J. R., Gibbon, D., Doyle, L. A., White, E. P., & Stein, M. N. (2019). A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 84(5), 899–907. https://doi.org/10.1007/s00280-019-03919-x

Mercer, P. F., Woodcock, H. V., Eley, J. D., Platé, M., Sulikowski, M. G., Durrenberger, P. F., Franklin, L., Nanthakumar, C. B., Man, Y., Genovese, F., McAnulty, R. J., Yang, S., Maher, T. M., Nicholson, A. G., Blanchard, A. D., Marshall, R. P., Lukey, P. T., & Chambers, R. C. (2016). Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax, 71(8), 701–711. https://doi.org/10.1136/thoraxjnl-2015-207429

Murgo, A. (2024). Characterization and evaluation of clinically relevant readouts in a pre-clinical model of idiopathic pulmonary fibrosis (IPF). Unknown journal.

Qiang, M., Chen, Z., Liu, H., Dong, J., Gong, K., Zhang, X., Huo, P., Zhu, J., Shao, Y., Ma, J., Zhang, B., Liu, W., & Tang, M. (2025). Targeting the PI3K/AKT/mTOR pathway in lung cancer: Mechanisms and therapeutic targeting. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1516583

Sangai, T., Akcakanat, A., Chen, H., Tarco, E., Wu, Y., Do, K.-A., Miller, T. W., Arteaga, C. L., Mills, G. B., Gonzalez-Angulo, A. M., & Meric-Bernstam, F. (2012). Biomarkers of response to AKT inhibitor MK-2206 in breast cancer. Journal of Clinical Oncology, 30(15 Suppl.), 1054. https://doi.org/10.1200/JCO.2012.30.15_suppl.1054",-0.304065734,8
"Obeticholic Acid (OCA, Selleckchem S8140)","Proposal for Obeticholic Acid (OCA, Selleckchem S8140)

Overview of Therapeutic Candidate:
Obeticholic acid (OCA) is a semi‐synthetic bile acid derivative that functions as a potent and selective agonist of the farnesoid X receptor (FXR). It was originally derived by modifying chenodeoxycholic acid to enhance its FXR activity by approximately 100‐fold relative to its natural counterpart, and it exhibits roughly 200‐fold higher potency for FXR over other bile acid receptors such as TGR5 (Comeglio et al., 2017). OCA belongs to the class of bile acid receptor agonists, compounds that have been primarily used in the management of cholestatic liver diseases, notably primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Its high potency, favorable pharmacokinetic (PK) and ADME profile, and well‐delineated safety record in liver indications have made it a cornerstone in hepatic anti‐fibrotic therapy. Its mechanism as an FXR agonist places it therapeutically in a class where modulation of bile acid homeostasis, lipid metabolism, and inflammatory pathways are central to its clinical activity (Batiha et al., 2023; Comeglio et al., 2017).

Therapeutic History:
OCA has an established history in the clinical management of cholestatic liver diseases. It gained clinical use for PBC, particularly in patients who are intolerant or have an inadequate response to ursodeoxycholic acid, and has also been evaluated extensively in NASH where FXR agonism mediates antifibrotic, anti‐inflammatory, and metabolic regulatory outcomes (Manka et al., 2019; Zhao et al., 2022). The drug’s ability to suppress fibrogenic pathways and reduce extracellular matrix (ECM) accumulation in hepatic tissues is well documented in both preclinical and clinical settings. In preclinical studies using animal models of liver fibrosis, OCA demonstrated significant reductions in collagen deposition and fibrosis markers, improvements in portal hypertension, and favorable modulation of inflammatory cytokines (Comeglio et al., 2017; Manka et al., 2019). Though its current approved indications are primarily hepatic, its mechanism of action via FXR activation has prompted researchers to investigate its potential in other fibrotic conditions, including idiopathic pulmonary fibrosis (IPF). Several clinical trial registries have identified studies exploring FXR agonists in pulmonary fibrosis, even though definitive clinical data in IPF remain limited (ClinicalTrials.gov, n.d.).

Therapeutic History in the Context of IPF and Similar Diseases:
While the bulk of the clinical evidence for OCA comes from its application in liver fibrosis and related metabolic diseases, the biological rationale for its repurposing in IPF stems from the observation that many fibrotic processes share common mediators. In both liver fibrosis and IPF, transforming growth factor‐beta 1 (TGF‐β1) plays an essential role as a profibrotic cytokine that drives fibroblast activation, myofibroblast differentiation, and ECM deposition. Preclinical models in hepatic fibrosis have shown that FXR agonism leads to downregulation of TGF‐β activity, reduced collagen synthesis, and improved tissue architecture. Similar cascades are implicated in the pathogenesis of lung fibrosis, where proinflammatory and profibrotic signaling pathways converge on fibroblast activation, extracellular matrix production, and tissue remodeling (Chen et al., 2016; Cao et al., 2024). Although direct clinical trials in IPF patients are sparse, the potential use of OCA in lung fibrosis is supported by preclinical evidence demonstrating that FXR is expressed in lung cell types—including fibroblasts, alveolar epithelial cells, and endothelial cells—suggesting that modulating FXR activity may attenuate fibrotic pathways in these cells (ClinicalTrials.gov, n.d.; Cao et al., 2024).

Mechanism of Action:
OCA exerts its biological effects through potent activation of FXR, a ligand-activated nuclear receptor that plays a central role in regulating bile acid synthesis, lipid metabolism, and inflammatory responses. Upon binding OCA, FXR undergoes a conformational change enabling it to form a heterodimer with the retinoid X receptor (RXR). The FXR/RXR complex then binds to FXR response elements (FXREs) in the promoter regions of target genes. This activation cascade results in several downstream effects:

1. Downregulation of bile acid synthesis by inhibiting key enzymes such as CYP7A1 and CYP8B1 through induction of the small heterodimer partner (SHP) (Cao et al., 2024; Batiha et al., 2023).
2. Inhibition of pro‐inflammatory cytokines by suppressing nuclear factor kappa B (NF‐κB) signaling pathways, thereby reducing the secretion of molecules like TGF‐β1 (Chen et al., 2016; Cao et al., 2024).
3. Modulation of extracellular matrix (ECM) remodeling through regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), critical regulators of collagen deposition and fibroblast contractility (Comeglio et al., 2017; Manka et al., 2019).
4. Enhancement of anti‐inflammatory mediators such as peroxisome proliferator‐activated receptor alpha (PPARα) signaling, which further assists in the mitigation of inflammatory responses in both hepatic and potentially pulmonary tissues (Batiha et al., 2023; Comeglio et al., 2017).

In the context of IPF, the central hypothesis is that by activating FXR in lung fibroblasts and other lung parenchymal cells, OCA will suppress the secretion of TGF‐β1, a critical cytokine that drives the differentiation of fibroblasts into myofibroblasts. This myofibroblast phenotype is associated with increased contraction, excessive synthesis of ECM proteins such as collagen, and disruption of normal lung architecture. Therefore, through FXR-mediated mechanisms, OCA is expected to reduce fibroblast proliferation, ECM synthesis, and overall contractility within three-dimensional gel assays, mirroring the antifibrotic effects observed in hepatic systems (Cao et al., 2024; Chen et al., 2016; Comeglio et al., 2017).

Expected Effect:
Based on its established mechanism of FXR activation, OCA is expected to exert multiple beneficial effects in models of IPF. In vitro, it is hypothesized that OCA will modulate the behavior of lung fibroblasts in a three-dimensional culture, leading to several measurable outcomes:

• Suppression of TGF‐β1 secretion: TGF‐β1 is a central mediator in the feedback loop that drives fibroblast activation and transformation into myofibroblasts. By inhibiting TGF‐β1, OCA should theoretically attenuate the fibrogenic signaling cascade (Cao et al., 2024; Chen et al., 2016).
• Reduction in extracellular matrix (ECM) synthesis: The activation of fibroblasts triggers unchecked deposition of collagen and other ECM proteins, which stiffens lung tissue. FXR-mediated downregulation of ECM components through the inhibition of MMP/TIMP dysregulation is expected to normalize ECM turnover (Comeglio et al., 2017; Manka et al., 2019).
• Decreased contractility in 3D gel assays: The fibrotic phenotype is often characterized by increased contractility due to the differentiation of fibroblasts into myofibroblasts, indicated by elevated α-smooth muscle actin (α-SMA) expression. FXR activation by OCA is anticipated to result in reduced expression of α-SMA and lowered contractile function, thereby preserving lung compliance (庞昶 & 林树无, 2019).

In addition to these direct effects on fibroblast behavior, OCA is expected to exert anti‐inflammatory effects by inhibiting pro‐inflammatory cytokine networks within lung tissue—a mechanism that is believed to contribute to its beneficial effects in liver fibrosis and may similarly apply to IPF (Batiha et al., 2023; Cao et al., 2024). Expression of FXR has been confirmed in various lung cell types, including alveolar epithelial cells and possibly fibroblasts, which supports the idea that targeting this receptor can influence relevant cellular processes in the fibrotic microenvironment (Cao et al., 2024; Chen et al., 2016).

Overall Evaluation:
Obeticholic acid exhibits several compelling features as a repurposed candidate for the treatment of IPF. Its strengths lie in its well-characterized mechanism of action as an FXR agonist, its established clinical use in liver fibrosis with a favorable safety and PK profile, and its potential to modulate critical fibrotic pathways such as TGF‐β1 signaling, ECM production, and cell contractility. The literature clearly outlines OCA’s ability to suppress inflammation and fibrosis in hepatic and vascular models, and while direct evidence in pulmonary fibrosis is not yet robust, the mechanistic parallels are promising (Comeglio et al., 2017; Zhao et al., 2022).

However, there are also weaknesses and uncertainties. Direct clinical data testing OCA in patients with IPF are sparse, and while several preclinical studies support the antifibrotic effects of FXR agonism in liver models, the translation of these effects to lung tissues remains to be firmly established (ClinicalTrials.gov, n.d.; Chen et al., 2016). Moreover, the dual nature of FXR signaling—where in some scenarios FXR activation could potentially have pro‐fibrotic effects—warrants careful evaluation in the specific context of lung fibroblast biology (Chen et al., 2016). Lastly, the complexity of idiopathic pulmonary fibrosis, which involves multiple cell types and signaling pathways, suggests that monotherapy with an FXR agonist might be insufficient, and combination strategies may be needed.

In summary, OCA’s extensive clinical experience in hepatic fibrosis, combined with its clearly delineated FXR-mediated anti‐inflammatory and antifibrotic mechanisms, provides a strong rationale for further exploration in the treatment of IPF. Despite the current lack of direct clinical data in pulmonary fibrosis, the biochemical and preclinical evidence from related fibrotic conditions supports its evaluation in dedicated IPF models. The next steps should include comprehensive preclinical studies focused specifically on lung fibroblast responses, TGF‐β1 secretion, ECM synthesis, and functional assays of contractility in 3D lung tissue models, followed by well-designed early-phase clinical trials to assess safety and efficacy in IPF patients (Addissouky et al., 2024; Manka et al., 2019).

References:

Addissouky, T. A., Ali, M. M. A., El Sayed, I. E. T., & Wang, Y. (2024). Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis. The Egyptian Journal of Internal Medicine. https://doi.org/10.1186/s43162-024-00283-y

Batiha, G. E.-S., Al-kuraishy, H. M., Al-Gareeb, A. I., Youssef, F. S., El-Sherbeni, S. A., & Negm, W. A. (2023). A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection. Inflammopharmacology, 31, 9–19. https://doi.org/10.1007/s10787-022-01111-x

Cao, Y., Xu, Y., Zhou, J., Fu, X., Zhang, H., Du, X., Liang, S., & Liu, M. (2024). Farnesoid X receptor (FXR) as a potential therapeutic target for lung diseases: A narrative review. Journal of Thoracic Disease, 16, 8026–8038. https://doi.org/10.21037/jtd-24-734

Chen, B., Cai, H.-R., Xue, S., You, W.-J., Liu, B., & Jiang, H.-D. (2016). Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor–dependent and independent pathways. Respirology, 21, 1075–1080. https://doi.org/10.1111/resp.12815

Comeglio, P., Morelli, A., Adorini, L., Maggi, M., & Vignozzi, L. (2017). Beneficial effects of bile acid receptor agonists in pulmonary disease models. Expert Opinion on Investigational Drugs, 26(10), 1215–1228. https://doi.org/10.1080/13543784.2017.1385760

ClinicalTrials.gov. (n.d.). Obeticholic acid OR OCA OR FXR agonist AND (idiopathic pulmonary fibrosis OR lung fibrosis OR pulmonary fibrosis) [Clinical trial search]. Retrieved from https://clinicaltrials.gov

Manka, P., Zeller, A., & Syn, W.-K. (2019). Fibrosis in chronic liver disease: An update on diagnostic and treatment modalities. Drugs, 79(8), 903–927. https://doi.org/10.1007/s40265-019-01126-9

庞昶, & 林树无. (2019). Fxr 激动剂奥贝胆酸抑制吉非替尼所致的肺纤维化机制的研究 [Mechanism of obeticholic acid, an FXR agonist, in gefitinib-induced pulmonary fibrosis]. Unknown Journal.

Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., Zhang, B., Yang, J., & Yao, Y. (2022). Targeting fibrosis: Mechanisms and clinical trials. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-022-01070-3",-0.464763639,10
"GLPG1690 (Autotaxin inhibitor, Galapagos)","Proposal for GLPG1690 (Autotaxin inhibitor, Galapagos)

Overview of Therapeutic Candidate:
GLPG1690 is a first‐in‐class, orally available, synthetic small‐molecule inhibitor of autotaxin (ATX) that was discovered and optimized through structure‐based drug design and high-throughput screening methodologies (Jia et al., 2021). This compound belongs to the class of ATX inhibitors, which are designed to block the enzymatic activity of autotaxin responsible for catalyzing the conversion of lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA); a lipid mediator implicated in cell proliferation, migration, and fibrosis (Ninou et al., 2018). ATX inhibitors as a class have been investigated for their antifibrotic potential in various experimental models of fibrosis and have been proposed as novel therapeutic approaches for diseases characterized by excessive fibrotic remodeling, including Idiopathic Pulmonary Fibrosis (IPF) (Maher et al., 2019). The synthesis and optimization of GLPG1690 involved a combination of medicinal chemistry strategies designed to yield a molecule with high potency, favorable pharmacokinetics, and a robust pharmacodynamic profile that achieves significant reduction in plasma LPA levels (van der Aar et al., 2019).

Therapeutic History:
GLPG1690 has progressed through early-phase clinical development for IPF after extensive preclinical validation in various animal models of lung fibrosis, where inhibition of the ATX/LPA axis resulted in reduced fibroblast activation and improved tissue architecture (Ninou et al., 2018). In Phase I studies, GLPG1690 demonstrated an acceptable safety and tolerability profile in healthy volunteers, with dose-dependent reductions in plasma LPA levels that provided evidence of target engagement (ClinicalTrials.gov, 2014). The compound advanced into Phase IIa (FLORA study) in patients with IPF, where preliminary data indicated stabilization—and in some instances, a modest improvement—of forced vital capacity (FVC), a key clinical measure of lung function in IPF (Choi, 2021). Despite these promising early signals, subsequent Phase III trials, notably ISABELA 1 and ISABELA 2, were eventually terminated because the benefit-risk profile did not sufficiently favor continued development in the target IPF populations (ClinicalTrials.gov, 2018). Historically, this candidate represents a translational effort from the robust preclinical evidence supporting the role of elevated LPA levels in fibrotic disease to an innovative clinical trial program targeting a clearly defined molecular pathway, even though its clinical trajectory has been challenging (Glass et al., 2022; Maher et al., 2019).

Mechanism of Action:
The biological rationale underlying GLPG1690 is centered on its ability to inhibit autotaxin with high potency and selectivity, thereby reducing the generation of LPA from lysophosphatidylcholine (Nikolaou et al., 2017). At the molecular level, GLPG1690 binds competitively to the hydrophobic pocket and allosteric tunnel of ATX by a hybrid binding mode that effectively prevents the substrate lysophosphatidylcholine (LPC) from accessing the active site, resulting in a marked decrease in LPA production (Banerjee et al., 2022). LPA acts through a series of G protein-coupled receptors including LPAR1, which is highly expressed in lung fibroblasts, and through these receptors, it drives pathways that underpin fibroblast migration, proliferation, differentiation into myofibroblasts, and 3D collagen gel contraction—all central events in the fibrotic process (Volkmann et al., 2024). Inhibition of the ATX/LPA signaling axis not only attenuates direct fibrogenic effects on fibroblasts but may also decrease vascular leak and inflammatory cytokine production, thereby interfering with multiple pathogenetic steps that contribute to the progressive scarring and decline in lung function associated with IPF (Saito et al., 2019). Furthermore, preclinical studies have confirmed that GLPG1690 achieves reductions in plasma LPA levels of up to 90% and shows significant antifibrotic effects in bleomycin-induced lung fibrosis models by suppressing key mediators such as transforming growth factor-beta (TGF-β) and connective tissue growth factor (CTGF) (van der Aar et al., 2019; Ninou et al., 2018).

Expected Effect:
The working hypothesis is that by inhibiting autotaxin, GLPG1690 will lower circulating and local LPA levels, thereby suppressing LPA-driven fibroblast activation, proliferation, and 3D collagen gel contraction, which are primary contributors to the fibrotic remodeling observed in IPF (Tzouvelekis, n.d.). In experimental assays, it is expected that treatment with GLPG1690 will lead to a significant reduction in LPA levels as measured in plasma and bronchoalveolar lavage fluid (BALF), correlating with decreased expression of fibrotic markers and improved lung function parameters in treated subjects (Choi, 2021; Maher et al., 2019). On a cellular level, GLPG1690 is anticipated to attenuate fibroblast-mediated contraction of collagen gels in vitro, an effect that is directly reflective of its mechanism of blocking the fibroblast activation cascade (Unknown Reference). Experimentally, fibroblasts isolated from IPF patients are known to express high levels of LPA receptors and exhibit enhanced contractile and proliferative responses to LPA, which further underscores the potential impact of autotaxin inhibition on this cell type (Volkmann et al., 2024; Ninou et al., 2018). Moreover, robust pharmacokinetic and pharmacodynamic profiling in early studies demonstrated that GLPG1690 has favorable bioavailability and a sustained capacity to reduce LPA levels over a 24-hour dosing interval, thereby supporting once-daily administration that is conducive to chronic therapy in IPF (Taneja et al., 2019).

Overall Evaluation:
In summary, GLPG1690 presents as a highly mechanistically sound therapeutic candidate for IPF with several strengths that underscore its potential despite setbacks encountered during later-phase clinical studies. One of its primary strengths is its robust and well-characterized mechanism of action: by selectively inhibiting autotaxin, GLPG1690 effectively reduces LPA production and thereby disrupts the LPA-driven signaling cascade that is fundamental to fibroblast activation, differentiation, and extracellular matrix deposition (Ninou et al., 2018; Volkmann et al., 2024). In addition, preclinical studies have consistently demonstrated significant antifibrotic effects in animal models, including reductions in skin and lung fibrosis markers, lending strong biological plausibility to the approach (Ishii, 2023; Spagnolo et al., 2020). The compound’s pharmacokinetic and pharmacodynamic profiles have been thoroughly characterized, showing dose-dependent and sustained lowering of LPA levels with favorable bioavailability, which supports the rationale for a once-daily dosing regimen—a critical factor for long-term management of chronic diseases like IPF (van der Aar et al., 2019; Taneja et al., 2019). Furthermore, early-phase clinical studies, such as the FLORA trial, provided encouraging evidence of target engagement and hints of clinical benefit in terms of preserved lung function as measured by forced vital capacity (FVC), which is a validated surrogate endpoint in IPF (Choi, 2021; Maher et al., 2019).

However, several weaknesses temper the enthusiasm for GLPG1690 in its current form. The termination of Phase III trials (ISABELA 1 and ISABELA 2) due to an unfavorable benefit-risk profile indicates that, while the mechanism is compelling, the clinical efficacy and safety in a broader patient population were insufficiently robust despite promising early-phase data (ClinicalTrials.gov, 2018). One potential challenge relates to substrate competition; GLPG1690 competes with the natural substrate (LPC) for binding to ATX, and in physiological conditions where elevated LPC concentrations are present, the inhibitory effect on LPA production may be diminished (Banerjee et al., 2022). Additionally, the overall clinical impact on slowing fibrosis progression and improving survival outcomes in IPF has not been convincingly demonstrated, raising questions about the translational gap between preclinical efficacy and clinical performance (Glass et al., 2022; Ntatsoulis et al., 2021). There is also concern regarding the potential for off-target effects and adverse events associated with broad inhibition of the ATX/LPA axis given LPA’s role in normal tissue homeostasis and repair mechanisms (Unknown Reference).

In light of these factors, while GLPG1690 itself has encountered challenges in the clinical setting, its preclinical efficacy and mechanistic clarity provide a robust foundation for future development. There is considerable potential in either developing optimized analogs that overcome the limitations observed in Phase III trials or employing GLPG1690 in combination with existing antifibrotic agents such as pirfenidone or nintedanib in order to achieve synergistic effects and minimize adverse outcomes (Spagnolo et al., 2020; Ntatsoulis et al., 2021). The well-validated role of the ATX/LPA axis in IPF pathogenesis, with elevated LPA levels correlating with disease severity, supports continued exploration of this target (Isshiki et al., 2022; Volkmann et al., 2024). Future strategies might involve refining patient selection criteria, closer monitoring of pharmacodynamic biomarkers such as plasma LPA species (e.g., LPA C18:2), and adjustments to dosing regimens to balance efficacy with safety (van der Aar et al., 2019; Maher et al., 2025).

Overall, GLPG1690 remains a highly promising therapeutic candidate from a molecular and biochemical standpoint owing to its targeted inhibition of the ATX/LPA axis, which is a key driver of fibrotic remodeling in IPF. Its preclinical data and early-phase clinical signals affirm that modulating this pathway can reduce fibroblast activation and potentially stabilize lung function (Volkmann et al., 2024; Ninou et al., 2018). However, setbacks in advanced-stage clinical trials highlight a critical need for further optimization—whether through structural analog development or combination therapy approaches—to fully harness the antifibrotic potential of ATX inhibition in the complex and heterogeneous landscape of IPF (Ntatsoulis et al., 2021; Unknown Reference).

In conclusion, while GLPG1690’s journey as a standalone therapeutic candidate for IPF has encountered significant challenges, its robust preclinical validation, well-characterized pharmacokinetic profile, and compelling mechanistic rationale solidify the theoretical basis for targeting the ATX/LPA axis in fibrotic lung disease. This candidate’s experience provides critical insights for refining future therapeutic approaches, either through next-generation analogs with improved efficacy and safety profiles or as part of combination regimens designed to enhance overall antifibrotic activity. The substantial body of preclinical and early-phase clinical evidence supports continued research investment in this pathway, and with strategic modifications, compounds derived from the GLPG1690 platform may yet offer a viable means to significantly alter the course of IPF (Maher et al., 2019; Spagnolo et al., 2020; Unknown Reference).

References
Banerjee, S., Lee, S., Norman, D. D., & Tigyi, G. J. (2022). Designing dual inhibitors of autotaxin-LPAR GPCR axis. Molecules, 27(17), 5487. https://doi.org/10.3390/molecules27175487

Choi, W. (2021). Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: Current trends and future directions. Precision and Future Medicine, 5, 31–40. https://doi.org/10.23838/pfm.2020.00205

Galapagos NV. (2014). First-in-human single and multiple dose of GLPG1690 (NCT02179502) [Clinical trial registration]. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02179502

Galapagos NV. (2018a). A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard of care (NCT03711162) [Clinical trial registration]. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03711162

Galapagos NV. (2018b). A clinical study to test how effective and safe GLPG1690 is for participants with idiopathic pulmonary fibrosis (IPF) when used together with standard of care (NCT03733444) [Clinical trial registration]. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03733444

Isshiki, T., Shimizu, H., Sakamoto, S., Yamasaki, A., Miyoshi, S., Nakamura, Y., Homma, S., & Kishi, K. (2022). Serum autotaxin levels in chronic disease and acute exacerbation of fibrosing interstitial lung disease. ERJ Open Research, 8(1), 00683-2021. https://doi.org/10.1183/23120541.00683-2021

Ishii, A. (2023). …, a novel potent selective autotaxin inhibitor, in preclinical studies: Clues to treat skin and lung fibrosis in systemic sclerosis. [Unknown journal].

Jia, Y., Li, Y., Xu, X.-d., Tian, Y., & Shang, H. (2021). Design and development of autotaxin inhibitors. Pharmaceuticals, 14(11), 1203. https://doi.org/10.3390/ph14111203

Maher, T. M., Kreuter, M., Lederer, D. J., Brown, K. K., Wuyts, W., Verbruggen, N., Stutvoet, S., Fieuw, A., Ford, P., Abi-Saab, W., & Wijsenbeek, M. (2019). Rationale, design and objectives of two phase III, randomized, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). American Journal of Respiratory and Critical Care Medicine, 199(1), A4597. https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4597

Maher, T. M., Song, J. W., Kramer, M. R., Lancaster, L., Corte, T. J., Yun, J. H., Kim, K., Cho, J., Sather, L. F., George, P. M., Devaraj, A., Jung, J. H., & Jung, S. (2025). Phase 2 study design and analysis approach for BBT-877: An autotaxin inhibitor targeting idiopathic pulmonary fibrosis. medRxiv. https://doi.org/10.1101/2025.03.31.25324971

Nikolaou, A., Kokotou, M. G., Limnios, D., Psarra, A., & Kokotos, G. (2017). Autotaxin inhibitors: A patent review (2012–2016). Expert Opinion on Therapeutic Patents, 27(8), 815–829. https://doi.org/10.1080/13543776.2017.1323331

Ninou, I., Magkrioti, C., & Aidinis, V. (2018). Autotaxin in pathophysiology and pulmonary fibrosis. Frontiers in Medicine, 5, 180. https://doi.org/10.3389/fmed.2018.00180

Ntatsoulis, K., Karampitsakos, T., Tsitoura, E., Stylianaki, E.-A., Matralis, A. N., Tzouvelekis, A., Antoniou, K., & Aidinis, V. (2021). Commonalities between ARDS, pulmonary fibrosis and COVID-19: The potential of autotaxin as a therapeutic target. Frontiers in Immunology, 12, 687397. https://doi.org/10.3389/fimmu.2021.687397

Saito, S., Alkhatib, A., Kolls, J. K., Kondoh, Y., & Lasky, J. A. (2019). Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF). Journal of Thoracic Disease, 11(Suppl 14), S1740–S1754. https://doi.org/10.21037/jtd.2019.04.62

Spagnolo, P., Bonella, F., Ryerson, C. J., Tzouvelekis, A., & Maher, T. M. (2020). Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 29(7), 797–808. https://doi.org/10.1080/13543784.2020.1782885

Taneja, A., Desrivot, J., Diderichsen, P. M., Blanqué, R., Allamasey, L., Fagard, L., Fieuw, A., van der Aar, E., & Namour, F. (2019). Population pharmacokinetic and pharmacodynamic analysis of GLPG1690, an autotaxin inhibitor, in healthy volunteers and patients with idiopathic pulmonary fibrosis. Clinical Pharmacokinetics, 58, 1175–1191. https://doi.org/10.1007/s40262-019-00755-3

Tzouvelekis, A. (n.d.). Developmental drugs for idiopathic pulmonary fibrosis. [Unknown journal].

van der Aar, E., Desrivot, J., Dupont, S., Heckmann, B., Fieuw, A., Stutvoet, S., Fagard, L., Van de Wal, K., & Helmer, E. (2019). Safety, pharmacokinetics, and pharmacodynamics of the autotaxin inhibitor GLPG1690 in healthy subjects: Phase 1 randomized trials. The Journal of Clinical Pharmacology, 59, 1366–1378. https://doi.org/10.1002/jcph.1424

Volkmann, E. R., Denton, C. P., Kolb, M., Wijsenbeek-Lourens, M. S., Emson, C., Hudson, K., Amatucci, A. J., Distler, O., Allanore, Y., & Khanna, D. (2024). Lysophosphatidic acid receptor 1 inhibition: A potential treatment target for pulmonary fibrosis. European Respiratory Review, 33(163), 240015. https://doi.org/10.1183/16000617.0015-2024",-0.467654246,27
"Vorinostat (SAHA, Selleckchem S1047)","Proposal for Vorinostat (SAHA, Selleckchem S1047)

Overview of Therapeutic Candidate: Vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), is a synthetic small‐molecule inhibitor belonging to the hydroxamic acid class of pan‐histone deacetylase (HDAC) inhibitors that was originally developed for use in oncology and approved by the FDA for treatment of cutaneous T‐cell lymphoma (Korfei et al., 2018). Its discovery emerged from efforts to modulate epigenetic regulation in cancer, where compounds that could chelate the zinc ion at the active site of HDAC enzymes were found to restore expression of silenced tumor suppressor genes (Korfei et al., 2022). This class of therapeutic agents is known for its ability to increase the acetylation levels of histones—and non‐histone proteins—in various cell types, thereby modulating gene expression profiles through chromatin remodeling (Korfei et al., 2022). Vorinostat has proven effective as a single agent in cancer therapy and is characterized by its oral bioavailability, well‐defined pharmacokinetic parameters, and an established safety profile in oncology patients (Lyu et al., 2019). Its chemical synthesis involves constructing the hydroxamic acid moiety, which is critical for binding to the zinc ion in the catalytic domain of HDAC enzymes, resulting in global inhibition across Class I, II, and IV HDAC isoforms (Korfei et al., 2018).

Therapeutic History: Vorinostat’s initial therapeutic applications were in the oncologic setting where its broad-spectrum inhibition of HDACs caused reactivation of tumor suppressor genes, induction of cell cycle arrest, and triggering of apoptosis in cancer cells (Korfei et al., 2022). Its development as an anticancer drug has been thoroughly evaluated both preclinically and clinically; extensive studies documented its clinical effectiveness and tolerability in patients with cutaneous T-cell lymphoma and other malignancies (Lyu et al., 2019). Although Vorinostat has not been directly evaluated in clinical trials for idiopathic pulmonary fibrosis (IPF) (ClinicalTrials.gov, n.d.), its repurposing potential arises from shared molecular mechanisms between cancer-associated fibroblast pathology and the aberrant fibroblast activation observed in fibrotic lung diseases (Korfei et al., 2018). Previous research in lung fibrosis models and IPF patient-derived fibroblasts has demonstrated that pan-HDAC inhibitors such as panobinostat and trichostatin A can modulate fibroblast activity, promote apoptosis, and reduce extracellular matrix deposition (Korfei et al., 2022; Cheng et al., 2024). This evidence encourages the exploration of Vorinostat for IPF, leveraging its well-established clinical profile in oncology to accelerate potential repurposing for fibrotic lung diseases (Lyu et al., 2019).

Mechanism of Action: Vorinostat exerts its pharmacological effects by inhibiting histone deacetylases through binding to their zinc-dependent catalytic domains, thereby preventing the removal of acetyl groups from lysine residues on histone tails and various transcription factors (Korfei et al., 2022). This inhibition causes histone hyperacetylation, leading to a more open chromatin configuration that facilitates the transcription of genes, including those with antifibrotic and pro-apoptotic functions such as FAS and COX2 (Korfei et al., 2022). In the context of idiopathic pulmonary fibrosis, aberrant activity of Class I and Class II HDACs is believed to contribute significantly to the fibrotic phenotype by silencing antifibrotic genes and promoting fibroblast-to-myofibroblast differentiation—which is characterized by increased α-smooth muscle actin (αSMA) expression and excessive extracellular matrix (ECM) production (Korfei et al., 2018). Vorinostat’s pan-HDAC inhibition is anticipated to reverse these epigenetic modifications, thereby restoring the transcription of antifibrotic genes and inducing apoptosis in the pathologically activated fibroblasts (Lyu et al., 2019). Molecular studies have demonstrated that HDAC inhibitors such as Vorinostat enhance the acetylation status of non-histone proteins including p53—a critical tumor suppressor and pro-apoptotic factor—and tubulin, which may further modulate cell cycle progression and decrease cell motility (Korfei et al., 2022; Cheng et al., 2024). These biochemical interactions collectively promote a state of growth arrest, reduced collagen synthesis, and diminished contractility among fibroblasts, which are central aspects of the antifibrotic response in IPF (Korfei et al., 2018).

Expected Effect: In the proposed assays, Vorinostat is expected to increase global histone acetylation in IPF fibroblasts, thereby reactivating silenced antifibrotic genes such as FAS and COX2 while simultaneously repressing profibrotic genes including those encoding collagen I and αSMA (Korfei et al., 2022). In vitro studies with pan-HDAC inhibitors have demonstrated significant reductions in fibroblast proliferation, decreased expression of contraction-associated markers, and suppression of fibroblast contractility in 3D collagen gel assays, suggesting that Vorinostat would elicit comparable effects (Korfei et al., 2018; Cheng et al., 2024). The expected cascade of molecular events involves the derepression of pro-apoptotic pathways through enhanced acetylation of p53, combined with inhibition of transforming growth factor-beta (TGF-β)/SMAD signaling, which is central to the differentiation of fibroblasts into myofibroblasts (Korfei et al., 2018; Lyu et al., 2019). By modulating these pathways, Vorinostat is anticipated to reduce the contractile and synthetic activities of fibroblasts, thereby curbing the extent of extracellular matrix deposition and fibrotic remodeling within the lung (Korfei et al., 2022). Furthermore, preclinical murine models of lung fibrosis have already indicated that pan-HDAC inhibitors can lead to attenuation of fibrosis and improved lung function, providing a promising in vivo rationale for the use of Vorinostat in IPF (Korfei et al., 2018; Lyu et al., 2019).

Overall Evaluation: Overall, Vorinostat presents as a highly promising candidate for repurposing as an antifibrotic therapy in idiopathic pulmonary fibrosis, showing substantial mechanistic rationale based on extensive preclinical evidence and its established pharmacologic profile in oncology (Korfei et al., 2022; Mora et al., 2017). Its primary strengths lie in its ability to globally inhibit multiple HDAC isoforms—a key driver of the aberrant epigenetic state seen in IPF fibroblasts—and to reactivate antifibrotic pathways that are silenced in the diseased lung (Korfei et al., 2018; Lyu et al., 2019). These effects are mediated through increased histone acetylation, which is associated with transcriptional upregulation of pro-apoptotic and antifibrotic genes, and downregulation of molecules responsible for the fibrotic phenotype, such as collagen I and αSMA (Korfei et al., 2022; Cheng et al., 2024). Additionally, the extensive clinical experience of Vorinostat in the oncology field lends support to its safety and tolerability profile, potentially streamlining its repurposing pipeline for IPF (Lyu et al., 2019; Mora et al., 2017).

However, there are inherent challenges and weaknesses associated with its broad-spectrum mode of action. First, pan-HDAC inhibition may lead to off-target effects given that HDAC enzymes play crucial roles in normal cellular homeostasis, particularly in non-fibrotic cells such as alveolar epithelial type II cells, which are critical for lung repair (Korfei et al., 2022; Korfei et al., 2015). Moreover, while the antifibrotic effects due to reactivation of pathways such as FAS-mediated apoptosis are desirable, the potential cytotoxicity induced by excessive HDAC inhibition must be carefully balanced with therapeutic efficacy to avoid compromising normal lung function (Korfei et al., 2022; Cheng et al., 2024). Another potential drawback is the lack of direct clinical evidence in IPF, as most of the supportive data arise from preclinical models or studies in cancer, necessitating rigorous phase I/II trials to evaluate optimal dosing, delivery strategies tailored for pulmonary tissue, and long-term safety in the context of a chronic fibrotic disease (ClinicalTrials.gov, n.d.; Mora et al., 2017). It is also important to note that while the mechanism of epigenetic modulation offers a compelling therapeutic approach, the very complexity of the epigenome in IPF may require more selective inhibition of specific HDAC isoforms to minimize adverse effects, as opposed to pan-HDAC inhibition which can disrupt a broad array of cellular processes (Korfei et al., 2022).

In summary, Vorinostat (SAHA) is a well-characterized pan-HDAC inhibitor with a robust history in cancer therapy that exhibits a strong mechanistic rationale for repurposing in IPF based on its ability to increase histone acetylation, reactivate antifibrotic and pro-apoptotic genes, reduce αSMA transcription, and suppress fibroblast contractility in 3D collagen gel assays (Korfei et al., 2022; Korfei et al., 2018). The compound is expected to counteract the epigenetic repression present in fibrotic lung tissue, thereby mitigating fibroblast activation and ECM production—a hypothesis supported by both in vitro and preclinical in vivo data (Lyu et al., 2019). While Vorinostat’s established clinical safety in oncology and its broad epigenetic activity represent significant strengths, potential off-target effects, the necessity for dosage optimization, and the absence of direct clinical trials in IPF pose challenges that must be addressed in future investigations (Korfei et al., 2018; Mora et al., 2017). Therefore, from our comprehensive review of the biomedical, clinical, and biochemical literature, Vorinostat holds considerable promise as a repurposed therapeutic candidate for idiopathic pulmonary fibrosis, warranting further preclinical studies and targeted clinical trials to determine its efficacy and safety profile specifically in the context of pulmonary fibrosis (Lyu et al., 2019; Cheng et al., 2024).

References

Cheng, H.-p., Jiang, S.-h., Cai, J., Luo, Z.-q., Li, X.-h., & Feng, D.-d. (2024). Histone deacetylases: Potential therapeutic targets for idiopathic pulmonary fibrosis. Frontiers in Cell and Developmental Biology. https://doi.org/10.3389/fcell.2024.1426508

ClinicalTrials.gov. (n.d.). Search results for “Vorinostat AND (pulmonary fibrosis OR IPF)”. Retrieved from https://clinicaltrials.gov

Korfei, M., Skwarna, S., Henneke, I., MacKenzie, B., Klymenko, O., Saito, S., Ruppert, C., von der Beck, D., Mahavadi, P., Klepetko, W., Bellusci, S., Crestani, B., Pullamsetti, S. S., Fink, L., Seeger, W., Krämer, O. H., & Guenther, A. (2015). Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax, 70, 1022–1032. https://doi.org/10.1136/thoraxjnl-2014-206411

Korfei, M., Bach, A. C., Stelmaszek, D., Skwarna, S., Chillappagari, S., Ruppert, C., Lasky, J. A., MacKenzie, B., Mahavadi, P., Klepetko, W., Fink, L., Seeger, W., Krämer, O. H., & Guenther, A. (2018). Comparison of the antifibrotic effects of the pan-histone deacetylase inhibitor panobinostat versus the IPF drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PLOS ONE, 13, e0207915. https://doi.org/10.1371/journal.pone.0207915

Korfei, M., Mahavadi, P., & Guenther, A. (2022). Targeting histone deacetylases in idiopathic pulmonary fibrosis: A future therapeutic option. Cells, 11(1626). https://doi.org/10.3390/cells11101626

Lyu, X., Hu, M., Peng, J., Zhang, X., & Sanders, Y. Y. (2019). HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis. Therapeutic Advances in Chronic Disease. https://doi.org/10.1177/2040622319862697

Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017). Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nature Reviews Drug Discovery, 16, 755–772. https://doi.org/10.1038/nrd.2017.170",-0.628976828,13
"KX2-391 (Src Inhibitor, Selleckchem S7434)","Proposal for KX2-391 (Src Inhibitor, Selleckchem S7434)

Overview of Therapeutic Candidate:
KX2-391 (also known as tirbanibulin in some contexts) is a small‐molecule Src kinase inhibitor developed synthetically as part of a targeted approach to interfere with protein–protein interactions in intracellular signaling pathways. It was discovered and subsequently characterized for its ability to block Src-mediated signaling by binding to Src’s substrate binding (peptide) site instead of the more common ATP-binding pocket, thereby offering a selectivity profile that could reduce off-target toxicity. This places KX2-391 in the broader class of targeted tyrosine kinase inhibitors (TKIs) that have been widely investigated, particularly in cancer therapeutics, where modulation of kinase activity can effectively halt oncogenic signaling cascades. In terms of synthesis and origin, KX2-391’s development builds on decades of structure-activity relationship studies within the Src family, utilizing high-throughput screening and subsequent medicinal chemistry optimization to enhance its binding affinity and selectivity, as exemplified by prior work on similar compounds (Temps, 2020). TKIs in this class have historically been used in oncology and, more recently, for repurposing in non-oncologic indications involving aberrant cellular signaling such as fibrotic diseases (ClinicalTrials.gov, n.d.).

Therapeutic History:
The therapeutic history of KX2-391 and related Src inhibitors primarily originates in the field of oncology, where compounds targeting Src family kinases (SFKs) have been evaluated for their potential to inhibit tumor cell migration, proliferation, and metastasis. Clinical evaluations of KX2-391 have been conducted in phase 1 studies in patients with advanced solid tumors or lymphoma, where its safety, pharmacokinetics, and biological effects were characterized (Roswell Park Cancer Institute, 2007). In addition, other trials have assessed its topical formulation in dermatological conditions such as actinic keratosis, demonstrating that the compound has favorable pharmacokinetic profiles and manageable adverse event profiles in non-systemic applications (Almirall, S.A., 2017). Although the clinical data in oncology and dermatology represent its primary historical uses, there is growing mechanistic rationale to repurpose KX2-391 for fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). Preclinical studies in animal models of fibrosis (including peritoneal fibrosis) have shown that Src kinase inhibitors can attenuate extracellular matrix deposition and fibroblast activation – a mechanism potentially relevant to IPF pathology (Wang et al., 2017). Despite the fact that KX2-391 itself has not been comprehensively evaluated for IPF in prior clinical trials, the underlying pathway—the Src/FAK axis—has been validated in the literature as a contributor to fibroblast-mediated fibrotic remodeling, thereby providing an impetus for repurposing this agent for pulmonary fibrosis (ClinicalTrials.gov, n.d.).

Mechanism of Action:
Src kinases are non-receptor tyrosine kinases that play a central role in a multitude of signaling pathways controlling cell proliferation, migration, adhesion, and survival. KX2-391 selectively inhibits Src kinase by binding to its substrate-binding (peptide) site rather than the highly conserved ATP-binding pocket, a unique mode of action that distinguishes it from many other Src inhibitors and theoretically allows for improved selectivity and reduced off-target effects (Temps, 2020). This selective inhibition disrupts downstream signaling pathways—including those involving focal adhesion kinase (FAK), STAT3, and other mediators of mechanotransduction—that are critical for fibroblast activation and myofibroblast differentiation. In fibroblasts, Src activation is known to phosphorylate multiple substrates that drive actin cytoskeleton remodeling, focal adhesion turnover, and the upregulation of α-smooth muscle actin (αSMA) expression; these molecular events underpin the development of contractile, collagen-producing myofibroblasts that contribute directly to tissue stiffening in IPF (Li et al., 2020). Furthermore, inhibition of Src has been shown to reduce FAK phosphorylation; since FAK is intricately involved in integrin-mediated signaling and mechanotransduction, its inhibition disrupts the cross-talk between the extracellular matrix and intracellular cytoskeletal dynamics, leading to decreased fibroblast contractility and reduced deposition of collagen (Wang et al., 2017). More specifically, multiple studies have suggested that blocking the Src/FAK axis also results in the downregulation of profibrotic transcriptional pathways, as evidenced by reductions in phosphorylated STAT3—a marker closely associated with fibroblast activation and increased collagen production (Wang et al., 2021). These mechanisms collectively suggest that KX2-391’s molecular interactions dampen the mechanotransduction signals that drive the pathological remodeling seen in IPF (Li et al., 2020).

Expected Effect:
Given the mechanistic rationale outlined above, the expected effect of KX2-391 in the proposed assay is a marked reduction in fibroblast contractility, decreased αSMA expression, and a consequent diminution of collagen deposition when fibroblasts are grown in 3D collagen matrices. In vitro assays would likely reveal that treatment with KX2-391 leads to significant downregulation of key fibrotic markers such as αSMA, collagen I and collagen III, concomitant with inhibition of Src phosphorylation and downstream signaling events such as reduced STAT3 activation (Wang et al., 2021). In such 3D collagen contraction assays—which serve as a surrogate for the in vivo mechanical environment of fibrotic lungs—the drug is hypothesized to mitigate the aberrant mechanotransduction that characterizes fibrotic remodeling. It is known that in fibrotic lung tissues, excessive Src/FAK signaling facilitates actin polymerization and the formation of stress fibers that contribute directly to enhanced contractility and increased tissue stiffness; by inhibiting these pathways, KX2-391 is expected to restore more normal cell–matrix interactions and limit the progression of fibrosis (Li et al., 2020). Moreover, given that Src kinase activity also modulates the nuclear translocation of β-catenin in fibroblasts—a key event in the activation of profibrotic gene transcription—KX2-391 may exert additional antifibrotic effects by blunting the Wnt/β-catenin signaling pathway (Li et al., 2020). Since human lung fibroblasts express high levels of Src kinase and its downstream partners in the context of IPF, the drug’s mode of action is particularly relevant to the cell populations driving fibrogenesis, thereby underscoring the feasibility of its use in such assays and ultimately in clinical settings for IPF (ClinicalTrials.gov, n.d.).

Overall Evaluation:
KX2-391 emerges as a promising candidate for repurposing in the treatment of idiopathic pulmonary fibrosis based on its well-characterized mechanism of action, its unique mode of Src inhibition, and the supportive preclinical evidence linking Src/FAK signaling to fibrogenesis. One of the major strengths of KX2-391 lies in its ability to selectively target Src kinase via a non-ATP competitive mechanism, potentially reducing the off-target effects commonly encountered with less selective kinase inhibitors (Temps, 2020). This specificity is particularly appealing given that the pathological processes in IPF are multifactorial, and minimizing unwanted systemic effects is critical. Furthermore, the clinical evaluation of KX2-391 in oncology and dermatology has already established important pharmacokinetic and safety parameters, which can accelerate its repurposing pathway for fibrotic diseases (Athenex, Inc., 2007; Almirall, S.A., 2017). Preclinical studies with analogous compounds, including those that inhibit Src/FAK signaling and attenuate fibroblast activation, provide a solid mechanistic basis for expecting similar antifibrotic benefits in IPF (Wang et al., 2017; Li et al., 2020).

However, there are several caveats and challenges that should be acknowledged. Despite strong mechanistic rationale and encouraging preclinical data from related Src inhibitors like saracatinib—which is undergoing evaluation in clinical trials for IPF (National Jewish Health, 2020)—there is currently limited direct evidence for KX2-391’s efficacy in fibrotic models of the lung specifically. Most available preclinical data are extrapolated from studies in alternative fibrosis models (such as peritoneal fibrosis) or from cancer models, and while these data support the general antifibrotic mechanism of Src inhibition, they do not definitively establish clinical efficacy in IPF. In addition, despite its selective targeting of the Src peptide-binding site, potential resistance mechanisms or off-target effects unique to the fibrotic milieu in the lung cannot be ruled out. The pharmacodynamic and pharmacokinetic properties established in oncology might differ in patients with IPF due to variations in tissue distribution, comorbidities, and disease-specific changes in lung architecture (Wang et al., 2021).

Moreover, while the proposed mechanism—namely, blockade of mechanotransduction via inhibition of focal adhesion kinase phosphorylation and actin remodeling—is well supported in the literature, the complex interplay of additional signaling pathways in IPF (including TGF-β, Wnt/β-catenin, and inflammatory mediators) may necessitate a combinatorial therapeutic approach rather than monotherapy with a Src inhibitor (Li et al., 2020). The reduction in αSMA expression and collagen deposition observed in preclinical studies offers an attractive endpoint; however, long-term effects on lung function, disease progression, and survival in IPF patients will need to be evaluated in rigorously designed clinical trials.

In summary, KX2-391 represents a mechanistically sound and therapeutically promising candidate for repurposing in IPF through its inhibition of Src-mediated pathways that regulate fibroblast activation, focusing on mechanotransduction processes that drive pathological tissue remodeling. Its strengths lie in its unique mechanism of Src inhibition, established clinical safety in other indications, and a robust preclinical rationale that aligns with key pathogenic features of IPF (Temps, 2020; Li et al., 2020; Wang et al., 2021). Nevertheless, further direct preclinical studies in lung fibrosis models and early-phase clinical trials specifically addressing IPF are necessary to validate its efficacy and safety in this new indication. Given these considerations, while the repurposing of KX2-391 holds significant promise, a cautious and methodical development strategy will be critical to its successful translation from oncology to fibrotic lung disease (ClinicalTrials.gov, n.d.).

References
Almirall, S.A. (2017). A multi-center study to evaluate the efficacy and safety of KX2-391 ointment 1% on AK on face or scalp (NCT03285477). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03285477

Athenex, Inc. (2007). Evaluation of KX2-391 in patients with advanced malignancies (NCT00658970). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00658970

ClinicalTrials.gov. (n.d.). Clinical trials search: KX2-391 OR Src inhibitor OR Src kinase inhibitor AND Idiopathic Pulmonary Fibrosis OR pulmonary fibrosis. Retrieved from https://clinicaltrials.gov

Li, X., Liu, X., Deng, R., Gao, S., Yu, H., Huang, K., Jiang, Q., Liu, R., Li, X., Zhang, L., Zhou, H., & Yang, C. (2020). Nintedanib inhibits Wnt3a-induced myofibroblast activation by suppressing the Src/β-catenin pathway. Frontiers in Pharmacology, 11, Article 310. https://doi.org/10.3389/fphar.2020.00310

National Jewish Health. (2020). Saracatinib in the treatment of idiopathic pulmonary fibrosis (NCT04598919). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04598919

Roswell Park Cancer Institute. (2007). KX2-391 in treating patients with advanced solid tumors or lymphoma that did not respond to treatment (NCT00646139). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00646139

Temps, C. (2020). Preclinical investigation of the novel Src inhibitor ECF506 in cancer. https://doi.org/10.7488/era/279

Wang, J., Wang, L., Xu, L., Shi, Y., Liu, F., Qi, H., Liu, N., & Zhuang, S. (2017). Targeting Src attenuates peritoneal fibrosis and inhibits the epithelial to mesenchymal transition. Oncotarget, 8, 83872–83889. https://doi.org/10.18632/oncotarget.20040

Wang, X., Ren, R., Xu, Z., Huang, H., Jiang, W., & Ma, J. (2021). Tirbanibulin attenuates pulmonary fibrosis by modulating Src/STAT3 signaling. Frontiers in Pharmacology, 12, Article 693906. https://doi.org/10.3389/fphar.2021.693906",-0.786809368,12
"CCG-257081 (CCG-257081, Cayman 10009426)","Proposal for CCG-257081 (CCG-257081, Cayman 10009426)

Overview of Therapeutic Candidate:
CCG-257081 is a synthetic small molecule that belongs to the class of MRTF/SRF inhibitors. It was originally discovered through high‐throughput screening efforts aimed at identifying compounds that block RhoA‐induced transcription mediated by the myocardin‐related transcription factor (MRTF) and its cofactor, the serum response factor (SRF). This compound has been chemically optimized from earlier analogues (such as CCG-203971, a close structural relative) to support robust target engagement and favorable pharmacokinetic properties, including ADME profiles that are suitable for in vivo use. As a member of the MRTF/SRF inhibitor family, CCG-257081 falls within a group of agents that have not been traditionally used to treat fibrotic diseases, but rather were originally developed in preclinical settings to dissect the role of the MRTF/SRF axis in transcriptional regulation, cell motility, and extracellular matrix remodeling. In fibrotic contexts, especially in idiopathic pulmonary fibrosis (IPF), the MRTF/SRF pathway drives the transcription of profibrotic genes such as ACTA2—which encodes α-smooth muscle actin (αSMA)—and connective tissue growth factor (CTGF). MRTF/SRF inhibitors have been proposed as a novel means to interrupt this fibrotic transcriptional program, and CCG-257081, in particular, has shown promising biochemical and preclinical antifibrotic data (Ma et al., 2023; Pawelec et al., 2022).

Therapeutic History:
The therapeutic history of compounds targeting the MRTF/SRF transcriptional axis is primarily limited to preclinical investigations, with several studies demonstrating that inhibition of MRTF activity can reduce fibroblast activation and subsequent fibrosis in animal models. For instance, several preclinical studies using bleomycin-induced lung fibrosis models have shown that MRTF/SRF inhibitors such as CCG-203971 reduce fibroblast activation markers, decrease collagen contraction, and lower biochemical markers of fibrosis (Pawelec et al., 2022). In addition, research into myocardin-related transcription factors has demonstrated that genetic depletion or pharmacological inhibition of MRTF-A results in decreased induction of pro-fibrotic genes and mitigates tissue remodeling in models of lung fibrosis (Sisson et al., 2015). While there is no direct record of CCG-257081 having been used clinically for idiopathic pulmonary fibrosis or similar fibrotic diseases, the strong preclinical evidence of MRTF/SRF inhibitors ameliorating fibroblast-driven fibrotic processes in lung models positions it as a promising candidate for repurposing in IPF. Moreover, the favorable ADME profiles reported in these studies further support its potential translational application (Ma et al., 2023; ClinicalTrials.gov, n.d.).

Mechanism of Action:
CCG-257081 acts by inhibiting the activity of the MRTF/SRF transcriptional complex. Under normal physiological conditions, MRTF-A resides in the cytoplasm in complex with monomeric globular actin (G-actin). Upon activation of Rho GTPase signaling pathways and subsequent actin polymerization (formation of filamentous actin, or F-actin), MRTF-A is released from G-actin and translocates into the nucleus. Once in the nucleus, MRTF-A partners with SRF to induce the transcription of genes that are critical for fibroblast activation and myofibroblast differentiation. These target genes include ACTA2 (which encodes αSMA) and CTGF, both of which are central to promoting extracellular matrix production, collagen contraction, and tissue remodeling (Ma et al., 2023; Sisson et al., 2015).
CCG-257081 functions by blocking nuclear translocation of MRTF-A, thereby preventing it from associating with SRF and initiating transcription of its downstream profibrotic targets. Studies have shown that pharmacological agents targeting the MRTF/SRF pathway can reduce mRNA and protein levels of CTGF and αSMA in fibroblasts, ultimately decreasing the contractile ability of these cells as evidenced by reduced 3D collagen gel contraction. In vitro assays have demonstrated that MRTF/SRF inhibitors act at low micromolar concentrations to diminish fibroblast activation, with a clear correlation between target engagement and suppression of the profibrotic gene network (Ma et al., 2023; Pawelec et al., 2022). Additionally, the compound's mechanism is supported by data indicating that inhibition of MRTF nuclear localization translates into measurable biochemical and cellular outcomes, such as lower CTGF expression and reduced collagen contraction in fibroblast cultures (Small, 2012).

Expected Effect:
The hypothesis underlying the use of CCG-257081 in IPF is that by blocking MRTF-A nuclear translocation, the compound will suppress the activation of lung fibroblasts. Specifically, its expected effects in the assay are multi-fold. First, it should reduce nuclear accumulation of MRTF-A in fibroblast foci, particularly in ACTA2+ myofibroblasts, thereby leading to a downregulation of profibrotic gene transcription. This, in turn, should result in decreased expression of key markers such as CTGF and α-smooth muscle actin—a direct indicator of diminished foam fibroblast activation and myofibroblast differentiation (Ma et al., 2023; Sisson et al., 2015). Secondly, in three-dimensional collagen gel contraction assays, treatment with CCG-257081 is expected to lead to a decrease in the contractility of IPF-derived fibroblasts. Such an effect is directly attributable to the reduced transcription of profibrotic genes governing cytoskeletal dynamics and matrix remodeling. Moreover, biochemical studies have shown that treatment with MRTF/SRF inhibitors results in lower mRNA levels of ACTA2 and CTGF, which correlates with a reduction in fibroblast-mediated collagen gel contraction, an important functional readout in assessing antifibrotic efficacy (Ma et al., 2023; Pawelec et al., 2022). The compound must consistently achieve these effects at concentrations that are pharmacologically relevant and non-toxic to lung fibroblasts, thereby demonstrating that its mechanism of action is specific to blocking fibrotic transcription without interfering with cell viability or essential housekeeping functions. This is further supported by data that show selective targeting of fibroblast activation with minimal impact on other cell types such as alveolar epithelial cells or immune cells, ensuring a favorable therapeutic index (Ma et al., 2023).

Overall Evaluation:
Overall, CCG-257081 appears to be a promising therapeutic candidate for the treatment of idiopathic pulmonary fibrosis based on several lines of evidence. The key strengths include its mechanistic specificity, as it directly targets the MRTF/SRF transcriptional pathway, which is critically involved in driving the expression of profibrotic genes like CTGF and ACTA2. Preclinical data in bleomycin-induced lung fibrosis models have demonstrated that inhibition of MRTF/SRF signaling can reduce fibroblast activation, collagen gel contraction, and overall fibrotic load, thereby validating the concept that blocking MRTF-A nuclear translocation is a viable strategy against IPF (Ma et al., 2023; Sisson et al., 2015). Additionally, the compound shows efficacy at low micromolar concentrations in vitro, with favorable ADME properties suggesting good pharmacokinetic behavior in vivo (Pawelec et al., 2022).

However, there are notable weaknesses and challenges as well. Although the preclinical models provide strong biochemical and cellular rationale for using MRTF/SRF inhibitors in IPF, clinical data with CCG-257081 are limited or absent. There is a need to establish long-term safety and efficacy in human subjects, as the MRTF/SRF pathway is also involved in homeostatic functions, and off-target effects or systemic toxicity might arise upon prolonged administration. Further, while the suppression of MRTF-mediated transcription is expected to reduce CTGF and αSMA expression, the translation of these effects into meaningful clinical outcomes such as improved lung function and reduced fibrosis progression in IPF patients remains to be validated in clinical trials. In addition, given that approved antifibrotic therapies (pirfenidone and nintedanib) slow rather than reverse disease progression, it is critical to determine whether MRTF/SRF inhibitors can provide additive or superior benefits either as monotherapy or in combination with existing treatments (Ma et al., 2023; Pawelec et al., 2022).

In summary, CCG-257081 exhibits considerable potential as a novel antifibrotic agent for IPF. Its targeted mechanism of action—blocking MRTF-A nuclear translocation and downstream SRF-mediated transcription of key profibrotic genes—addresses a fundamental source of fibroblast activation and extracellular matrix remodeling in the disease. Preclinical studies have demonstrated promising results in terms of reducing myofibroblast activation, collagen contraction, and expression of CTGF and αSMA. While challenges remain in translating these findings to the clinical setting, especially regarding long-term safety and efficacy in human patients, the strong mechanistic rationale and favorable preclinical profile warrant further investigation of CCG-257081 in clinical trials for idiopathic pulmonary fibrosis (Ma et al., 2023; Pawelec et al., 2022; Sisson et al., 2015).

References
ClinicalTrials.gov. (n.d.). ClinicalTrials.gov search: CCG-257081 OR MRTF inhibitor OR myocardin-related transcription factor inhibitor OR serum response factor inhibitor OR CCG-257081 antifibrotic OR CTGF inhibitor AND idiopathic pulmonary fibrosis. Retrieved from https://clinicaltrials.gov

Ma, H.-Y., Vander Heiden, J. A., Uttarwar, S., Xi, Y., N'Diaye, E.-N., LaCanna, R., Caplazi, P., Gierke, S., Moffat, J., Wolters, P. J., & Ding, N. (2023). Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone. European Respiratory Journal, 61, 2200604. https://doi.org/10.1183/13993003.00604-2022

Pawelec, K. M., Varnum, M., Harkema, J. R., Auerbach, B., Larsen, S. D., & Neubig, R. R. (2022). Prevention of bleomycin-induced lung fibrosis via inhibition of the MRTF/SRF transcription pathway. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1028

Sisson, T. H., Ajayi, I. O., Subbotina, N., Dodi, A. E., Rodansky, E. S., Chibucos, L. N., Kim, K. K., Keshamouni, V. G., White, E. S., Zhou, Y., Higgins, P. D. R., Larsen, S. D., Neubig, R. R., & Horowitz, J. C. (2015). Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis. The American Journal of Pathology, 185(4), 969–986. https://doi.org/10.1016/j.ajpath.2014.12.005

Small, E. M. (2012). The actin–MRTF–SRF gene regulatory axis and myofibroblast differentiation. Journal of Cardiovascular Translational Research, 5(6), 794–804. https://doi.org/10.1007/s12265-012-9397-0",-0.985390648,26
"A-485 (CBP/p300 inhibitor, Cayman 17811)","Proposal for A-485 (CBP/p300 inhibitor, Cayman 17811)

Overview of Therapeutic Candidate:
A-485 is a small‐molecule, drug‐like inhibitor that was discovered via structure‐based drug design and medicinal chemistry optimization targeting the histone acetyltransferase (HAT) activity of the transcriptional coactivators CBP and p300. It belongs to the epigenetic modifier class, specifically the catalytic inhibitors of CBP/p300, and is characterized by its spiro-oxazolidinedione scaffold. Originally developed as a chemical probe to interrogate the functions of CBP/p300 in oncogenic transcription and chromatin regulation, A-485 displays potent and selective catalytic inhibition with low nanomolar inhibitory concentrations (approximately 9.8 nM for p300) (Rubio et al., 2023). This class of compounds has been previously used in cancer research to modulate histone acetylation, thereby altering enhancer activity and oncogene-driven transcription programs. More broadly, such inhibitors have been employed in preclinical studies to explore epigenetic pathways that underpin aberrant gene expression programs in various diseases, and increasingly their potential has been extended to fibrotic disorders through the concept of repurposing agents targeting epigenetic dysregulation (Rubio et al., 2019; Crawford et al., 2023).

Therapeutic History:
A-485’s therapeutic history is predominantly rooted in preclinical oncology research where its capacity to inhibit the enzymatic activity of CBP/p300 was shown to diminish histone acetylation marks such as H3K27ac, resulting in the downregulation of key proliferative and survival pathways including those involving c-Myc and androgen receptor targets (Lasko et al., 2017; Rubio et al., 2023). Preclinical studies have demonstrated its ability to reduce tumor growth in xenograft models such as those of prostate cancer, and it has also been evaluated in the context of other malignancies where aberrant CBP/p300 activity contributes to disease progression (Crawford et al., 2023; McKinsey et al., 2018). Although A-485 has not yet been evaluated in clinical trials for cancer and there is limited direct clinical translation data available, its mechanism of reducing histone acetylation has provided strong proof-of-concept in several in vitro and animal models. Importantly, in fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), hyperactive p300 has been implicated in promoting excessive extracellular matrix production, fibroblast activation, and myofibroblast differentiation (Rubio et al., 2019). Studies using the inhibition of p300 in lung fibrosis models have shown that interfering with its catalytic activity can reduce hallmark features of fibrosis, including diminished collagen deposition and lowered expression of profibrotic markers. Hence, while A-485’s historical application has primarily focused on cancer, the underlying biology of CBP/p300 in regulating fibrotic gene expression supports the rationale for repurposing A-485 for IPF (Rubio et al., 2019; Rubio et al., 2023).

Mechanism of Action:
A-485 functions by directly interacting with the catalytic domain of CBP/p300, competitively inhibiting the binding of acetyl-CoA, which is necessary for the acetylation of lysine residues on histone tails and non-histone proteins. This inhibition prevents the acetylation of histones such as H3K27 and H3K18, leading to a more closed chromatin structure and subsequent transcriptional repression of gene expression (Rubio et al., 2023; Crawford et al., 2023). Mechanistically, in the context of fibrosis, CBP/p300 are critical coactivators of TGF-β/SMAD pathways as well as MRTF-A/SRF signaling; both pathways converge to upregulate profibrotic genes including ACTA2 (encoding alpha-smooth muscle actin, αSMA) and various collagen genes. A-485 by blocking the HAT activity of CBP/p300 can thereby hinder the acetylation-dependent activation of transcription factors such as SMAD3 and MRTF-A, which are key drivers of fibroblast activation and myofibroblast differentiation (Rubio et al., 2023; Tao et al., 2018). Furthermore, experimental data in preclinical models of fibrosis have shown that inhibition of EP300 can restore nuclear HDAC activity, which is compromised in IPF fibroblasts, thus rebalancing the acetylation/deacetylation equilibrium and promoting the re-silencing of aberrantly activated fibrotic genes (Rubio et al., 2019). In addition to modulating histone acetylation, A-485 may also affect the acetylation status of non-histone proteins including transcription factors and co-regulators that participate in the assembly of enhancer complexes critical for sustaining the profibrotic transcriptional program.

Expected Effect:
Based on its mechanism of action, the expected effect of A-485 in an IPF assay would be a significant reduction in the acetylation of key histones and transcription factors that drive profibrotic gene expression. Specifically, in fibroblast assays using 3D collagen gels, A-485 is anticipated to reduce the transcriptional activation of genes such as ACTA2, thereby lowering the expression levels of αSMA, which is a marker of myofibroblast differentiation. The inhibition of p300-mediated acetylation is expected to disrupt the TGF-β/SMAD signaling cascade, ultimately leading to reduced fibroblast contraction and a decrease in extracellular matrix deposition. Supporting evidence comes from experiments showing that EP300 inhibition, in general, leads to decreased collagen deposition, lower fibrotic scores, and reduced expression of profibrotic markers in preclinical models of lung fibrosis (Rubio et al., 2019; Rubio et al., 2023). Moreover, the effect of A-485 on reactivating nuclear HDAC activity may further contribute to reinstating a more quiescent chromatin state, thus repressing genes that are otherwise upregulated in IPF. Since CBP/p300 are also implicated in chemoattractant signaling and fibroblast proliferation, their inhibition should also mitigate the paracrine activation of fibroblasts, contributing to an overall antifibrotic phenotype observed in 3D contraction assays and in vivo models of pulmonary fibrosis (Sehgal et al., 2022; Rubio et al., 2023).

Overall Evaluation:
A-485 presents a promising therapeutic candidate for the treatment of idiopathic pulmonary fibrosis due to its well-characterized mechanism as a highly selective inhibitor of CBP/p300 histone acetyltransferase activity. One of the main strengths of A-485 is its ability to directly target epigenetic regulators that function as key molecular integrators in profibrotic transcriptional programs. Given that CBP/p300 coactivates TGF-β/SMAD and MRTF-A signaling pathways, which are critical for the induction of fibrotic genes, A-485’s potent catalytic inhibition (with IC50 values in the nanomolar range) suggests that even low doses could achieve significant modulation of these pathways (Rubio et al., 2023; Crawford et al., 2023). Additionally, preclinical studies in various fibrotic models, including lung, cardiac, and hepatic fibrosis, have demonstrated that pharmacological inhibition of EP300 can lead to decreased collagen deposition and attenuated fibrotic endpoints (Rubio et al., 2019; Kim et al., 2023). This establishes a strong mechanistic rationale for testing A-485 in IPF, where current treatments only slow progression without reversing the fibrotic process.

However, despite these promising features, there are notable weaknesses and challenges that must be addressed before A-485 can be advanced as an IPF therapeutic candidate. First, while its efficacy in cancer models and preclinical fibrotic assays has been encouraging, there is a lack of direct clinical data on its use in IPF or other fibrotic diseases. The safety profile, pharmacokinetics, and potential off-target effects of inhibiting a ubiquitous epigenetic regulator like CBP/p300 require careful evaluation. Given the pleiotropic roles of CBP/p300 in normal cellular homeostasis—including their involvement in stem cell differentiation, immune regulation, and tissue repair—systemic inhibition may carry risks of adverse events that have yet to be fully characterized (Rubio et al., 2023; Katavolos et al., 2020). Additionally, while the rebalancing of acetylation states in fibrotic cells is desirable, there is a possibility that broad epigenetic modulation may result in unintended suppression of genes critical for normal cellular functions, raising concerns regarding long-term safety and tolerability.

In summary, the strengths of A-485 for the treatment of IPF lie in its potent and selective inhibition of the CBP/p300 HAT domain, its ability to block key profibrotic transcriptional programs through modulation of acetylation-dependent activation of SMAD3 and MRTF-A, and the supportive preclinical data in fibrotic models. Its design as an epigenetic modulator that can reduce αSMA expression and fibroblast contraction in 3D models provides a strong mechanistic basis for its antifibrotic potential. On the other hand, the weaknesses include the current lack of direct clinical evidence in IPF, the potential for adverse effects due to the broad roles of CBP/p300 in normal physiology, and the need to thoroughly characterize its pharmacokinetic profile and safety in the context of chronic fibrotic diseases. Overall, A-485 represents a highly promising candidate for repurposing as an IPF therapeutic; however, additional detailed preclinical studies focusing on lung fibrosis models, comprehensive toxicology assessments, and eventual early-phase clinical trials in IPF patients will be essential to determine its feasibility and therapeutic index in this new context (Rubio et al., 2019; Rubio et al., 2023; Sehgal et al., 2022; Crawford et al., 2023).

References:
Crawford, M. C., Tripu, D. R., Barritt, S. A., Jing, Y., Gallimore, D., Kales, S. C., Bhanu, N. V., Xiong, Y., Fang, Y., Butler, K. A. T., LeClair, C. A., Coussens, N. P., Simeonov, A., Garcia, B. A., Dibble, C. C., & Meier, J. L. (2023). Comparative analysis of drug‐like ep300/crebbp acetyltransferase inhibitors. ACS Chemical Biology, 18, 2249–2258. https://doi.org/10.1021/acschembio.3c00293

Katavolos, P., Cain, G., Farman, C., Romero, F. A., Magnuson, S., Ly, J. Q., Choo, E. F., Katakam, A. K., Andaya, R., & Maher, J. (2020). Preclinical safety assessment of a highly selective and potent dual small‐molecule inhibitor of CBP/p300 in rats and dogs. Toxicologic Pathology, 48, 465–480. https://doi.org/10.1177/0192623319898469

Kim, H., Park, S.-Y., Lee, S. Y., Kwon, J.-H., Byun, S., Kim, M. J., Yu, S., Yoo, J.-Y., & Yoon, H.-G. (2023). Therapeutic effects of selective p300 histone acetyl‐transferase inhibitor on liver fibrosis. BMB Reports, 56, 114–119. https://doi.org/10.5483/bmbrep.2022-0188

Lasko, L. M., Jakob, C. G., Edalji, R. P., Qiu, W., Montgomery, D., Digiammarino, E. L., Hansen, T. M., Risi, R. M., Frey, R., Manaves, V., Shaw, B., Algire, M., Hessler, P., Lam, L. T., Uziel, T., Faivre, E., Ferguson, D., Buchanan, F. G., Martin, R. L., Torrent, M., Chiang, G. G., Karukurichi, K., Langston, J. W., Weinert, B. T., Choudhary, C., de Vries, P., Kluge, A. F., Patane, M. A., Van Drie, J. H., Wang, C., McElligott, D., Kesicki, E., Marmorstein, R., Sun, C., Cole, P. A., Rosenberg, S. H., Michaelides, M. R., Lai, A., & Bromberg, K. D. (2017). Discovery of a selective catalytic p300/CBP inhibitor that targets lineage‐specific tumours. Nature, 550, 128–132. https://doi.org/10.1038/nature24028

McKinsey, T. A., Vondriska, T. M., & Wang, Y. (2018). Epigenomic regulation of heart failure: Integrating histone marks, long noncoding RNAs, and chromatin architecture. F1000Research, 7, 1713. https://doi.org/10.12688/f1000research.15797.1

Rubio, K., Singh, I., Dobersch, S., Sarvari, P., Günther, S., Cordero, J., Mehta, A., Wujak, L., Cabrera-Fuentes, H., Chao, C.-M., Braubach, P., Bellusci, S., Seeger, W., Günther, A., Preissner, K., Wygrecka, M., Savai, R., Papy-Garcia, D., Dobreva, G., Heikenwalder, M., Savai-Pullamsetti, S., Braun, T., & Barreto, G. (2019). Inactivation of nuclear histone deacetylases by EP300 disrupts the MICEE complex in idiopathic pulmonary fibrosis. Nature Communications, 10, 1626. https://doi.org/10.1038/s41467-019-10066-7

Rubio, K., Molina-Herrera, A., Pérez-González, A., Hernández-Galdámez, H. V., Piña-Vázquez, C., Araujo-Ramos, T., & Singh, I. (2023). EP300 as a molecular integrator of fibrotic transcriptional programs. International Journal of Molecular Sciences, 24, 12302. https://doi.org/10.3390/ijms241512302

Sehgal, M., Jakhete, S. M., Manekar, A. G., & Sasikumar, S. (2022). Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosis. Heliyon, 8, e09773. https://doi.org/10.1016/j.heliyon.2022.e09773

Tao, J., Zhang, M., Wen, Z., Wang, B.-G., Zhang, L., Ou, Y., Tang, X., Yu, X., & Jiang, Q. (2018). Inhibition of EP300 and DDR1 synergistically alleviates pulmonary fibrosis in vitro and in vivo. Biomedicine & Pharmacotherapy, 106, 1727–1733. https://doi.org/10.1016/j.biopha.2018.07.132",-1.145006587,17
"Mdivi-1 (Drp1 Inhibitor, Selleckchem S8439)","Proposal for Mdivi-1 (Drp1 Inhibitor, Selleckchem S8439)

Overview of Therapeutic Candidate:
Mdivi-1 is a synthetic small‐molecule inhibitor that was discovered through high‐throughput chemical screening efforts designed to modulate mitochondrial dynamics. As a quinazolinone derivative, Mdivi-1 specifically targets dynamin‐related protein 1 (Drp1), which is a key regulator of mitochondrial fission. Drp1 is a cytosolic GTPase that, upon activation, translocates to the mitochondrial outer membrane to mediate fission through oligomerization and GTP hydrolysis. Mdivi-1 prevents the proper assembly and translocation of Drp1 thereby favoring a more fused mitochondrial network and stabilizing mitochondrial morphology. This therapeutic candidate belongs to the emerging class of mitochondrial fission inhibitors, which have drawn considerable attention in the last decade because of their potential to modulate mitochondrial structure and function in conditions in which abnormal fission contributes to pathology. In earlier preclinical studies, compounds in this class have been employed to ameliorate mitochondrial fragmentation in models of ischemia-reperfusion injury, neurodegenerative disorders, and conditions marked by aberrant proliferative responses such as pulmonary arterial hypertension (Tian et al., 2018; Duan et al., 2020).

Therapeutic History:
The initial uses of Mdivi-1 have been predominantly in the realm of preclinical research where it served as an indispensable tool for exploring the mechanistic roles of mitochondrial fission in cellular physiology and pathophysiology. In biochemical studies involving cardiac, neural, and vascular cells, Mdivi-1 has been employed to inhibit Drp1-mediated mitochondrial fragmentation and thereby prevent mitochondrial dysfunction, which is often evidenced by changes in reactive oxygen species (ROS) production and alterations in cell metabolism. For example, in experimental models of pulmonary arterial hypertension (PAH), treatment with Mdivi-1 resulted in reduced Drp1 activity in pulmonary artery smooth muscle cells, which led to decreased cellular hyperproliferation and collagen production—a process that mirrors some aspects of fibroblast activation in fibrotic diseases (Tian et al., 2018). Moreover, studies in models of paraquat-induced pulmonary fibrosis have provided evidence that targeting Drp1 with Mdivi-1 can reduce mitochondrial fragmentation and attenuate pro-inflammatory signaling cascades, such as those mediated by the TLR9-NF-κB pathway, indicating a robust antifibrotic effect in lung tissue (Unknown Reference). Furthermore, additional investigations in related lung injury models and evaluations in non-alcoholic steatohepatitis (NASH) liver organoids have also underscored the relevance of mitochondrial dynamics modulation in reducing fibrotic gene expression and ECM deposition (Elbadawy et al., 2023). Although there is limited direct clinical evidence in Idiopathic Pulmonary Fibrosis (IPF) models, the emerging trend in clinical trial searches for Drp1 inhibitors in fibrotic lung diseases reflects a growing consensus among researchers that modulating mitochondrial dynamics might offer translatable benefit in IPF (ClinicalTrials.gov, n.d.).

Mechanism of Action:
At the molecular level, the process of mitochondrial fission is tightly regulated by Drp1. In its inactive state, Drp1 resides in the cytosol. However, upon receiving activation signals—including phosphorylation events such as at serine 616 (p-Drp1^S616)—Drp1 is recruited to the mitochondrial outer membrane where it interacts with receptor proteins and oligomerizes to physically constrict and divide mitochondria. Elevated lactate levels in pulmonary fibroblasts can stimulate the ERK1/2 pathway, which then phosphorylates Drp1 at serine 616, promoting the excessive mitochondrial fission observed in fibrotic conditions (Sun et al., 2024). Mdivi-1 acts by interfering with the oligomerization step of Drp1, thereby preventing its effective binding to the mitochondrial membrane and the subsequent fission event. This inhibition not only stabilizes mitochondrial morphology, fostering an elongated, interconnected network, but also restores proper mitochondrial function by reducing aberrant ROS generation that typically results from fragmented mitochondria (Sun et al., 2024). In addition, the normalization of mitochondrial dynamics by Mdivi-1 has been linked to an improved balance in cellular bioenergetics; specifically, a reduction in the Warburg-like glycolytic reprogramming that is often observed in pathological fibroblasts (Tian et al., 2018). By enhancing electron transport chain efficiency and reducing mitochondrial ROS, Mdivi-1 indirectly dampens the activation of pro-fibrotic mediators such as transforming growth factor-beta (TGF-β). Elevated ROS levels are well-known activators of the NF-κB signaling cascade, particularly the p65 subunit, which can lead to increased expression of fibrotic markers including α-smooth muscle actin (α-SMA) and collagen I (COL1A1) (Lin et al., 2024). Thus, Mdivi-1’s mechanism of restoring mitochondrial integrity reaches beyond a mere morphological effect; it also modulates key signaling pathways that underpin fibroblast activation, collagen synthesis, and contractility.

Expected Effect:
The hypothesis that Mdivi-1 will ameliorate idiopathic pulmonary fibrosis (IPF) is built on the expectation that targeting mitochondrial fission will lead to normalization of fibroblast mitochondrial dynamics, reduction in oxidative stress, and consequent dampening of downstream pro-fibrotic signaling cascades. In a 3D collagen gel contraction assay using lung fibroblasts derived from IPF patients, the expected effect is multifold. First, by inhibiting Drp1-mediated mitochondrial fission, Mdivi-1 should restore an elongated mitochondrial network. This morphological normalization is anticipated to result in decreased production of mitochondrial ROS, which are implicated in the persistent activation of TGF-β signaling—a central mediator of fibrosis (Sun et al., 2024). As fibroblasts in the IPF lung typically exhibit a metabolic shift towards glycolysis along with increased ROS, the re-establishment of proper mitochondrial morphology is expected to shift cellular metabolism back towards oxidative phosphorylation, thereby attenuating the hyperproliferative and synthetic state of these cells (Tian et al., 2018).

Second, the reduction in ROS production should lead to a significant decrease in the activation of TGF-β. TGF-β is a critical cytokine involved in the differentiation of fibroblasts into myofibroblasts, which express high levels of contractile proteins such as α-SMA and are responsible for the excessive deposition of extracellular matrix proteins like collagen. By lowering ROS levels, Mdivi-1 is expected to blunt TGF-β activation and thereby reduce the expression of α-SMA and collagen I, resulting in a measurable reduction in gel contraction in 3D collagen assays (Guo et al., 2023; Unknown Reference).

Furthermore, the normalization of mitochondrial dynamics may also directly influence fibroblast contractility. Abnormal mitochondrial fission and ROS production are known to enhance fibroblast contractility, contributing to the pathological stiffening of lung tissue that is a hallmark of IPF. Therefore, treatment with Mdivi-1 is projected to result in diminished fibroblast contractility, as evidenced by a reduction in the degree of collagen gel contraction. On a molecular level, this effect is likely to correlate with reduced levels of pro-fibrotic markers, improved mitochondrial respiration, and a more normalized cellular phenotype that is less supportive of the autocrine loops that fuel fibrosis (Li et al., 2020).

Overall Evaluation:
The comprehensive evaluation of Mdivi-1 as a repurposed therapeutic candidate for Idiopathic Pulmonary Fibrosis (IPF) reveals both promising strengths and significant considerations that must be addressed in the translation process. On the strengths side, Mdivi-1 offers a unique mechanism of action that directly targets dysregulated mitochondrial dynamics—a fundamental aspect of the pathogenesis of fibrotic lung diseases. The ability of Mdivi-1 to inhibit Drp1-mediated mitochondrial fission addresses a primary defect in IPF fibroblasts, restoring an elongated and interconnected mitochondrial network. This restoration is essential for reducing mitochondrial ROS production, thereby dampening the TGF-β-driven signaling cascades that promote myofibroblast differentiation, collagen deposition, and tissue stiffening (Sun et al., 2024; Tian et al., 2018). Preclinical data from models of PAH and paraquat-induced pulmonary fibrosis provide robust biochemical evidence supporting the antifibrotic effects of Drp1 inhibition (Unknown Reference; Tian et al., 2018). Furthermore, ongoing clinical trial searches for agents targeting mitochondrial fission in lung fibrosis underscore the translational potential and growing interest in this therapeutic approach (ClinicalTrials.gov, n.d.; Elbadawy et al., 2023).

However, several weaknesses and challenges must be carefully considered. One of the principal concerns is the specificity of Mdivi-1 for Drp1. Evidence from studies in skeletal muscle and neuronal models indicates that while Mdivi-1 effectively inhibits mitochondrial fission at certain concentrations, at higher doses it can also inhibit components of the mitochondrial electron transport chain (such as Complex I), leading to off-target effects that may compromise cellular bioenergetics (Rexius-Hall et al., 2020; Yeon et al., 2015). This raises potential safety concerns, particularly when considering long-term treatments in a chronic disease like IPF. The balance between pathological and physiological mitochondrial fission is delicate; while excessive fission is deleterious, a baseline level of fission is necessary for mitochondrial quality control and efficient mitophagy. Therefore, the therapeutic window for Mdivi-1 must be carefully defined to ensure that its antifibrotic benefits are achieved without impairing essential metabolic processes (Li et al., 2020).

Pharmacokinetics and tissue distribution represent additional challenges. Although preclinical studies have demonstrated effective doses in cellular and animal models, the bioavailability, half-life, and distribution of Mdivi-1 in lung tissue remain insufficiently characterized. This gap in knowledge could complicate dosing strategies for eventual clinical application in IPF. Moreover, the chronic nature of IPF requires that any therapeutic candidate not only exhibit acute antifibrotic effects but also maintain long-term safety and efficacy. Given the current limited data on the use of Mdivi-1 in chronic fibrosis models, further work is needed to validate its safety profile over extended treatment periods (Marx et al., 2024; Guo et al., 2023).

Another consideration is the complexity of the fibrotic microenvironment in IPF. While preclinical models such as those using fibroblasts in 3D collagen gels provide valuable insights into the cellular mechanisms driving fibrosis, the in vivo context in IPF is characterized by complex interactions among multiple cell types, persistent inflammatory stimuli, and dysregulated extracellular matrix remodeling. Combination therapies that include Mdivi-1 along with agents that target other pro-fibrotic pathways (for example, modulators of the TGF-β axis) may ultimately be necessary to achieve a clinically significant impact on disease progression (Zank et al., 2018; Mercader-Barceló et al., 2023).

Additionally, careful attention must be given to the dualistic role of mitochondrial fission. In some contexts, mitochondrial fission is required for cell division and the removal of damaged mitochondria; therefore, prolonged inhibition of Drp1 could theoretically result in the accumulation of dysfunctional mitochondria, impaired cellular turnover, and unexpected adverse events. This is particularly relevant in lung tissue, where homeostasis depends on a delicate balance between cell proliferation, apoptosis, and regeneration in response to ongoing environmental insults (Luo et al., 2019).

Despite these potential hurdles, Mdivi-1 holds distinct promise thanks to its mechanistic targeting of mitochondrial dysfunction—a process that is increasingly recognized as central to the pathogenesis of IPF. By mitigating mitochondrial fragmentation and reducing oxidative stress, Mdivi-1 could feasibly interrupt the cascade of events leading to fibroblast activation, myofibroblast differentiation, and ultimately fibrotic remodeling. The net effect is anticipated to be a reduction in both the biochemical markers of fibrosis, such as TGF-β, α-SMA, and collagen deposition, as well as a measurable improvement in fibroblast contractility, as assessed through 3D collagen contraction assays (Guo et al., 2023; Unknown Reference).

The available preclinical data, particularly those obtained in settings of paraquat-induced pulmonary fibrosis and PAH-related vascular remodeling, offer a strong rationale for further investigation of Mdivi-1 in IPF-specific models. Future studies should focus on validating its efficacy in primary human lung fibroblasts derived from IPF patients as well as in animal models that recapitulate the chronicity and heterogeneity of the disease. Detailed pharmacokinetic analyses, as well as dosing and safety studies, will be imperative to establish Mdivi-1’s clinical viability. It may also be beneficial to explore combination therapies that pair Mdivi-1 with currently approved antifibrotic agents to determine if synergistic effects can be achieved, potentially lowering the required dose of either agent and minimizing adverse events (Burzangi, 2020; Tian et al., 2018).

Overall, the preclinical and mechanistic data suggest that Mdivi-1 offers a compelling and innovative approach to treating IPF by precisely targeting dysregulated mitochondrial dynamics, a key upstream driver of fibrogenesis. Its ability to restore mitochondrial network integrity, reduce ROS production, and consequently diminish TGF-β-induced fibroblast activation positions it as a strong candidate in the development pipeline for IPF therapeutics. Nonetheless, the issues related to drug specificity, optimal therapeutic window, and long-term safety must be comprehensively addressed through rigorous experimental validation before considering progression to clinical trials (ClinicalTrials.gov, n.d.; Rexius-Hall et al., 2020).

In conclusion, Mdivi-1 represents a promising repurposed therapeutic candidate for Idiopathic Pulmonary Fibrosis owing to its unique mechanism of action that targets mitochondrial fission via Drp1 inhibition. The capacity of Mdivi-1 to normalize mitochondrial dynamics, reduce ROS production, shift cellular metabolism from a glycolytic phenotype back toward oxidative phosphorylation, and ultimately attenuate fibrotic signaling through reduced TGF-β activity and decreased fibroblast contractility is well-supported by a growing body of preclinical evidence (Sun et al., 2024; Unknown Reference). However, careful optimization of dosing strategies, assessment of potential off-target effects, and validation in IPF-relevant translational models remain critical steps. The dual role of mitochondrial fission in both physiological maintenance and pathological remodeling presents a complex challenge, one that necessitates a finely tuned therapeutic approach. Given the considerable unmet clinical need in IPF and the innovative nature of targeting mitochondrial dynamics, further preclinical research and eventual clinical evaluation of Mdivi-1 are warranted. With rigorous investigation, Mdivi-1 could potentially offer a novel therapeutic option that not only halts the progression of fibrosis but also improves lung function and patient outcomes in a disease that has thus far been refractory to many conventional therapies (Mercader-Barceló et al., 2023; Tian et al., 2018).

References
Burzangi, A. H. S. H. (2020). The role of mitochondria in regulating smooth muscle cell proliferation and migration in pulmonary hypertension. [Unknown journal].

ClinicalTrials.gov. (n.d.). Search for “Mdivi-1 OR Drp1 inhibitor OR mitochondrial fission inhibitor AND (idiopathic pulmonary fibrosis OR lung fibrosis)”. Retrieved July 1, 2024, from https://clinicaltrials.gov

Duan, C., Wang, L., Zhang, J., Xiang, X., Wu, Y., Zhang, Z., Li, Q., Tian, K., Xue, M., Liu, L., & Li, T. (2020). Mdivi-1 attenuates oxidative stress and exerts vascular protection in ischemic/hypoxic injury by a mechanism independent of Drp1 GTPase activity. Redox Biology, 37, 101706. https://doi.org/10.1016/j.redox.2020.101706

Elbadawy, M., Tanabe, K., Yamamoto, H., Ishihara, Y., Mochizuki, M., Abugomaa, A., Yamawaki, H., Kaneda, M., Usui, T., & Sasaki, K. (2023). Evaluation of the efficacy of mitochondrial fission inhibitor (Mdivi-1) using non-alcoholic steatohepatitis (NASH) liver organoids. Frontiers in Pharmacology, 14, Article 1243258. https://doi.org/10.3389/fphar.2023.1243258

Guo, T., Jiang, C.-s., Yang, S.-z., Zhu, Y., He, C., Carter, A. B., Antony, V. B., Peng, H., & Zhou, Y. (2023). Mitochondrial fission and bioenergetics mediate human lung fibroblast durotaxis. JCI Insight, 8(1), e157348. https://doi.org/10.1172/jci.insight.157348

Li, X., Zhang, W., Cao, Q., Wang, Z., Zhao, M., Xu, L., & Zhuang, Q. (2020). Mitochondrial dysfunction in fibrotic diseases. Cell Death Discovery, 6, Article 316. https://doi.org/10.1038/s41420-020-00316-9

Lin, Y., Wang, D., Li, B., Wang, J., Xu, L., Sun, X., Ji, K., Yan, C., Liu, F., & Zhao, Y. (2024). Targeting Drp1 with Mdivi-1 to correct mitochondrial abnormalities in ADOA+ syndrome. JCI Insight, 9(12), e180582. https://doi.org/10.1172/jci.insight.180582

Luo, X., Liu, R., Zhang, Z., Chen, Z., He, J., & Liu, Y. (2019). Mitochondrial division inhibitor 1 attenuates mitophagy in a rat model of acute lung injury. BioMed Research International, 2019, Article 2193706. https://doi.org/10.1155/2019/2193706

Marx, N., Ritter, N., Disse, P., Seebohm, G., & Busch, K. B. (2024). Detailed analysis of Mdivi-1 effects on Complex I and respiratory supercomplex assembly. Scientific Reports, 14, Article 69748. https://doi.org/10.1038/s41598-024-69748-y

Mercader-Barceló, J., Martín-Medina, A., Truyols-Vives, J., Escarrer-Garau, G., Elowsson, L., Montes-Worboys, A., Río-Bocos, C., Muncunill-Farreny, J., Velasco-Roca, J., Cederberg, A., Kadefors, M., Molina-Molina, M., Westergren-Thorsson, G., & Sala-Llinás, E. (2023). Mitochondrial dysfunction in lung resident mesenchymal stem cells from idiopathic pulmonary fibrosis patients. Cells, 12(16), 2084. https://doi.org/10.3390/cells12162084

Rexius-Hall, M. L., Khalil, N. N., Andres, A. M., & McCain, M. L. (2020). Mitochondrial division inhibitor 1 (Mdivi-1) increases oxidative capacity and contractile stress generated by engineered skeletal muscle. The FASEB Journal, 34(8), 11562–11576. https://doi.org/10.1096/fj.201901039RR

Sun, Z., Ji, Z., Meng, H., He, W., Li, B., Pan, X., Zhou, Y., & Yu, G. (2024). Lactate facilitated mitochondrial fission-derived ROS to promote pulmonary fibrosis via ERK/Drp-1 signaling. Journal of Translational Medicine, 22, 389. https://doi.org/10.1186/s12967-024-05289-2

Tian, L., Potus, F., Wu, D., Dasgupta, A., Chen, K.-H., Mewburn, J., Lima, P., & Archer, S. L. (2018). Increased Drp1-mediated mitochondrial fission promotes proliferation and collagen production by right ventricular fibroblasts in experimental pulmonary arterial hypertension. Frontiers in Physiology, 9, 828. https://doi.org/10.3389/fphys.2018.00828

Unknown Reference. (2023). … Fission and oxidative stress contributes to mitochondrial-DNA-mediated inflammation and epithelial-mesenchymal transition in paraquat-induced pulmonary fibrosis.

Yeon, J.-Y., Min, S.-H., Park, H.-J., Kim, J.-W., Lee, Y.-H., Park, S.-Y., Jeong, P.-S., Park, H., Lee, D.-S., Kim, S.-U., Chang, K.-T., & Koo, D.-B. (2015). Mdivi-1, mitochondrial fission inhibitor, impairs developmental competence and mitochondrial function of embryos and cells in pigs. Journal of Reproduction and Development, 61(2), 81–89. https://doi.org/10.1262/jrd.2014-070

Zank, D. C., Bueno, M., Mora, A. L., & Rojas, M. (2018). Idiopathic pulmonary fibrosis: Aging, mitochondrial dysfunction, and cellular bioenergetics. Frontiers in Medicine, 5, 10. https://doi.org/10.3389/fmed.2018.00010",-1.274774416,7
"Lenvatinib (E7080, Selleckchem S2184)","Proposal for Lenvatinib (E7080, Selleckchem S2184)

Overview of Therapeutic Candidate:
Lenvatinib (E7080, Selleckchem S2184) is a synthetic, orally available small‐molecule multi‐kinase inhibitor that was initially discovered through high‐throughput screening efforts aimed at identifying compounds capable of inhibiting angiogenesis and tumor cell proliferation targets (Hussein et al., 2017, pp. 10–11). It belongs to the class of receptor tyrosine kinase inhibitors (TKIs), a well‐established group of therapeutic compounds that have been used extensively in oncology to arrest tumor growth, angiogenesis, and metastasis by blocking signaling through receptors such as vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), and platelet‐derived growth factor receptors (PDGFRs) (Grimminger et al., 2015, pp. 1–2). Lenvatinib is a product of an optimization process stemming from earlier antiangiogenic agents and has been synthesized with the intention of providing broad-spectrum inhibition of proangiogenic and growth factor pathways; its chemical structure has been refined to achieve nanomolar potency against its targets (Hussein et al., 2017, pp. 8–10). As a representative of its class, lenvatinib differs from several first-generation TKIs by virtue of its activity against multiple receptor subtypes, including inhibition of VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT, which positions it as capable of interfering with a range of signaling cascades implicated in aberrant cell proliferation and fibrotic remodeling (Grimminger et al., 2015, pp. 6–7).

Therapeutic History:
Lenvatinib has an established therapeutic history in oncology, having received regulatory approval for the treatment of unresectable thyroid cancer and hepatocellular carcinoma based on a robust clinical dataset demonstrating its antiangiogenic and antitumor properties (Hussein et al., 2017, pp. 10–11; Imakura et al., 2022, pp. 1–2). Its clinical development in these tumor settings has provided extensive data on its pharmacokinetics, dosing regimens, and safety profile in humans, and its oral availability makes it a convenient option for chronic administration in cancer patients (Hussein et al., 2017, pp. 10–11). Although lenvatinib’s use in idiopathic pulmonary fibrosis (IPF) has not been clinically evaluated—as evidenced by searches on Clinical Trials showing no registered trials specific to IPF with lenvatinib (ClinicalTrials.gov, n.d.)—its mechanism of action suggests that it might be repurposed for fibrotic lung diseases (ClinicalTrials.gov, n.d.). In preclinical studies conducted in non‐pulmonary fibrotic settings, such as liver fibrosis models, lenvatinib has been shown to inhibit the activation of hepatic stellate cells—key mediators of fibrosis—thereby reducing extracellular matrix production and capillarization (Ogawa et al., 2021, pp. 2–4). This finding is relevant because the molecular drivers of fibrosis in the liver—mediated by pathways involving VEGFR, FGFR, and PDGFR—are similar to those operative in the pathogenesis of IPF, suggesting a potential therapeutic overlap (Grimminger et al., 2015, pp. 7–8). Although no direct veterinary or clinical data exist for lenvatinib in the context of IPF, the successful repurposing of other multi‐kinase inhibitors such as nintedanib in IPF provides a precedent that supports the exploration of lenvatinib as a therapeutic candidate for this devastating lung disease (Hostettler et al., 2014, pp. 1–2).

Mechanism of Action:
The primary mechanism of action of lenvatinib is through the potent and selective inhibition of key receptor tyrosine kinases involved in angiogenesis and fibrogenesis, namely VEGFR1–3, FGFR1–4, and PDGFRα (Hussein et al., 2017, pp. 8–10; Grimminger et al., 2015, pp. 4–5). By binding to the ATP‐binding pocket of these receptors, lenvatinib competitively inhibits their kinase activity, which prevents receptor autophosphorylation and the subsequent activation of downstream signaling pathways such as the PI3K/Akt and MAPK/ERK cascades (Bhatt et al., 2025, pp. 2–4; Hussein et al., 2017, pp. 8–10). The inhibition of these pathways is significant in the context of fibrotic diseases because they are responsible for mediating cellular processes including fibroblast proliferation, survival, extracellular matrix (ECM) synthesis, and 3D collagen contraction (Grimminger et al., 2015, pp. 2–4). In IPF, overactivation of mitogenic signals such as those driven by platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) contributes to the persistent activation of fibroblasts and myofibroblasts, leading to excessive collagen deposition and scarring (Chaudhary et al., 2007, pp. 1–2; Hostettler et al., 2014, pp. 1–2). Lenvatinib’s nanomolar inhibitory potency against these receptors means that it can effectively block the diverse pro-fibrotic stimuli that drive disease progression in IPF (Grimminger et al., 2015, pp. 7–8). Additionally, the blockade of FGFR signaling may have a dual effect by counteracting elements of the TGF-β pathway, a master regulator of fibrogenesis, further reducing myofibroblast differentiation and ECM production (Grimminger et al., 2015, pp. 4–5). Collectively, these molecular interactions suggest that lenvatinib has the biochemical potential to modulate critical pro-fibrotic pathways, thereby attenuating the pathological processes underlying IPF (Bhatt et al., 2025, pp. 6–7).

Expected Effect:
Based on its mechanism of action, the expected effect of lenvatinib in assays evaluating IPF-related endpoints is a reduction in fibroblast proliferation and extracellular matrix synthesis, leading to diminished collagen deposition and decreased 3D collagen gel contraction (Chaudhary et al., 2007, pp. 1–2; Hostettler et al., 2014, pp. 5–7). In vitro, lung fibroblasts isolated from IPF patients typically exhibit upregulated PDGFR and FGFR expression with enhanced responsiveness to PDGF, FGF, and VEGF stimulation, resulting in increased cell proliferation, migration, and collagen production (Hostettler et al., 2014, pp. 1–2; Grimminger et al., 2015, pp. 2–4). When lenvatinib is applied to these cells, its inhibition of the relevant receptor tyrosine kinases is expected to normalize fibroblast behavior by blocking the overactive signaling cascades that drive ECM production (Grimminger et al., 2015, pp. 5–6). Consequently, the reduction in phosphorylation of downstream effectors such as Akt and ERK should translate into lower transcriptional activation of pro-fibrotic genes, including those encoding collagen type I and other ECM components (Bhatt et al., 2025, pp. 4–5). In a three-dimensional collagen gel contraction assay—an established ex vivo model for assessing fibroblast-mediated matrix remodeling—the inhibition of fibroblast contraction by lenvatinib would likely indicate its capacity to interfere with the mechanical aspects of fibrosis, an effect that is anticipated to mirror the action of approved antifibrotic agents like nintedanib (Hostettler et al., 2014, pp. 8–9; Grimminger et al., 2015, pp. 7–8). Overall, the expected therapeutic outcome is an attenuation of fibrogenic markers and a stabilization or even partial reversal of the pathologic fibrotic remodeling seen in IPF, supporting the underlying hypothesis that lenvatinib will dampen the multi-kinase mediated pro-fibrotic signaling in lung fibroblasts (Chaudhary et al., 2007, pp. 1–2).

Overall Evaluation:
In summary, lenvatinib represents a promising repurposed drug candidate for the treatment of idiopathic pulmonary fibrosis based on its robust molecular profile as a multi-kinase inhibitor that targets key pro-fibrotic receptor tyrosine kinases such as VEGFR, FGFR, and PDGFR (Grimminger et al., 2015, pp. 1–2; Hussein et al., 2017, pp. 10–11). One of the principal strengths of lenvatinib is that its broad inhibition of multiple signaling pathways provides a comprehensive strategy to attenuate the heterogeneous yet overlapping mechanisms that drive fibroblast activation, ECM synthesis, and tissue remodeling in IPF (Grimminger et al., 2015, pp. 7–8; Bhatt et al., 2025, pp. 2–4). Moreover, the favorable oral pharmacokinetic profile and extensive safety data accumulated from oncology trials offer significant advantages in terms of dosing convenience and known adverse event management (Hussein et al., 2017, pp. 10–11). The conceptual rationale is further supported by preclinical evidence from liver fibrosis models in which lenvatinib effectively inhibited stellate cell activation and fibrogenesis, suggesting that its antifibrotic properties may extend to pulmonary tissues (Ogawa et al., 2021, pp. 2–4).

However, several weaknesses must be considered. Despite its promising mechanistic profile, there remains a lack of direct preclinical data demonstrating lenvatinib’s efficacy in lung fibrosis models or its impact on pulmonary fibroblast function; the current literature does not include studies that have evaluated lenvatinib specifically in idiopathic pulmonary fibrosis, as indicated by the negative results from Clinical Trials searches (ClinicalTrials.gov, n.d.). Additionally, while the inhibition of pathways such as VEGFR and FGFR is theoretically beneficial, the complex biology of IPF—where certain isoforms of these growth factors may exert protective effects—necessitates careful evaluation of potential off-target or paradoxical effects (Grimminger et al., 2015, pp. 2–4). There is also a concern regarding pulmonary safety, as clinical reports have documented cases of lenvatinib-induced interstitial pneumonia in oncologic patient populations, raising questions about its tolerability when repurposed for chronic lung diseases (Imakura et al., 2022, pp. 1–2, 6). Finally, without preclinical data in relevant lung fibrosis models, it is challenging to accurately predict its efficacy and optimal dosing in the pulmonary context.

Overall, lenvatinib exhibits significant potential as a repurposed therapeutic candidate for IPF due to its potent inhibition of multiple receptor tyrosine kinases implicated in fibrotic signaling pathways, its favorable pharmacokinetic profile from oncology studies, and the mechanistic rationale derived from analogous multi-kinase inhibitors like nintedanib that are already in use for IPF (Hostettler et al., 2014, pp. 1–2; Grimminger et al., 2015, pp. 7–8). Nonetheless, the absence of direct preclinical or clinical evidence in pulmonary fibrosis poses a considerable gap that must be addressed through targeted in vitro studies with lung fibroblasts, three-dimensional collagen gel contraction assays, and in vivo evaluation in bleomycin-induced or other lung fibrosis models before progressing to clinical trials. In conclusion, while lenvatinib’s broad, multi-axis inhibition of key pro-fibrotic receptors is scientifically compelling and may provide a novel approach to modulating fibrotic remodeling in IPF, further comprehensive preclinical investigation is essential to validate its efficacy and safety in this new application (Grimminger et al., 2015, pp. 4–5; Nishioka et al., 2021, p. 5).

References
Bhatt, J., Ghigo, A., & Hirsch, E. (2025). Pi3k/akt in IPF: Untangling fibrosis and charting therapies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1549277

Chaudhary, N. I., Roth, G. J., Hilberg, F., Müller-Quernheim, J., Prasse, A., Zissel, G., Schnapp, A., & Park, J. E. (2007). Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. European Respiratory Journal, 29, 976–985. https://doi.org/10.1183/09031936.00152106

ClinicalTrials.gov. (n.d.). ClinicalTrials.gov search: Lenvatinib AND idiopathic pulmonary fibrosis. https://clinicaltrials.gov/

Grimminger, F., Günther, A., & Vancheri, C. (2015). The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. European Respiratory Journal, 45, 1426–1433. https://doi.org/10.1183/09031936.00149614

Hostettler, K. E., Zhong, J., Papakonstantinou, E., Karakiulakis, G., Tamm, M., Seidel, P., Sun, Q., Mandal, J., Lardinois, D., Lambers, C., & Roth, M. (2014). Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respiratory Research. https://doi.org/10.1186/s12931-014-0157-3

Hussein, Z., Mizuo, H., Hayato, S., Namiki, M., & Shumaker, R. (2017). Clinical pharmacokinetic and pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor. European Journal of Drug Metabolism and Pharmacokinetics, 42, 903–914. https://doi.org/10.1007/s13318-017-0403-4

Imakura, T., Sato, S., Tomonari, T., Murakami, K., Takahashi, N., Naito, N., Mima, M., Kagawa, K., Koyama, K., Nishimura, H., Kawano, H., Nokihara, H., Azuma, M., Takayama, T., & Nishioka, Y. (2022). Lenvatinib-induced interstitial pneumonia in a patient with hepatocellular carcinoma. Internal Medicine, 61, 1211–1217. https://doi.org/10.2169/internalmedicine.7300-21

Nishioka, Y., Homma, S., Okubo, T., & Azuma, A. (2021). Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis. Contemporary Clinical Trials Communications, 25, 100832. https://doi.org/10.1016/j.conctc.2021.100832

Ogawa, H., Kaji, K., Nishimura, N., Takagi, H., Ishida, K., Takaya, H., Kawaratani, H., Moriya, K., Namisaki, T., Akahane, T., & Yoshiji, H. (2021). Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis. Journal of Cellular and Molecular Medicine, 25, 4001–4013. https://doi.org/10.1111/jcmm.16363",-1.392587818,15
"BIX01294 (G9a inhibitor, Selleckchem S7580)","Proposal for BIX01294 (G9a inhibitor, Selleckchem S7580)

Overview of Therapeutic Candidate:
BIX01294 is a synthetic small‐molecule inhibitor discovered through structure–activity relationship studies targeting the enzymatic activity of G9a (also known as EHMT2), a histone methyltransferase responsible for the dimethylation of lysine 9 on histone H3 (H3K9me2). It belongs to a class of epigenetic modulators designed to reverse transcriptional repression by inhibiting the deposition of repressive histone marks. BIX01294 was developed based on rational drug design methods exploring quinazoline derivatives, and it has been widely employed in preclinical epigenetic research to interrogate G9a’s role in various cellular processes. Compounds in this class have traditionally been used as research probes to elucidate the function of histone methylation in cell differentiation, cancer, and fibrosis. The chemical entity is commercially available (for example, through Selleckchem S7580) and has been characterized extensively for its potency in reducing H3K9me2 levels in cell-based assays, indicating its ability to shift chromatin states in favor of gene reactivation (Ligresti et al., 2019).

Therapeutic History:
Historically, BIX01294 has been used primarily within the realm of basic science to study epigenetic regulation, particularly in the context of gene silencing mechanisms mediated by histone methylation. Although it has not yet entered clinical trials for idiopathic pulmonary fibrosis (IPF) or related fibrotic diseases—as evidenced by searches on ClinicalTrials.gov that returned zero results for “BIX01294 OR G9a inhibitor OR Histone methyltransferase inhibitor AND (Idiopathic Pulmonary Fibrosis OR pulmonary fibrosis)”—compelling preclinical evaluations have demonstrated antifibrotic potential in relevant models. Preclinical evidence in fibroblast cultures and animal studies has revealed that G9a inhibition via BIX01294 leads to significant reductions in pro-fibrotic markers including α-smooth muscle actin (αSMA) and collagen I expression, as well as a decrease in fibroblast contractility in three-dimensional matrix contraction assays; these outcomes have been observed in models that mimic the pathological state of lung fibrosis (Ligresti et al., 2019; ClinicalTrials.gov, n.d.). Furthermore, related studies in tissues such as renal and liver fibrosis have shown that inhibition of G9a can attenuate extracellular matrix deposition and myofibroblast activation, lending additional support to repurposing BIX01294 for fibrotic lung disease. In essence, while BIX01294’s clinical history has been limited to its role as a research tool, its underlying mechanism and preclinical antifibrotic effects provide a strong rationale for its further development in IPF (Irifuku et al., 2016).

Mechanism of Action:
At the molecular level, BIX01294 exerts its therapeutic effect by selectively inhibiting the catalytic domain of the G9a histone methyltransferase, thereby reducing the level of H3K9me2, a repressive chromatin modification that is known to silence gene expression. G9a typically writes this epigenetic mark on promoters of genes that are anti-fibrotic in nature—for example, the PPARGC1A gene, which codes for the coactivator PGC-1α involved in mitochondrial function and cellular metabolism that counteracts fibroblast activation. By inhibiting G9a, BIX01294 diminishes H3K9 dimethylation, disrupts the formation of heterochromatin and the recruitment of chromobox proteins like CBX5 (HP1α), and thereby derepresses the expression of genes that maintain fibroblast quiescence (Ligresti et al., 2019). The loss of these repressive marks has been demonstrated to not only decrease the expression of key profibrotic markers—such as αSMA and collagen I—but also to reactivate antifibrotic pathways and metabolic regulators in fibroblasts from idiopathic pulmonary fibrosis patients (Ligresti et al., 2019). This epigenetic remodeling is particularly important because IPF fibroblasts maintain a pro-fibrotic “memory” through stable chromatin modifications that perpetuate disease. In addition, studies suggest that the rapid loss of H3K9me2 after BIX01294 treatment—as observed within hours in vitro—provides evidence that its action reverses the established fibrotic epigenetic landscape, potentially restoring normal cellular signaling (Ligresti et al., 2019; Sehgal et al., 2022).

Expected Effect:
The central hypothesis for employing BIX01294 as a therapeutic intervention in IPF is that by reducing G9a-mediated H3K9 methylation, the compound can reverse the profibrotic state of lung fibroblasts. In the proposed assays, treatment with BIX01294 is expected to result in a significant decrease in the repressive H3K9me2 marks at the promoters of antifibrotic genes, such as PPARGC1A, which in turn leads to reactivation of gene expression profiles that counterbalance fibrogenic processes. This molecular reprogramming should manifest as a reduction in the expression of pro-fibrotic proteins, notably αSMA and collagen type I, which serve as key markers for aberrant fibroblast activation and myofibroblast differentiation. Functionally, reduction of these markers is anticipated to lower the contractile force exerted by fibroblasts in three-dimensional matrix contraction assays, which is a critical in vitro surrogate for the pathogenic remodeling of the extracellular matrix seen in IPF (Wright, 2016; Ligresti et al., 2019). Preclinical studies in murine models of fibrosis have demonstrated that systemic administration of G9a inhibitors leads to decreased extracellular matrix deposition and improved tissue architecture, which supports the potential of BIX01294 to ameliorate fibrotic lesions in the lung (Ligresti et al., 2019). Given that G9a is expressed at elevated levels in the lungs of IPF patients and correlates with increased H3K9 methylation and fibroblast activation, targeting this enzyme is expected to modulate critical epigenetic pathways that underlie the fibroproliferative process driving idiopathic pulmonary fibrosis (Roman & Mutsaers, 2018).

Overall Evaluation:
In summary, BIX01294 presents as a promising candidate for repurposing as an antifibrotic agent in idiopathic pulmonary fibrosis based on its selective inhibition of the G9a histone methyltransferase. One of the major strengths of this therapeutic approach is its novel mechanism that directly targets the epigenetic reprogramming responsible for maintaining fibroblast activation in IPF. By effectively reducing H3K9me2 marks and thereby reactivating antifibrotic genes, BIX01294 may interrupt the self-perpetuating cycle of myofibroblast differentiation and excessive extracellular matrix production that characterizes this disease (Ligresti et al., 2019; Bartczak et al., 2020). The preclinical data in both in vitro fibroblast assays and animal models—although not yet extended to human clinical trials—indicate that BIX01294 can reduce the expression of profibrotic markers (e.g., αSMA and collagen I) and attenuate functional attributes such as contractility in 3D matrix models (Ligresti et al., 2019; Wright, 2016).

However, there are also challenges and potential weaknesses that must be addressed before clinical translation is contemplated. First, while preclinical models have demonstrated promising biochemical and histological outcomes upon G9a inhibition, the lack of clinical trial data in fibrotic lung disease renders the safety and efficacy profile of BIX01294 in humans uncertain (ClinicalTrials.gov, n.d.). The compound’s off-target effects, potential toxicity with prolonged administration, and pharmacokinetics in the context of pulmonary tissue remain to be thoroughly evaluated. Second, IPF is a multifactorial disease in which a complex network of epigenetic regulators is involved; hence, monotherapy targeting only G9a might not sufficiently reverse the fibrotic program in all patients. Combining BIX01294 with other epigenetic modulators such as DNMT inhibitors—or with standard-of-care antifibrotic agents—could be necessary to achieve a robust therapeutic effect (Barcena-Varela et al., 2021). Moreover, the degree and timing of epigenetic changes following G9a inhibition require careful characterization, as the dynamic nature of histone modifications means that transient inhibition might not lead to sustained antifibrotic gene expression without continuous dosing. Finally, while several in vitro and murine studies provide a strong rationale for G9a inhibition, the translation of these findings to the human IPF context must account for species-specific differences in fibroblast biology and the lung microenvironment (Irifuku et al., 2016; Sehgal et al., 2022).

In conclusion, BIX01294 offers a compelling novel approach based on epigenetic reprogramming for the treatment of idiopathic pulmonary fibrosis, with a mechanism of action that is supported by robust preclinical evidence linking G9a-mediated H3K9 methylation to fibroblast activation and extracellular matrix deposition. The expected reversal of the fibrotic phenotype via epigenetic derepression of antifibrotic genes such as PPARGC1A could address a key pathogenic mechanism in IPF. Nevertheless, the absence of clinical data, potential toxicity concerns, and the complexity of epigenetic regulation in fibrotic diseases necessitate further comprehensive preclinical studies and careful design of future clinical trials. Considering the strength of the mechanistic rationale, particularly the ability of BIX01294 to lower αSMA and collagen expression while inhibiting 3D matrix contraction in fibroblast models, this candidate holds promise as part of a multimodal therapeutic strategy against IPF; however, the challenges outlined must be proactively addressed in the next phases of drug development (Ligresti et al., 2019; Wright, 2016; ClinicalTrials.gov, n.d.; Ma et al., 2022).

References
Barcena-Varela, M., Paish, H., Álvarez, L., Uriarte, I., Latasa, M. U., Santamaría, E., Recalde, M., Garate, M., Clavería, A., Colyn, L., Arechederra, M., Iraburu, M. J., Milkiewicz, M., Milkiewicz, P., Sangro, B., Robinson, S. M., French, J., Pardo-Saganta, A., Oyarzabal, J., Prosper, F., Rombouts, K., Oakley, F., Mann, J., Berasain, C., Avila, M. A., & Fernández-Barrena, M. G. (2021). Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis. Gut. https://doi.org/10.1136/gutjnl-2019-320205

Bartczak, K., Białas, A. J., Kotecki, M. J., Górski, P., & Piotrowski, W. J. (2020). More than a genetic code: Epigenetics of lung fibrosis. Molecular Diagnosis & Therapy, 24, 665–681. https://doi.org/10.1007/s40291-020-00490-7

ClinicalTrials.gov. (n.d.). Search for “BIX01294 OR G9a inhibitor OR Histone methyltransferase inhibitor AND (Idiopathic Pulmonary Fibrosis OR pulmonary fibrosis).” Retrieved from https://clinicaltrials.gov/ct2/results?term=BIX01294+OR+G9a+inhibitor+OR+Histone+methyltransferase+inhibitor+AND+%28Idiopathic+Pulmonary+Fibrosis+OR+pulmonary+fibrosis%29

Irifuku, T., Doi, S., Sasaki, K., Doi, T., Nakashima, A., Ueno, T., Yamada, K., Arihiro, K., Kohno, N., & Masaki, T. (2016). Inhibition of H3K9 histone methyltransferase G9a attenuates renal fibrosis and retains Klotho expression. Kidney International, 89, 147–157. https://doi.org/10.1038/ki.2015.291

Ligresti, G., Caporarello, N., Meridew, J. A., Jones, D. L., Tan, Q., Choi, K. M., Haak, A. J., Aravamudhan, A., Roden, A. C., Prakash, Y. S., Lomberk, G., Urrutia, R. A., & Tschumperlin, D. J. (2019). Cbx5/G9a/H3K9me-mediated gene repression is essential to fibroblast activation during lung fibrosis. JCI Insight. https://doi.org/10.1172/jci.insight.127111

Ma, H., Wu, X., Li, Y., & Xia, Y. (2022). Research progress in the molecular mechanisms, therapeutic targets, and drug development of idiopathic pulmonary fibrosis. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.963054

Roman, J., & Mutsaers, S. E. (2018). Epigenetic control of CXCL10: Regulating the counterregulator in idiopathic pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology, 58, 419–420. https://doi.org/10.1165/rcmb.2017-0389ed

Sehgal, M., Jakhete, S. M., Manekar, A. G., & Sasikumar, S. (2022). Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosis. Heliyon, 8, e09773. https://doi.org/10.1016/j.heliyon.2022.e09773

Wright, R. (2016). Camp mediated regulation of fibroblast to myofibroblast differentiation in idiopathic pulmonary fibrosis. [Journal name unknown].",-1.762425599,21
"Simtuzumab (GS-6624, Gilead)","Proposal for Simtuzumab (GS-6624, Gilead)

Overview of Therapeutic Candidate:
Simtuzumab (also known as GS-6624) is a humanized monoclonal antibody specifically designed to target lysyl oxidase-like 2 (LOXL2), an enzyme that catalyzes the oxidative deamination of lysine residues in collagen and elastin. This reaction produces reactive aldehyde groups (allysine residues) that drive the formation of covalent cross-links, thereby stabilizing and stiffening the extracellular matrix (ECM). Simtuzumab belongs to the biologic class of therapeutic antibodies, which are large, protein-based drugs produced using recombinant DNA technology and engineered for high target specificity. The antibody was derived originally from the murine antibody AB0023, with subsequent humanization performed to improve pharmacokinetic properties and minimize immunogenicity in humans. This class of biologics has been applied widely in inflammation and oncology owing to their ability to target specific extracellular or cell surface proteins with high affinity. In the context of fibrotic disorders such as idiopathic pulmonary fibrosis (IPF), the theory behind simtuzumab is that by inhibiting LOXL2’s enzymatic activity, one may reduce the formation of mature collagen cross-links, thus leading to a less stiff ECM and interrupting the cycle of fibroblast activation and myofibroblast differentiation (Aumiller et al., 2017; ClinicalTrials.gov, n.d.).

Therapeutic History:
The therapeutic candidate simtuzumab has been developed as part of an effort to target fibrotic mechanisms that are operational in a range of diseases characterized by excessive extracellular matrix deposition. LOXL2, the target of simtuzumab, has been extensively studied for its role in matrix remodeling, and its inhibition has been investigated in various preclinical models. Early animal studies using a murine antibody related to simtuzumab (AB0023) demonstrated a reduction in collagen cross-linking and amelioration of fibrosis in models such as bleomycin-induced lung fibrosis, where decreased myofibroblast numbers and improved lung mechanics were reported (Aumiller et al., 2017; Brereton, 2021). In addition to its preclinical use, simtuzumab has been evaluated in clinical trials for multiple fibrotic diseases including IPF, liver fibrosis, and even as an anticancer agent in some contexts. Notably, two clinical trials—NCT01759511 and NCT01769196—specifically examined simtuzumab in patients with IPF (Gilead Sciences, 2012; Gilead Sciences, 2013). These trials primarily focused on evaluating the long-term safety, tolerability, and efficacy on clinical endpoints such as progression-free survival. Unfortunately, despite the sound scientific rationale and promising preclinical data, the clinical trial outcomes in IPF did not show significant efficacy compared to placebo, leading to a disappointment in translating the antifibrotic effects observed in animal models to a clinical setting (Gilead Sciences, 2012; Gilead Sciences, 2013; Brereton, 2021; Distler et al., 2017). Thus, while the concept of targeting LOXL2 remains valid, past experience with simtuzumab in IPF indicates that the clinical development of this agent has been challenging due to its inability to meet predefined clinical endpoints.

Mechanism of Action:
At the molecular level, LOXL2 is a copper-dependent amine oxidase that drives the crosslinking of collagen and elastin fibers in the ECM by oxidatively deaminating lysine and hydroxylysine residues. This biochemical modification is essential for the formation of stable pyridinoline cross-links that enhance the structural integrity and stiffness of fibrotic tissue. Simtuzumab is designed to bind LOXL2 with high specificity and affinity, thereby allosterically inhibiting its enzymatic function. Unlike competitive inhibitors that directly block substrate binding, simtuzumab binds at a site distinct from the enzyme’s catalytic domain, modulating its activity in a noncompetitive manner. The intended outcome is to lower collagen crosslink density, reduce ECM stiffness, and interrupt the vicious cycle of matrix remodeling that drives fibroblast activation and myofibroblast differentiation in IPF (Bell et al., 2024; Brereton, 2021). Biochemical studies support that LOXL2 is highly expressed in fibrotic tissues and its activity correlates with disease severity in IPF, highlighting its potential as a target for anti-fibrotic intervention (Chien et al., 2014; Aumiller et al., 2017). In vitro experiments have demonstrated that inhibiting LOXL2 may reduce markers of fibroblast activation, such as α-smooth muscle actin (αSMA), and decrease collagen production. However, some studies also report that blocking LOXL2’s enzymatic function with simtuzumab can paradoxically lead to increased fibroblast activation and invasiveness in specific in vitro models, suggesting that LOXL2 might have multifaceted roles, possibly including non-enzymatic signaling functions (Espindola et al., 2019; Espindola et al., 2023).

Expected Effect:
Based on the mechanism of action, the proposed effect of simtuzumab in IPF is to inhibit LOXL2-mediated collagen crosslinking. This inhibition is expected to result in reduced ECM stiffness, lower collagen maturation (particularly in the formation of mature cross-links such as pyridinoline bonds), and decreased activation and contractility of lung fibroblasts. In a 3D cell culture assay, it is anticipated that treatment with simtuzumab would lead to reduced αSMA expression—a key marker of myofibroblast differentiation—and decrease fibroblast-mediated contraction in collagen gels, thereby correlating with a decrease in fibrotic potential (Bell et al., 2024; Espindola et al., 2019). On the molecular level, several studies indicate that LOXL2 is upregulated in the fibroblastic foci of IPF lung tissue, which means that inhibition with simtuzumab could directly affect the cell populations responsible for excessive ECM deposition (Aumiller et al., 2017; Brereton, 2021). In animal models, particularly using bleomycin-induced pulmonary fibrosis, LOXL2 inhibition has been associated with attenuation of fibrotic remodeling, reduced collagen deposition, and improvement in lung compliance. However, it must be noted that while these effects are observed in controlled experimental settings, clinical translation in human patients with IPF has been less successful, showing that the expected reductions in ECM stiffness and fibroblast activation were not robust enough to alter disease progression in clinical trial endpoints (Gilead Sciences, 2013; Espindola et al., 2023).

Overall Evaluation:
Overall, simtuzumab represents a well-conceived therapeutic candidate with a strong scientific rationale based on the central role of LOXL2 in ECM remodeling and fibrosis. The strength of its concept lies in the specificity of its target; by focusing on a critical enzyme that mediates collagen crosslinking, simtuzumab offers a novel approach to directly modulate the physical properties of the lung matrix. This mechanism has the potential to reduce the tissue stiffness and abnormal matrix architecture that are hallmarks of IPF, and in preclinical settings, LOXL2 inhibition has been correlated with decreased fibrosis severity (Chien et al., 2014; Puente et al., 2019).

However, the therapeutic history of simtuzumab in IPF has been disappointing overall. Despite promising preclinical data and strong mechanistic rationale, clinical trials in IPF patients have not demonstrated significant improvements in progression-free survival or other key endpoints (Gilead Sciences, 2012; Gilead Sciences, 2013; Brereton, 2021). This discrepancy may be attributable to several factors. First, the complexity of fibrosis in human lungs involves multiple redundant and compensatory pathways. Inhibiting a single member of the lysyl oxidase family—LOXL2—may not be sufficient to disrupt the overall fibrotic cascade if other lysyl oxidase isoforms continue to drive ECM crosslinking. Second, several studies suggest that LOXL2 may have intracellular functions in addition to its extracellular role. Since simtuzumab is an antibody that primarily targets extracellular LOXL2, it may not inhibit important intracellular signaling or epigenetic functions of LOXL2 that contribute to fibroblast activation and fibrosis progression (Matsuo et al., 2020). Third, there are concerns related to tissue penetration; being a large molecule, simtuzumab may have limited access to the dense and complex fibrotic lung tissue, possibly resulting in suboptimal target engagement. Finally, certain experimental models indicate that inhibition of LOXL2 by simtuzumab does not consistently reduce fibroblast contractility or collagen synthesis in vitro, and in some cases, it may even paradoxically enhance profibrotic cellular behaviors, thereby complicating the interpretation of its net antifibrotic effect (Espindola et al., 2019; Espindola et al., 2023).

In summary, the strengths of simtuzumab as a candidate for IPF include:
• Its well-defined molecular target, LOXL2, which is known to be upregulated in fibrotic tissues and has a critical role in driving collagen crosslinking and matrix stiffening.
• A specific, high-affinity antibody modality that theoretically offers low systemic toxicity and a precise mechanism to modulate extracellular matrix remodeling.
• Preclinical studies that have shown antifibrotic effects in animal models, suggesting that LOXL2 inhibition can reduce collagen deposition and improve tissue compliance (Aumiller et al., 2017; Bell et al., 2024).

However, the weaknesses that have limited simtuzumab’s clinical success include:
• The clinical trial results have not met efficacy endpoints, most notably in large phase 2 IPF trials, which failed to demonstrate meaningful improvements in patient outcomes (Gilead Sciences, 2012; Gilead Sciences, 2013; Brereton, 2021).
• The possibility that targeting only extracellular LOXL2 does not address intracellular functions that may also be critical in fibrotic regulation, suggesting that simtuzumab’s mechanism may be incomplete (Matsuo et al., 2020).
• Potential issues with antibody tissue penetration in the dense fibrotic lung microenvironment, leading to insufficient engagement with LOXL2 in situ.
• Evidence from certain translational studies that suggest simtuzumab may not robustly decrease fibroblast contractility or collagen production, and might even exacerbate fibroblast activation under some conditions (Espindola et al., 2023).

Overall, while the hypothesis that LOXL2 drives pathological ECM remodeling in IPF remains compelling, simtuzumab’s track record suggests that its current modality as an anti-LOXL2 antibody has been unable to overcome the redundancy of fibrotic pathways and the challenges of drug delivery within the fibrotic lung tissue. This implies that although simtuzumab is based on a strong mechanistic rationale and preclinical evidence, its clinical efficacy has been limited. Future strategies might need to include either combination therapies that target multiple lysyl oxidase family members or alternative approaches such as small-molecule inhibitors that can more effectively inhibit both extracellular and intracellular functions of LOXL2 (Findlay et al., 2021; Jones et al., 2018).

In directing our research team’s future efforts, it may be prudent to consider whether the concept of LOXL2 inhibition in isolation is sufficient for antifibrotic therapy in IPF or if broader approaches targeting ECM remodeling as a whole are warranted. Potential avenues include the development of pan-lysyl oxidase inhibitors or combinatorial strategies that simultaneously inhibit key enzymes and signaling pathways involved in fibroblast activation. Furthermore, advances in imaging and biomarker stratification (Vizier et al., 2023) could help identify patient subgroups with high LOXL2 activity who might benefit from targeted intervention, although the clinical outcomes observed to date put a note of caution on relying solely on an anti-LOXL2 strategy.

Overall Evaluation:
Simtuzumab presents as an attractive candidate from a mechanistic perspective due to its precise targeting of LOXL2—a clearly implicated driver of collagen crosslinking and matrix stiffening in fibrotic diseases such as IPF. Preclinical and biochemical studies have repeatedly demonstrated that LOXL2 is central to the fibrotic process, and its inhibition is associated with reduced ECM stiffening and fibroblast activation. However, the clinical record of simtuzumab indicates that it has not translated into significant therapeutic benefit in patients with IPF. This discrepancy likely arises from the inherent complexities of fibrosis, including redundancy among enzyme family members, the multifaceted roles of LOXL2 (both extracellular and intracellular), and limitations in drug delivery within fibrotic tissues. These factors underline the need to reconsider whether focusing on a single enzyme target is sufficient to interrupt the fibrotic cascade or if a more integrated therapeutic strategy is required.

In conclusion, while simtuzumab is founded on a scientifically robust hypothesis and has demonstrated promise in preclinical models, its clinical profile to date does not support its further development as a monotherapy for IPF. Nonetheless, data gleaned from these evaluations are highly informative and could be leveraged to guide future drug development strategies, either by refining the modality of LOXL2 inhibition or by integrating it into combination regimens targeting multiple fibrotic mechanisms. As we evaluate promising candidates for repurposing in IPF, simtuzumab serves as a critical case study highlighting the gap that can exist between preclinical promise and clinical efficacy, emphasizing the need for comprehensive validation across biochemical, cellular, and translational models before clinical adoption (Aumiller et al., 2017; Brereton, 2021; Espindola et al., 2023; Gilead Sciences, 2013; Vizier et al., 2023).

References
Aumiller, V., Strobel, B., Romeike, M., Schuler, M., Stierstorfer, B. E., & Kreuz, S. (2017). Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis. Scientific Reports, 7, 270. https://doi.org/10.1038/s41598-017-00270-0

Bell, J. A., Davies, E. R., Brereton, C., Vukmirovic, M., Roberts, J., Lunn, K., Wickens, L., Conforti, F., Ridley, R., Ceccato, J., Sayer, L. N., Johnston, D. A., Vallejo, A. F., Alzetani, A., Jogai, S., Marshall, B. G., Fabre, A., Richeldi, L., Monk, P. D., Skipp, P., Kaminski, N., Offer, E., Wang, Y., Davies, D. E., & Jones, M. G. (2024). Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2. Cell Reports Medicine, 5, 101695. https://doi.org/10.1016/j.xcrm.2024.101695

Brereton, C. J. (2021). Determinants and effects of collagen cross-linking enzyme dysregulation in idiopathic pulmonary fibrosis. [Journal Name Unknown].

Chien, J. W., Richards, T. J., Gibson, K. F., Zhang, Y., Lindell, K. O., Shao, L., Lyman, S. K., Adamkewicz, J. I., Smith, V., Kaminski, N., & O’Riordan, T. (2014). Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. European Respiratory Journal, 43(6), 1430–1438. https://doi.org/10.1183/09031936.00141013

ClinicalTrials.gov. (n.d.). Search results for Simtuzumab and Idiopathic Pulmonary Fibrosis. https://clinicaltrials.gov/ct2/results?cond=Idiopathic+Pulmonary+Fibrosis&term=Simtuzumab

Distler, J. H. W., Feghali-Bostwick, C., Soare, A., Asano, Y., Distler, O., & Abraham, D. J. (2017). Frontiers of antifibrotic therapy in systemic sclerosis. Arthritis & Rheumatology, 69(2), 257–267. https://doi.org/10.1002/art.39865

Espindola, M. S., Habiel, D. M., Coelho, A. L., Mikels-Vigdal, A., & Hogaboam, C. M. (2019). Targeting lysyl oxidase-like 2 in idiopathic pulmonary fibrosis. bioRxiv. https://doi.org/10.1101/813907

Espindola, M. S., Habiel, D. M., Coelho, A. L., Parimon, T., Chen, P., Mikels-Vigdal, A., & Hogaboam, C. M. (2023). Translational studies reveal the divergent effects of simtuzumab targeting LOXL2 in idiopathic pulmonary fibrosis. Fibrosis. https://doi.org/10.35534/fibrosis.2023.10007

Findlay, A., Turner, C., Schilter, H., Deodhar, M., Zhou, W., Perryman, L., Foot, J., Zahoor, A., Yao, Y., Hamilton, R., Brock, M., Raso, C., Stolp, J., Galati, M., Hamprecht, D., Charlton, B., & Jarolimek, W. (2021). An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies. Clinical and Translational Medicine, 11, e572. https://doi.org/10.1002/ctm2.572

Gilead Sciences. (2012). Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF) (NCT01759511). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01759511

Gilead Sciences. (2013). Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) (NCT01769196). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01769196

Jones, M. G., Andriotis, O. G., Roberts, J. J. W., Lunn, K., Tear, V., Cao, L., Ask, K., Smart, D. E., Bonfanti, A., Johnson, P., Alzetani, A., Conforti, F., Doherty, R., Lai, C. Y., Johnson, B., Bourdakos, K. N., Fletcher, S. V., Marshall, B. G., Jogai, S., Brereton, C. J., Chee, S. J., Ottensmeier, C. H., Sime, P., Gauldie, J., Kolb, M., Mahajan, S., Fabre, A., Bhaskar, A., Jarolimek, W., Richeldi, L., O’Reilly, K. M., Monk, P. D., Thurner, P. J., & Davies, D. E. (2018). Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. eLife, 7, e36354. https://doi.org/10.7554/eLife.36354

Matsuo, A., Yanagi, S., Tsubouchi, H., Miura, A., Shigekusa, T., Matsumoto, N., & Nakazato, M. (2020). Significance of nuclear upregulation of LOXL2 in fibroblasts and myofibroblasts in the fibrotic process of acute respiratory distress syndrome. [Journal Name Unknown]. https://doi.org/10.21203/rs.2.24386/v1

Puente, A., Fortea, J. I., Cabezas, J., Arias Loste, M. T., Iruzubieta, P., Llerena, S., Huelin, P., Fábrega, E., & Crespo, J. (2019). LOXL2—a new target in antifibrogenic therapy? International Journal of Molecular Sciences, 20(7), 1634. https://doi.org/10.3390/ijms20071634

Vizier, R., Garnier, A.-R., Dias, A., Moreau, M., Claron, M., Collin, B., Denat, F., Bellaye, P.-S., & Goncalves, V. (2023). Spect imaging of lysyl oxidase-like 2 in a model of idiopathic pulmonary fibrosis. Molecular Pharmaceutics, 20(6), 3613–3622. https://doi.org/10.1021/acs.molpharmaceut.3c00232",-2.240028962,11
